[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f0PF1f5hJIarEing73ic0STRpSJGw_QK_nmH_LBilHGk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Regeneron Pharmaceuticals",[4],389,false,112,98,1126371,11,[13,16,19,22,25,28,30,33],{"name":14,"count":15},"Healthy Volunteers",25,{"name":17,"count":18},"Atopic Dermatitis",18,{"name":20,"count":21},"Healthy",16,{"name":23,"count":24},"Hypercholesterolemia",12,{"name":26,"count":27},"Healthy Volunteer",10,{"name":29,"count":27},"Melanoma",{"name":31,"count":32},"Paroxysmal Nocturnal Hemoglobinuria",8,{"name":34,"count":35},"Cutaneous Squamous Cell Carcinoma",7,[37,42,47,52,57,62,67,72,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03916627","Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","2025-03-31","cemiplimab",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05070858","A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis","2025-07-08","Pozelimab + Cemdisiran",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05394116","A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)","2025-07-17","Garetosmab",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06491914","A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","2025-08-26","Aflibercept 8 mg",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05831176","A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have","2026-02-18","Dupilumab",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05352672","Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma","2026-03-12","Fianlimab",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06593600","Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)","2026-04-13","REGN7544",{"nctId":73,"briefTitle":74,"date":75,"intervention":66},"NCT06161441","A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery","2026-04-20",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04287621","Registry of Asthma Patients Initiating DUPIXENT®","2026-04-27","DUPIXENT®",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06299098","A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation","2026-05-18","Trevogrumab-Part A",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,276,764,929,974,992,1479,1537,1662,1792,1826,1884,1914,1944,2002,2055,2100,2134,2168,2202,2232,2258,2284,2310,2336,2362,2388,2455,2514,2540,2562,2584,2637,2667,2693,2715,2737,2759,2777,2795,2813,2831,2849,2867,2885,2903,2921,2958,3009,3048,3074,3100,3145,3173,3201,3238,3260,3380,3421,3455,3488,3514,3532,3550,3568,3586,3610,3635,3653,3671,3689,3707,3733,3751,3776,3803,3821,3846,3872,3890,3908,3926,3944,3969,3995,4013,4031,4056,4074,4092,4110,4128,4146,4164,4182,4275,4311,4334,4352,4370,4394,4412,4430,4448,4471,4489,4511,4529,4554,4583,4647,4670,4693,4791,4825,4860,4878,4976,5048,5126,5183,5239,5299,5352,5378,5418,5440,5462,5484,5506,5528,5550,5572,5609,5633,5651,5677,5705,5723,5741,5764,5782,5807,5825,5843,5861,5885,5909,5933,5951,5969,5987,6005,6068,6126,6173,6199,6234,6267,6299,6329,6356,6374,6392,6410,6435,6459,6477,6495,6513,6531,6549,6567,6589,6611,6636,6654,6672,6690,6715,6733,6751,6775,6800,6847,6881,6917,6948,6979,7007,7037,7067,7092,7120,7142,7165,7190,7208,7226,7244,7262,7280,7298,7320,7343,7367,7389,7413,7436,7454,7472,7490,7508,7526,7544,7568,7590,7614,7632,7650,7674,7697,7715,7733,7755,7773,7797,7815,7838,7860,7885,7903,7921,7961,8002,8028,8058,8086,8112,8135,8156,8181,8199],{"intervention":95,"totalTrials":96,"cells":97},"Linvoseltamab",14,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":137,"PHASE3":213,"PHASE4":259,"NA":274},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":136,"soonestReadout":108},[103,116],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NCT06369467","Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy","RECRUITING",[88],"2028-03-28","2024-05-17",6,[112],"Food Allergy",[114,115],"linvoseltamab","dupilumab",{"nctId":117,"briefTitle":118,"status":106,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT05137054","A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments",[88],"2028-04-11","2034-09-26","2022-08-17",317,[125],"Multiple Myeloma",[95,127,128,129,130,131,132,66,133,134,135],"Daratumumab","Carfilzomib","Lenalidomide","Bortezomib","Pomalidomide","Isatuximab","Cemiplimab","Nirogacestat","Cevostamab",2,{"trials":138,"activeCount":35,"soonestReadout":194},[139,150,160,171,181,190,201],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT05955508","A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma","ACTIVE_NOT_RECRUITING",[89],"2033-01-25","2024-01-30",40,[148],"Smoldering Multiple Myeloma (SMM)",[95],{"nctId":151,"briefTitle":152,"status":106,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":159},"NCT03761108","Phase 1\u002F2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma",[88,89],"2033-03-30","2033-06-16","2019-01-23",387,[125],[95],{"nctId":161,"briefTitle":162,"status":106,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT07455851","A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed\u002FRefractory Multiple Myeloma",[88,89],"2033-09-30","2026-03-26",150,[168],"Relapsed Refractory Multiple Myeloma (RRMM)",[95,170],"REGN17372+Linvoseltamab",{"nctId":172,"briefTitle":173,"status":106,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT06140524","A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma",[89],"2032-05-18","2024-09-16",116,[179,148],"Monoclonal Gammopathy of Undetermined Significance (MGUS)",[95],{"nctId":182,"briefTitle":183,"status":106,"phases":184,"primaryCompletion":185,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":189},"NCT05828511","A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment",[88,89],"2035-11-02","2023-12-19",149,[125],[95],{"nctId":191,"briefTitle":192,"status":106,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT06292780","A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)",[88,89],"2028-08-20","2035-02-20","2024-08-07",220,[199],"Relapsed\u002FRefractory Systemic Light Chain Amyloidosis",[95],{"nctId":202,"briefTitle":203,"status":106,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},"NCT06669247","A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed\u002FRefractory Multiple Myeloma",[88,89],"2033-11-11","2035-11-01","2024-12-11",186,[210],"Relapsed\u002FRefractory Multiple Myeloma",[95,212],"REGN7945+Linvoseltamab",{"trials":214,"activeCount":258,"soonestReadout":251},[215,227,237,247],{"nctId":216,"briefTitle":217,"status":218,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT07428369","A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","NOT_YET_RECRUITING",[89,90],"2038-05-21","2026-06-05",1570,[224],"Multiple Myeloma (MM)",[95,130,129,127,226],"Dexamethasone",{"nctId":228,"briefTitle":229,"status":218,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":236},"NCT07393282","A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)",[90],"2033-07-22","2026-03-25",270,[235],"High Risk Smoldering Multiple Myeloma (HR-SMM)",[95,127],{"nctId":238,"briefTitle":239,"status":106,"phases":240,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":245},"NCT05730036","A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed\u002FRefractory Multiple Myeloma",[90],"2033-04-19","2023-09-18",410,[168],[95,246,131,226],"Elotuzumab",{"nctId":248,"briefTitle":249,"status":106,"phases":250,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":257},"NCT07222761","A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM)",[90],"2029-05-21","2034-08-23","2026-01-02",915,[256],"Relapsed and\u002For Refractory Multiple Myeloma (RRMM)",[95,128,127,226,131,130],4,{"trials":260,"activeCount":273,"soonestReadout":265},[261],{"nctId":262,"briefTitle":263,"status":218,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT07609940","Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)",[91],"2027-10-11","2028-12-06","2026-07-17",30,[270],"Relapsed\u002FRefractory Multiple Myeloma (RRMM)",[95,272],"Tocilizumab",1,{"trials":275,"activeCount":100},[],{"intervention":61,"totalTrials":277,"cells":278},47,{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":335,"PHASE3":472,"PHASE4":631,"NA":683},{"trials":280,"activeCount":100},[],{"trials":282,"activeCount":273,"soonestReadout":108},[283,297,301,314,326],{"nctId":284,"briefTitle":285,"status":286,"phases":287,"primaryCompletion":288,"completion":288,"start":289,"enrollment":96,"conditions":290,"interventions":291},"NCT02647086","Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668\u002FSAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)","COMPLETED",[88],"2016-07","2015-12",[17],[61,292,293,294,295,296],"Midazolam","Omeprazole","Warfarin","Caffeine","Metoprolol",{"nctId":104,"briefTitle":105,"status":106,"phases":298,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":299,"interventions":300},[88],[112],[114,115],{"nctId":302,"briefTitle":303,"status":286,"phases":304,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":311},"NCT03112577","Study of REGN3500 and Dupilumab in Patients With Asthma",[88],"2019-03-20","2019-12-09","2017-06-15",32,[310],"Asthma, Allergic",[312,61,313],"REGN3500","Fluticasone propionate",{"nctId":315,"briefTitle":316,"status":286,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":325},"NCT03050151","Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis",[88],"2017-11-14","2018-02-12","2017-02-28",176,[323,324],"Atopic Disorders","Eczema, Atopic",[61],{"nctId":327,"briefTitle":328,"status":286,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":334},"NCT01385657","Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis",[88],"2012-03-31","2011-07-31",37,[17],[61],{"trials":336,"activeCount":273,"soonestReadout":60},[337,347,359,371,382,391,402,411,423,433,443,452,463],{"nctId":338,"briefTitle":339,"status":286,"phases":340,"primaryCompletion":341,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":346},"NCT01548404","Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis",[89],"2013-03","2013-06","2012-04",109,[17],[61],{"nctId":348,"briefTitle":349,"status":286,"phases":350,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":357},"NCT03558997","Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy",[89],"2019-05-14","2019-06-13","2018-06-07",103,[356],"Allergic Rhinitis",[61,358],"Timothy Grass SCIT",{"nctId":360,"briefTitle":361,"status":286,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},"NCT03682770","Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)",[89],"2020-10-16","2021-07-23","2018-10-03",148,[368],"Peanut Allergy",[61,370],"AR101",{"nctId":372,"briefTitle":373,"status":286,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},"NCT01979016","Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)",[89],"2014-12-31","2015-01-31","2013-12-31",54,[380],"Atopic Dermatitis (AD)",[61],{"nctId":383,"briefTitle":384,"status":286,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":390},"NCT02407756","A Study to Determine the Safety and Tolerability of Dupilumab (REGN668\u002FSAR231893) in Patients Aged ≥6 to \u003C18 Years With Atopic Dermatitis (Eczema)",[89],"2016-03-31","2015-03-31",78,[17],[61],{"nctId":58,"briefTitle":59,"status":142,"phases":392,"primaryCompletion":60,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":401},[89],"2026-11-25","2023-05-03",22,[397,398,399,400],"Eosinophilic Gastritis (EoG)","Eosinophilic Duodenitis (EoD)","Eosinophilic Gastrointestinal Disease (EGID)","Eosinophilic Gastroenteritis",[61],{"nctId":403,"briefTitle":404,"status":286,"phases":405,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":410},"NCT02210780","Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)",[89],"2015-09-15","2014-08-05",194,[17],[61],{"nctId":412,"briefTitle":413,"status":414,"phases":415,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":421},"NCT03736967","Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis","TERMINATED",[89],"2020-03-13","2020-07-28","2018-11-12",206,[17],[312,61,422],"REGN3500 + Dupilumab Combo",{"nctId":424,"briefTitle":425,"status":286,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":432},"NCT01859988","Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis",[89],"2014-05","2014-09","2013-05",380,[17],[61],{"nctId":434,"briefTitle":435,"status":286,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":277,"conditions":440,"interventions":442},"NCT02379052","Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)",[89],"2017-02-17","2017-07-10","2015-05-12",[441],"Eosinophilic Esophagitis",[61],{"nctId":444,"briefTitle":445,"status":286,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":15,"conditions":450,"interventions":451},"NCT03793608","Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy",[89],"2021-02-19","2021-05-12","2019-03-12",[368],[61],{"nctId":453,"briefTitle":454,"status":286,"phases":455,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":462},"NCT04442269","Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)",[89],"2023-07-27","2024-02-09","2020-09-15",62,[461],"Allergic Bronchopulmonary Aspergillosis",[115],{"nctId":464,"briefTitle":465,"status":286,"phases":466,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":471},"NCT01639040","Study to Assess the Safety of Dupilumab (REGN668\u002FSAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)",[89],"2012-12","2012-07",31,[17],[61],{"trials":473,"activeCount":136,"soonestReadout":497},[474,484,493,502,521,532,542,552,561,571,580,590,601,610,622],{"nctId":475,"briefTitle":476,"status":286,"phases":477,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":483},"NCT02755649","A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable",[90],"2017-01-04","2017-03-31","2016-01-31",325,[17],[61],{"nctId":485,"briefTitle":486,"status":286,"phases":487,"primaryCompletion":288,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":492},"NCT02395133","A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)",[90],"2016-10-18","2015-03-25",422,[17],[61],{"nctId":494,"briefTitle":495,"status":142,"phases":496,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":501},"NCT02612454","Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to \u003C18 Years of Age With Atopic Dermatitis (AD)",[90],"2026-10-07","2015-10-15",880,[17],[61],{"nctId":503,"briefTitle":504,"status":286,"phases":505,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":520},"NCT03054428","Efficacy and Safety of Dupilumab in Participants ≥12 to \u003C18 Years of Age, With Moderate-to-severe Atopic Dermatitis",[90],"2018-04-04","2018-06-05","2017-03-21",251,[511,512,513,514,515,516,517,518,519],"Moderate-to-Severe Atopic Dermatitis","Dermatitis, Dermatitis Atopic","Eczema, Skin Diseases, Skin","Diseases Genetic, Genetic","Diseases Inborn, Skin","Disease, Eczematous Skin","Hypersensitivity, Immediate","Hypersensitivity, Immune System Diseases","Dermatitis, Atopic",[61],{"nctId":522,"briefTitle":523,"status":106,"phases":524,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":529,"interventions":531},"NCT07112378","A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis",[90],"2028-06-19","2028-10-09","2025-11-10",20,[530],"Eosinophilic Esophagitis (EoE)",[115],{"nctId":533,"briefTitle":534,"status":286,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":541},"NCT03633617","Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)",[90],"2021-09-09","2022-06-07","2018-09-24",321,[441],[61],{"nctId":543,"briefTitle":544,"status":286,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":551},"NCT02277743","Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis",[90],"2015-11","2016-02","2014-10",671,[519],[61],{"nctId":553,"briefTitle":554,"status":286,"phases":555,"primaryCompletion":556,"completion":480,"start":557,"enrollment":558,"conditions":559,"interventions":560},"NCT02277769","Study of Dupilumab (REGN668\u002FSAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis",[90],"2015-10-31","2014-11-30",708,[519],[61],{"nctId":562,"briefTitle":563,"status":286,"phases":564,"primaryCompletion":565,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":570},"NCT03345914","Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to \u003C12 Years With Severe Atopic Dermatitis (AD)",[90],"2019-06-20","2019-09-10","2017-11-17",367,[519],[61],{"nctId":572,"briefTitle":573,"status":286,"phases":574,"primaryCompletion":575,"completion":576,"start":428,"enrollment":577,"conditions":578,"interventions":579},"NCT02260986","Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668\u002FSAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis",[90],"2015-08","2016-10",740,[17],[61],{"nctId":581,"briefTitle":582,"status":286,"phases":583,"primaryCompletion":584,"completion":585,"start":586,"enrollment":587,"conditions":588,"interventions":589},"NCT04394351","Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)",[90],"2022-06-02","2024-05-14","2020-09-01",102,[530],[61],{"nctId":591,"briefTitle":592,"status":286,"phases":593,"primaryCompletion":594,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":600},"NCT04417894","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)",[90],"2022-08-31","2022-11-23","2021-04-14",133,[599],"Moderate to Severe Atopic Hand and Foot Dermatitis",[115],{"nctId":602,"briefTitle":603,"status":286,"phases":604,"primaryCompletion":605,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":609},"NCT03346434","Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to \u003C6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)",[89,90],"2021-07-08","2017-11-30",202,[519],[61],{"nctId":611,"briefTitle":612,"status":286,"phases":613,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":620},"NCT04206553","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid",[89,90],"2024-07-12","2025-01-05","2020-10-28",106,[619],"Bullous Pemphigoid",[115,621],"Oral corticosteroids",{"nctId":623,"briefTitle":624,"status":286,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":630},"NCT01949311","Open-label Study of Dupilumab in Patients With Atopic Dermatitis",[90],"2022-06-27","2013-10-10",2733,[17],[61],{"trials":632,"activeCount":136,"soonestReadout":677},[633,643,652,663,673],{"nctId":634,"briefTitle":635,"status":218,"phases":636,"primaryCompletion":637,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":642},"NCT07587658","This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization",[91],"2028-07-30","2026-06-30",754,[641],"Chronic Obstructive Pulmonary Disease (COPD)",[115],{"nctId":644,"briefTitle":645,"status":286,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":146,"conditions":649,"interventions":651},"NCT04203797","A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma",[91],"2023-07-15","2020-07-16",[650],"Asthma",[115],{"nctId":653,"briefTitle":654,"status":655,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":100,"conditions":660,"interventions":662},"NCT07187089","Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab","WITHDRAWN",[91],"2027-12-23","2028-01-05","2025-11-11",[661],"Severe Atopic Dermatitis (AD)",[115],{"nctId":664,"briefTitle":665,"status":286,"phases":666,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT05590585","Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial",[91],"2024-11-14","2023-01-11",124,[511,671],"Atopic Eczema",[115],{"nctId":674,"briefTitle":675,"status":142,"phases":676,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":681},"NCT06572228","Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid\u002FLong-acting Beta-agonist (ICS\u002FLABA) in Comparison to ICS Dose Escalation to High Dose ICS\u002FLABA in Adolescent and Adult Patients With Uncontrolled Asthma",[91],"2027-04-24","2024-08-26",120,[650],[115,682],"ICS\u002FLABA",{"trials":684,"activeCount":763,"soonestReadout":715},[685,692,702,711,721,730,737,747,754],{"nctId":686,"briefTitle":687,"status":688,"phases":689,"conditions":690,"interventions":691},"NCT05906706","Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid","APPROVED_FOR_MARKETING",[],[619],[115],{"nctId":693,"briefTitle":694,"status":286,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT05203380","Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis",[],"2023-03-10","2022-01-27",45,[700],"Moderate-to-severe Atopic Dermatitis",[115],{"nctId":703,"briefTitle":704,"status":286,"phases":705,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":710},"NCT04173442","Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy",[],"2025-11-04","2018-10-24",581,[380,650],[115],{"nctId":712,"briefTitle":713,"status":106,"phases":714,"primaryCompletion":715,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":720},"NCT03936335","An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)",[],"2027-01-21","2019-09-30",3930,[719,17],"Adverse Pregnancy Outcomes",[115],{"nctId":722,"briefTitle":723,"status":142,"phases":724,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":728,"interventions":729},"NCT03428646","Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)",[],"2027-03-30","2018-04-06",858,[519],[61],{"nctId":731,"briefTitle":732,"status":688,"phases":733,"conditions":734,"interventions":736},"NCT04776694","Compassionate Use of Dupilumab",[],[735],"Type 2 Inflammatory Disorders",[61],{"nctId":738,"briefTitle":739,"status":286,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":746},"NCT04287608","Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis",[],"2023-03-29","2021-03-10",50,[745,17],"Conjunctivitis",[115],{"nctId":748,"briefTitle":749,"status":750,"phases":751,"conditions":752,"interventions":753},"NCT06631677","Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (EgE)-Mediated Food Allergy Previously Treated With Linvoseltamab","TEMPORARILY_NOT_AVAILABLE",[],[112],[61],{"nctId":755,"briefTitle":756,"status":106,"phases":757,"primaryCompletion":758,"completion":758,"start":759,"enrollment":760,"conditions":761,"interventions":762},"NCT06693531","A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care",[],"2030-05-22","2024-11-22",350,[530],[115],3,{"intervention":765,"totalTrials":766,"cells":767},"Pozelimab",17,{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":806,"PHASE3":826,"PHASE4":896,"NA":907},{"trials":769,"activeCount":100},[],{"trials":771,"activeCount":273,"soonestReadout":785},[772,781,790,798],{"nctId":773,"briefTitle":774,"status":286,"phases":775,"primaryCompletion":364,"completion":364,"start":776,"enrollment":777,"conditions":778,"interventions":779},"NCT04601844","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers",[88],"2020-11-16",19,[20],[765,780],"Cemdisiran",{"nctId":782,"briefTitle":783,"status":106,"phases":784,"primaryCompletion":785,"completion":785,"start":786,"enrollment":378,"conditions":787,"interventions":789},"NCT07230834","Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants",[88],"2028-07-03","2026-01-19",[788],"Geographic Atrophy (GA)",[765],{"nctId":791,"briefTitle":792,"status":286,"phases":793,"primaryCompletion":794,"completion":794,"start":795,"enrollment":268,"conditions":796,"interventions":797},"NCT04940364","A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers",[88],"2022-06-22","2021-08-04",[20],[765,780],{"nctId":799,"briefTitle":800,"status":286,"phases":801,"primaryCompletion":802,"completion":802,"start":803,"enrollment":146,"conditions":804,"interventions":805},"NCT04491838","Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants",[88],"2021-03-05","2020-08-03",[26],[765],{"trials":807,"activeCount":100},[808,816],{"nctId":809,"briefTitle":810,"status":286,"phases":811,"primaryCompletion":812,"completion":813,"start":605,"enrollment":110,"conditions":814,"interventions":815},"NCT04888507","Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy",[89],"2022-05-05","2023-05-04",[31],[765,780],{"nctId":817,"briefTitle":818,"status":286,"phases":819,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":825},"NCT04811716","Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy",[89],"2022-10-25","2023-10-18","2021-07-29",24,[31],[765,780],{"trials":827,"activeCount":895,"soonestReadout":45},[828,839,850,861,869,879,887],{"nctId":829,"briefTitle":830,"status":286,"phases":831,"primaryCompletion":832,"completion":833,"start":834,"enrollment":27,"conditions":835,"interventions":838},"NCT04209634","Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)",[89,90],"2021-11-09","2024-05-02","2020-01-27",[836,837],"CD55-deficient Protein-losing Enteropathy","CHAPLE",[765],{"nctId":840,"briefTitle":841,"status":106,"phases":842,"primaryCompletion":843,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":849},"NCT06541704","A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy",[90],"2027-11-29","2032-05-21","2024-10-30",975,[848,788],"Age-related Macular Degeneration (AMD)",[765,780],{"nctId":851,"briefTitle":852,"status":142,"phases":853,"primaryCompletion":854,"completion":855,"start":856,"enrollment":607,"conditions":857,"interventions":858},"NCT05133531","A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment",[90],"2026-10-12","2026-10-26","2022-08-01",[31],[859,765,780,860],"Ravulizumab","Eculizumab",{"nctId":862,"briefTitle":863,"status":106,"phases":864,"primaryCompletion":865,"completion":865,"start":866,"enrollment":607,"conditions":867,"interventions":868},"NCT05744921","A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works",[90],"2029-02-26","2023-03-07",[31],[765,780],{"nctId":870,"briefTitle":871,"status":106,"phases":872,"primaryCompletion":873,"completion":874,"start":875,"enrollment":876,"conditions":877,"interventions":878},"NCT07154745","A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently",[90],"2030-01-06","2031-11-22","2026-05-30",35,[31],[765,780],{"nctId":880,"briefTitle":881,"status":414,"phases":882,"primaryCompletion":883,"completion":883,"start":884,"enrollment":763,"conditions":885,"interventions":886},"NCT05131204","Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria",[90],"2023-07-12","2022-10-06",[31],[780,860,765,859],{"nctId":43,"briefTitle":44,"status":142,"phases":888,"primaryCompletion":45,"completion":889,"start":890,"enrollment":891,"conditions":892,"interventions":894},[90],"2028-11-11","2021-12-14",288,[893],"Generalized Myasthenia Gravis",[46,780,765],5,{"trials":897,"activeCount":273,"soonestReadout":902},[898],{"nctId":899,"briefTitle":900,"status":106,"phases":901,"primaryCompletion":902,"completion":902,"start":903,"enrollment":895,"conditions":904,"interventions":906},"NCT07142343","A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease",[91],"2030-02-12","2026-03-19",[905],"CHAPLE Disease",[765],{"trials":908,"activeCount":100},[909,915,922],{"nctId":910,"briefTitle":911,"status":688,"phases":912,"conditions":913,"interventions":914},"NCT05232110","Compassionate Use of Pozelimab",[],[836],[765],{"nctId":916,"briefTitle":917,"status":918,"phases":919,"conditions":920,"interventions":921},"NCT06028594","Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria","NO_LONGER_AVAILABLE",[],[31],[765,780],{"nctId":923,"briefTitle":924,"status":688,"phases":925,"conditions":926,"interventions":928},"NCT06003881","Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy",[],[927],"CD55-Deficient Protein-Losing Enteropathy",[765],{"intervention":272,"totalTrials":763,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":946,"PHASE3":964,"PHASE4":966,"NA":972},{"trials":932,"activeCount":100},[],{"trials":934,"activeCount":100},[935],{"nctId":936,"briefTitle":937,"status":286,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":944},"NCT02097524","Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88\u002FSAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)",[88],"2015-04","2014-03",105,[943],"Rheumatoid Arthritis",[945,272],"Sarilumab",{"trials":947,"activeCount":273,"soonestReadout":952},[948],{"nctId":949,"briefTitle":950,"status":106,"phases":951,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":962},"NCT03564340","Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers",[88,89],"2027-05-10","2018-05-21",890,[956,957,958,959,960,961],"Recurrent Ovarian Cancer","Recurrent Fallopian Tube Cancer","Recurrent Primary Peritoneal Cancer","Recurrent Endometrial Cancer","Endometrial Cancer","Low-grade Serous Ovarian Cancer",[963,133,945,272],"Ubamatamab",{"trials":965,"activeCount":100},[],{"trials":967,"activeCount":273,"soonestReadout":265},[968],{"nctId":262,"briefTitle":263,"status":218,"phases":969,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":970,"interventions":971},[91],[270],[95,272],{"trials":973,"activeCount":100},[],{"intervention":682,"totalTrials":273,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":984,"NA":990},{"trials":977,"activeCount":100},[],{"trials":979,"activeCount":100},[],{"trials":981,"activeCount":100},[],{"trials":983,"activeCount":100},[],{"trials":985,"activeCount":273,"soonestReadout":677},[986],{"nctId":674,"briefTitle":675,"status":142,"phases":987,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":988,"interventions":989},[91],[650],[115,682],{"trials":991,"activeCount":100},[],{"intervention":133,"totalTrials":698,"cells":993},{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":1117,"PHASE3":1349,"PHASE4":1444,"NA":1446},{"trials":995,"activeCount":100},[],{"trials":997,"activeCount":258,"soonestReadout":1088},[998,1008,1018,1033,1037,1048,1059,1073,1084,1095,1104],{"nctId":999,"briefTitle":1000,"status":286,"phases":1001,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":941,"conditions":1004,"interventions":1006},"NCT02651662","A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies",[88],"2026-04-29","2016-01-11",[1005],"Relapsed\u002FRefractory Aggressive B-Cell Lymphoma",[41,1007],"odronextamab",{"nctId":1009,"briefTitle":1010,"status":414,"phases":1011,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":766,"conditions":1014,"interventions":1016},"NCT03580694","Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[88],"2019-12-04","2018-06-27",[1015],"Carcinoma, Non-Small-Cell Lung",[1017,133],"REGN4659",{"nctId":1019,"briefTitle":1020,"status":142,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1027},"NCT03233139","Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies",[88],"2027-09-30","2017-06-21",146,[1026],"Advanced Malignancies",[133,1028,1029,1030,1031,1032,66],"Ipilimumab","Platinum-doublet chemotherapy","Gemcitabine","Pemetrexed","Paclitaxel",{"nctId":117,"briefTitle":118,"status":106,"phases":1034,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":1035,"interventions":1036},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"nctId":1038,"briefTitle":1039,"status":286,"phases":1040,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1046},"NCT03005782","Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers",[88],"2024-04-02","2016-11-07",333,[1045],"Malignancies",[1047,41],"REGN3767",{"nctId":1049,"briefTitle":1050,"status":414,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1057},"NCT04465487","Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies",[88],"2025-02-07","2020-10-05",38,[1056],"Squamous Cell Carcinoma of Head and Neck",[1058,133],"REGN6569",{"nctId":1060,"briefTitle":1061,"status":286,"phases":1062,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1068},"NCT02383212","Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies",[88],"2019-11-18","2015-02-02",398,[1067,1026],"Advanced Cancer",[133,1069,1070,1071,1072,1032,1031],"Cyclophosphamide","Docetaxel","Carboplatin","GM-CSF",{"nctId":1074,"briefTitle":1075,"status":286,"phases":1076,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1083},"NCT03889912","Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma",[88],"2025-11-13","2025-12-10","2019-04-11",97,[34,1082],"Basal Cell Carcinoma",[133],{"nctId":1085,"briefTitle":1086,"status":106,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":743,"conditions":1090,"interventions":1093},"NCT05259709","A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab",[88],"2027-01-06","2023-02-07",[1091,1092],"Advanced Solid Tumor","Metastatic Solid Tumor",[1094,41],"89Zr˗DFO˗REGN5054",{"nctId":1096,"briefTitle":1097,"status":414,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":832,"enrollment":268,"conditions":1100,"interventions":1102},"NCT04982224","Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer",[88],"2025-10-15",[1101],"Advanced NSCLC",[1103,133],"REGN5093-M114",{"nctId":1105,"briefTitle":1106,"status":106,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1115},"NCT06469281","A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers",[88],"2030-05-27","2024-08-06",90,[1112,1113,1114],"Epithelial Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Cancer",[133,1116],"Bevacizumab",{"trials":1118,"activeCount":1348,"soonestReadout":40},[1119,1131,1142,1153,1166,1180,1191,1203,1215,1224,1235,1245,1257,1269,1281,1291,1303,1315,1319,1327,1339],{"nctId":1120,"briefTitle":1121,"status":106,"phases":1122,"primaryCompletion":1123,"completion":1124,"start":1125,"enrollment":679,"conditions":1126,"interventions":1128},"NCT06465329","A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)",[89],"2027-05-20","2030-05-02","2024-11-18",[1127],"Non-Small Cell Lung Cancer",[133,1129,1130],"Platinum-based chemotherapy","REGN7075",{"nctId":1132,"briefTitle":1133,"status":286,"phases":1134,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1141},"NCT03132636","PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy",[89],"2021-05-20","2023-04-27","2017-06-29",138,[1140],"Carcinoma, Basal Cell",[41],{"nctId":1143,"briefTitle":1144,"status":106,"phases":1145,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":197,"conditions":1148,"interventions":1151},"NCT06787612","Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer",[89],"2028-10-30","2025-05-28",[1149,1114,1150],"Ovarian Cancer","Primary Peritoneal Cancer",[963,1116,133,66,1152,945],"PLD",{"nctId":1154,"briefTitle":1155,"status":414,"phases":1156,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":1159,"conditions":1160,"interventions":1164},"NCT04916002","A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer",[89],"2024-10-31","2021-11-30",77,[1161,34,1082,1162,1127,1163],"Merkel Cell Carcinoma","Triple Negative Breast Cancer","Oropharynx Squamous Cell Carcinoma",[1165,41],"vidutolimod",{"nctId":1167,"briefTitle":1168,"status":414,"phases":1169,"primaryCompletion":1170,"completion":1170,"start":538,"enrollment":1171,"conditions":1172,"interventions":1179},"NCT03690869","REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma",[88,89],"2023-05-10",57,[1173,1174,1175,1176,1177,1178],"Relapsed Solid Tumor","Refractory Solid Tumor","Relapsed Central Nervous System Tumor","Refractory Central Nervous System Tumor","Diffuse Intrinsic Pontine Glioma","High Grade Glioma",[41,41],{"nctId":1181,"briefTitle":1182,"status":142,"phases":1183,"primaryCompletion":1184,"completion":1185,"start":1186,"enrollment":1187,"conditions":1188,"interventions":1189},"NCT06190951","A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma",[89],"2026-11-02","2030-12-09","2024-09-18",151,[29],[41,1190],"Fixed Dose Combination (FDC) cemiplimab+fianlimab",{"nctId":1192,"briefTitle":1193,"status":218,"phases":1194,"primaryCompletion":1195,"completion":1196,"start":1197,"enrollment":679,"conditions":1198,"interventions":1201},"NCT07567469","A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma",[88,89],"2032-08-27","2034-08-17","2026-08-31",[1199,1200],"High-Grade Glioma (HGG)","Posterior Fossa-A Ependymoma",[133,1202],"Cemiplimab+Fianlimab Fixed Dose Combination",{"nctId":1204,"briefTitle":1205,"status":286,"phases":1206,"primaryCompletion":1207,"completion":1208,"start":1209,"enrollment":1210,"conditions":1211,"interventions":1213},"NCT04646005","Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent\u002FMetastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy",[89],"2023-05-22","2024-05-29","2021-06-28",113,[1212],"Cervical Cancer",[133,1214],"ISA101b",{"nctId":1216,"briefTitle":1217,"status":286,"phases":1218,"primaryCompletion":821,"completion":821,"start":1219,"enrollment":1220,"conditions":1221,"interventions":1223},"NCT02760498","Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma",[89],"2016-04-07",432,[1222],"Advanced Cutaneous Squamous Cell Carcinoma",[41],{"nctId":1225,"briefTitle":1226,"status":106,"phases":1227,"primaryCompletion":1228,"completion":1229,"start":1230,"enrollment":679,"conditions":1231,"interventions":1233},"NCT06769698","A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[89],"2028-06-04","2030-12-28","2026-04-14",[1232],"Head and Neck Squamous Cell Carcinoma (HNSCC)",[1234,133],"FDC fianlimab+cemiplimab",{"nctId":1236,"briefTitle":1237,"status":286,"phases":1238,"primaryCompletion":1239,"completion":1240,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1244},"NCT04154943","Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma",[89],"2021-12-01","2025-11-19","2020-03-10",79,[34],[133],{"nctId":1246,"briefTitle":1247,"status":106,"phases":1248,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1254},"NCT04590326","A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab",[88,89],"2027-03-25","2027-11-30","2020-12-08",612,[1149,1114,1150,960],[1255,133,963,945,1256],"REGN5668","Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]",{"nctId":1258,"briefTitle":1259,"status":106,"phases":1260,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":1263,"conditions":1264,"interventions":1267},"NCT03972657","A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors",[88,89],"2027-11-15","2019-08-12",345,[1265,1266],"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Clear Cell Renal Cell Carcinoma (ccRCC)",[1268,133],"REGN5678",{"nctId":1270,"briefTitle":1271,"status":106,"phases":1272,"primaryCompletion":1273,"completion":1273,"start":1274,"enrollment":1275,"conditions":1276,"interventions":1279},"NCT06413680","A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body",[88,89],"2030-02-03","2024-09-23",240,[29,1277,1278],"Clear-Cell Renal-Cell Carcinoma (ccRCC)","Advanced Solid Tumors",[1280,133],"REGN10597",{"nctId":1282,"briefTitle":1283,"status":655,"phases":1284,"primaryCompletion":1285,"completion":1286,"start":1287,"enrollment":100,"conditions":1288,"interventions":1290},"NCT04373083","Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma",[89],"2022-12-20","2025-02-20","2020-11-15",[1289],"Hodgkin Lymphoma",[133],{"nctId":38,"briefTitle":39,"status":142,"phases":1292,"primaryCompletion":40,"completion":1293,"start":1294,"enrollment":1295,"conditions":1296,"interventions":1300},[89],"2030-05-14","2019-07-23",65,[1297,1298,1299],"Non-small Cell Lung Cancer","Hepatocellular Carcinoma","Head and Neck Squamous Cell Carcinoma",[41,1301,1302],"Platinum Doublet","fianlimab",{"nctId":1304,"briefTitle":1305,"status":142,"phases":1306,"primaryCompletion":1307,"completion":1308,"start":1309,"enrollment":1310,"conditions":1311,"interventions":1313},"NCT05557591","A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)",[89],"2028-01-26","2028-05-16","2023-04-21",51,[1312],"Advanced Non-Small Cell Lung Cancer",[1314,133],"BNT116",{"nctId":949,"briefTitle":950,"status":106,"phases":1316,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":1317,"interventions":1318},[88,89],[956,957,958,959,960,961],[963,133,945,272],{"nctId":1320,"briefTitle":1321,"status":655,"phases":1322,"primaryCompletion":1323,"completion":1324,"start":667,"enrollment":100,"conditions":1325,"interventions":1326},"NCT06384820","Study of Cemiplimab Alone or in Combination With Fianlimab and\u002For Other Experimental Agents in Adult Participants With Peri-operative Stage III\u002FIV Cutaneous Squamous Cell Carcinoma (CSCC)",[89],"2026-06-08","2030-05-06",[34],[41,1302],{"nctId":1328,"briefTitle":1329,"status":106,"phases":1330,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1336},"NCT04626635","A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers",[88,89],"2026-08-19","2027-04-07","2020-12-21",933,[1278],[1130,133,1337,1116,1338],"Platinum-based doublet chemotherapy","Trifluridine-tipiracil",{"nctId":73,"briefTitle":74,"status":142,"phases":1340,"primaryCompletion":75,"completion":1341,"start":1342,"enrollment":1343,"conditions":1344,"interventions":1346},[89],"2029-11-04","2024-07-16",195,[1345],"Resectable Non-small Cell Lung Cancer",[66,133,1031,1032,1071,1347],"Cisplatin",13,{"trials":1350,"activeCount":35,"soonestReadout":65},[1351,1359,1369,1378,1388,1399,1409,1422,1435],{"nctId":63,"briefTitle":64,"status":142,"phases":1352,"primaryCompletion":65,"completion":1353,"start":1354,"enrollment":1355,"conditions":1356,"interventions":1357},[90],"2031-09-16","2022-07-14",1546,[29],[66,133,1358],"Pembrolizumab",{"nctId":1360,"briefTitle":1361,"status":106,"phases":1362,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1368},"NCT06585410","Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma",[90],"2030-05-03","2025-01-02",369,[1367],"Cutaneous Squamous Cell Carcinoma (CSCC)",[133],{"nctId":1370,"briefTitle":1371,"status":142,"phases":1372,"primaryCompletion":1308,"completion":1373,"start":1374,"enrollment":1375,"conditions":1376,"interventions":1377},"NCT05608291","A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery",[90],"2030-02-15","2023-01-16",1564,[29],[66,133,1358],{"nctId":1379,"briefTitle":1380,"status":142,"phases":1381,"primaryCompletion":1382,"completion":1383,"start":1384,"enrollment":1385,"conditions":1386,"interventions":1387},"NCT05785767","A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)",[89,90],"2030-03-11","2032-02-05","2023-06-30",850,[1312],[1302,41],{"nctId":1389,"briefTitle":1390,"status":106,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1397},"NCT06246916","A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",[90],"2027-03-22","2033-07-10","2024-09-09",560,[29],[1302,41,1398],"relatlimab+nivolumab",{"nctId":1400,"briefTitle":1401,"status":142,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1408},"NCT05800015","A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer",[89,90],"2030-01-16","2031-12-23","2023-08-08",950,[1297],[1302,41,1031,1032,1071,1347],{"nctId":1410,"briefTitle":1411,"status":286,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1421},"NCT03088540","Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)",[90],"2025-04-18","2017-05-29",712,[1417,1418,1419,1420],"Carcinoma，Non-Small-Cell Lung","Lung Carcinomas, Non-Small-Cell","Non-small-cell Lung Carcinoma","Nonsmall Cell Lung Cancer",[1031,1032,1030,1347,1071,41],{"nctId":1423,"briefTitle":1424,"status":286,"phases":1425,"primaryCompletion":1426,"completion":1427,"start":1428,"enrollment":1429,"conditions":1430,"interventions":1433},"NCT03257267","Study of Cemiplimab in Adults With Cervical Cancer",[90],"2021-03-15","2023-04-20","2017-09-05",608,[1431,1432],"Squamous Cell Carcinoma (SCC)","Recurrent or Metastatic, Platinum-refractory Cervical Cancer",[133,1434],"Investigator Choice (IC) Chemotherapy",{"nctId":1436,"briefTitle":1437,"status":142,"phases":1438,"primaryCompletion":1439,"completion":1439,"start":1440,"enrollment":1441,"conditions":1442,"interventions":1443},"NCT03969004","Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma",[90],"2028-01-07","2019-06-04",415,[34],[133],{"trials":1445,"activeCount":100},[],{"trials":1447,"activeCount":273,"soonestReadout":1146},[1448,1457,1465,1471],{"nctId":1449,"briefTitle":1450,"status":286,"phases":1451,"primaryCompletion":1452,"completion":1452,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1456},"NCT03836105","CemiplimAb Survivorship Epidemiology",[],"2025-09-29","2019-06-27",287,[34,1082],[41],{"nctId":1458,"briefTitle":1459,"status":688,"phases":1460,"conditions":1461,"interventions":1464},"NCT06132191","Expanded Access Use of Cemiplimab in Patients With Solid Tumors",[],[1462,1463,1367],"Non-Small Cell Lung Cancer (NSCLC)","Basal Cell Carcinoma (BCC)",[133],{"nctId":1466,"briefTitle":1467,"status":918,"phases":1468,"conditions":1469,"interventions":1470},"NCT03492489","Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma",[],[34],[41],{"nctId":1472,"briefTitle":1473,"status":106,"phases":1474,"primaryCompletion":1146,"completion":1146,"start":1475,"enrollment":1476,"conditions":1477,"interventions":1478},"NCT05363319","An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe",[],"2022-10-26",500,[1297],[133,1129],{"intervention":66,"totalTrials":11,"cells":1480},{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1493,"PHASE3":1511,"PHASE4":1533,"NA":1535},{"trials":1482,"activeCount":100},[],{"trials":1484,"activeCount":136,"soonestReadout":1022},[1485,1489],{"nctId":1019,"briefTitle":1020,"status":142,"phases":1486,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1487,"interventions":1488},[88],[1026],[133,1028,1029,1030,1031,1032,66],{"nctId":117,"briefTitle":118,"status":106,"phases":1490,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":1491,"interventions":1492},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"trials":1494,"activeCount":763,"soonestReadout":40},[1495,1499,1503,1507],{"nctId":1143,"briefTitle":1144,"status":106,"phases":1496,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":197,"conditions":1497,"interventions":1498},[89],[1149,1114,1150],[963,1116,133,66,1152,945],{"nctId":38,"briefTitle":39,"status":142,"phases":1500,"primaryCompletion":40,"completion":1293,"start":1294,"enrollment":1295,"conditions":1501,"interventions":1502},[89],[1297,1298,1299],[41,1301,1302],{"nctId":1320,"briefTitle":1321,"status":655,"phases":1504,"primaryCompletion":1323,"completion":1324,"start":667,"enrollment":100,"conditions":1505,"interventions":1506},[89],[34],[41,1302],{"nctId":73,"briefTitle":74,"status":142,"phases":1508,"primaryCompletion":75,"completion":1341,"start":1342,"enrollment":1343,"conditions":1509,"interventions":1510},[89],[1345],[66,133,1031,1032,1071,1347],{"trials":1512,"activeCount":895,"soonestReadout":65},[1513,1517,1521,1525,1529],{"nctId":63,"briefTitle":64,"status":142,"phases":1514,"primaryCompletion":65,"completion":1353,"start":1354,"enrollment":1355,"conditions":1515,"interventions":1516},[90],[29],[66,133,1358],{"nctId":1370,"briefTitle":1371,"status":142,"phases":1518,"primaryCompletion":1308,"completion":1373,"start":1374,"enrollment":1375,"conditions":1519,"interventions":1520},[90],[29],[66,133,1358],{"nctId":1379,"briefTitle":1380,"status":142,"phases":1522,"primaryCompletion":1382,"completion":1383,"start":1384,"enrollment":1385,"conditions":1523,"interventions":1524},[89,90],[1312],[1302,41],{"nctId":1389,"briefTitle":1390,"status":106,"phases":1526,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1527,"interventions":1528},[90],[29],[1302,41,1398],{"nctId":1400,"briefTitle":1401,"status":142,"phases":1530,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":1531,"interventions":1532},[89,90],[1297],[1302,41,1031,1032,1071,1347],{"trials":1534,"activeCount":100},[],{"trials":1536,"activeCount":100},[],{"intervention":1538,"totalTrials":27,"cells":1539},"Odronextamab",{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1569,"PHASE3":1582,"PHASE4":1647,"NA":1649},{"trials":1541,"activeCount":100},[],{"trials":1543,"activeCount":136,"soonestReadout":1563},[1544,1548,1559],{"nctId":999,"briefTitle":1000,"status":286,"phases":1545,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":941,"conditions":1546,"interventions":1547},[88],[1005],[41,1007],{"nctId":1549,"briefTitle":1550,"status":106,"phases":1551,"primaryCompletion":1552,"completion":1553,"start":1427,"enrollment":1554,"conditions":1555,"interventions":1557},"NCT05685173","A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas",[88],"2029-02-16","2030-01-13",107,[1556],"B-cell Non-Hodgkins Lymphoma (B-NHL)",[1538,1558],"REGN5837",{"nctId":1560,"briefTitle":1561,"status":106,"phases":1562,"primaryCompletion":1563,"completion":1563,"start":1564,"enrollment":1110,"conditions":1565,"interventions":1567},"NCT06975787","Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis",[88],"2028-07-23","2025-12-22",[1566],"Lupus Nephritis (LN)",[1568,1538],"Vonsetamig",{"trials":1570,"activeCount":273,"soonestReadout":1575},[1571],{"nctId":1572,"briefTitle":1573,"status":142,"phases":1574,"primaryCompletion":1575,"completion":1576,"start":1577,"enrollment":1578,"conditions":1579,"interventions":1581},"NCT03888105","A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies",[89],"2026-07-06","2028-12-15","2019-11-13",515,[1580],"B-cell Non-Hodgkin Lymphoma (B-NHL)",[1538],{"trials":1583,"activeCount":895,"soonestReadout":1602},[1584,1598,1610,1624,1636],{"nctId":1585,"briefTitle":1586,"status":142,"phases":1587,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":1591,"interventions":1593},"NCT06097364","A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma",[90],"2029-07-29","2023-11-14",733,[1592],"Follicular Lymphoma (FL)",[1538,1594,1069,1595,1596,1597],"Rituximab","Doxorubicin","Vincristine","Prednisone\u002FPrenisolone",{"nctId":1599,"briefTitle":1600,"status":106,"phases":1601,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":1605,"conditions":1606,"interventions":1607},"NCT06091254","A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma",[90],"2028-02-07","2029-11-03","2023-12-12",822,[1592],[1538,1594,1069,1595,1596,1608,1609],"Prednisone\u002Fprednisolone","Bendamustine",{"nctId":1611,"briefTitle":1612,"status":142,"phases":1613,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1620},"NCT06230224","A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma",[90],"2028-05-29","2029-05-29","2024-02-15",216,[1619],"B-Cell Non-Hodgkin Lymphoma (B-NHL)",[1538,1621,1071,1622,1594,226,1347,1623,1030],"Ifosfamide","Etoposide","Cytarabine",{"nctId":1625,"briefTitle":1626,"status":106,"phases":1627,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":1631,"conditions":1632,"interventions":1634},"NCT06091865","A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma",[90],"2028-03-30","2029-09-12","2023-12-13",904,[1633],"Diffuse Large B-cell Lymphoma (DLBCL)",[1538,1594,1069,1595,1596,1635],"Prednisone\u002FPrednisolone",{"nctId":1637,"briefTitle":1638,"status":106,"phases":1639,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":1642,"conditions":1643,"interventions":1646},"NCT06149286","A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",[90],"2029-01-23","2023-12-28",470,[1644,1645],"Relapsed\u002FRefractory Follicular Lymphoma","Relapsed\u002FRefractory Marginal Zone Lymphoma (R\u002FR MZL)",[1538,129,1594],{"trials":1648,"activeCount":100},[],{"trials":1650,"activeCount":100},[1651],{"nctId":1652,"briefTitle":1653,"status":1654,"phases":1655,"conditions":1656,"interventions":1661},"NCT05619367","A Compassionate Use (CU) Program of Odronextamab","AVAILABLE",[],[1657,1658,1659,1660],"Relapsed or Refractory (R\u002FR) Follicular Lymphoma (FL)","Diffuse Large B-Cell Lymphoma (DLBCL)","B-Cell Non-Hodgkin Lymphoma (NHL)","High-Grade B-Cell Lymphoma (HGBCL)",[1538],{"intervention":1663,"totalTrials":11,"cells":1664},"REGN7508",{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1691,"PHASE3":1725,"PHASE4":1788,"NA":1790},{"trials":1666,"activeCount":100},[],{"trials":1668,"activeCount":100},[1669,1682],{"nctId":1670,"briefTitle":1671,"status":286,"phases":1672,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":1676,"conditions":1677,"interventions":1678},"NCT06444178","Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants",[88],"2025-04-07","2025-07-09","2024-09-30",224,[14],[1679,1680,1663,1681],"Aspirin","REGN9933","Rivaroxaban",{"nctId":1683,"briefTitle":1684,"status":286,"phases":1685,"primaryCompletion":1686,"completion":1686,"start":1687,"enrollment":1688,"conditions":1689,"interventions":1690},"NCT05603195","A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants",[88],"2024-09-17","2023-01-12",80,[26],[1663,1663],{"trials":1692,"activeCount":273,"soonestReadout":1706},[1693,1702,1714],{"nctId":1694,"briefTitle":1695,"status":286,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1343,"conditions":1699,"interventions":1701},"NCT06299111","A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)",[89],"2026-03-27","2024-09-20",[1700],"Venous Thromboembolism",[1680,1663],{"nctId":1703,"briefTitle":1704,"status":106,"phases":1705,"primaryCompletion":1706,"completion":1707,"start":1708,"enrollment":1709,"conditions":1710,"interventions":1712},"NCT07175428","Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation",[89],"2027-02-09","2027-04-21","2025-10-20",1200,[1711],"Atrial Fibrillation (AF)",[1663,1680,1713],"Apixaban",{"nctId":1715,"briefTitle":1716,"status":286,"phases":1717,"primaryCompletion":1718,"completion":1719,"start":1720,"enrollment":1721,"conditions":1722,"interventions":1723},"NCT06454630","A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants",[89],"2024-11-19","2025-01-21","2024-06-27",179,[1700],[1663,1724],"Enoxaparin",{"trials":1726,"activeCount":110,"soonestReadout":1783},[1727,1736,1748,1759,1769,1779],{"nctId":1728,"briefTitle":1729,"status":106,"phases":1730,"primaryCompletion":1731,"completion":1731,"start":638,"enrollment":1732,"conditions":1733,"interventions":1735},"NCT07493304","Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers",[90],"2031-07-08",1600,[1734],"Venous Thromboembolism (VTE)",[1663,1713],{"nctId":1737,"briefTitle":1738,"status":106,"phases":1739,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1743,"conditions":1744,"interventions":1746},"NCT07213778","REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants",[90],"2027-05-17","2027-07-16","2025-11-24",2000,[1745],"Symptomatic Venous Thromboembolism (VTE)",[1663,1747],"Acetylsalicylic Acid",{"nctId":1749,"briefTitle":1750,"status":106,"phases":1751,"primaryCompletion":1752,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1758},"NCT07318610","Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease",[90],"2029-08-18","2029-11-16","2026-05-29",7050,[1757],"Peripheral Artery Disease (PAD)",[1663,1680,1681],{"nctId":1760,"briefTitle":1761,"status":106,"phases":1762,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":1767,"interventions":1768},"NCT07430956","Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable",[90],"2029-03-28","2029-06-26","2026-04-03",2628,[1711],[1663,1680],{"nctId":1770,"briefTitle":1771,"status":106,"phases":1772,"primaryCompletion":1773,"completion":1324,"start":1774,"enrollment":1775,"conditions":1776,"interventions":1778},"NCT07410117","REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis",[90],"2030-01-23","2026-03-09",1120,[1777],"Cancer-Associated Thrombosis (CAT)",[1663],{"nctId":1780,"briefTitle":1781,"status":106,"phases":1782,"primaryCompletion":1783,"completion":1784,"start":1785,"enrollment":1743,"conditions":1786,"interventions":1787},"NCT07015905","REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults",[90],"2027-02-20","2027-05-12","2025-06-25",[1734],[1663,1713,1724],{"trials":1789,"activeCount":100},[],{"trials":1791,"activeCount":100},[],{"intervention":1594,"totalTrials":895,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1800,"PHASE4":1822,"NA":1824},{"trials":1795,"activeCount":100},[],{"trials":1797,"activeCount":100},[],{"trials":1799,"activeCount":100},[],{"trials":1801,"activeCount":895,"soonestReadout":1602},[1802,1806,1810,1814,1818],{"nctId":1585,"briefTitle":1586,"status":142,"phases":1803,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":1804,"interventions":1805},[90],[1592],[1538,1594,1069,1595,1596,1597],{"nctId":1599,"briefTitle":1600,"status":106,"phases":1807,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":1605,"conditions":1808,"interventions":1809},[90],[1592],[1538,1594,1069,1595,1596,1608,1609],{"nctId":1611,"briefTitle":1612,"status":142,"phases":1811,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1812,"interventions":1813},[90],[1619],[1538,1621,1071,1622,1594,226,1347,1623,1030],{"nctId":1625,"briefTitle":1626,"status":106,"phases":1815,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":1631,"conditions":1816,"interventions":1817},[90],[1633],[1538,1594,1069,1595,1596,1635],{"nctId":1637,"briefTitle":1638,"status":106,"phases":1819,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":1642,"conditions":1820,"interventions":1821},[90],[1644,1645],[1538,129,1594],{"trials":1823,"activeCount":100},[],{"trials":1825,"activeCount":100},[],{"intervention":780,"totalTrials":11,"cells":1827},{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1840,"PHASE3":1850,"PHASE4":1876,"NA":1878},{"trials":1829,"activeCount":100},[],{"trials":1831,"activeCount":100},[1832,1836],{"nctId":773,"briefTitle":774,"status":286,"phases":1833,"primaryCompletion":364,"completion":364,"start":776,"enrollment":777,"conditions":1834,"interventions":1835},[88],[20],[765,780],{"nctId":791,"briefTitle":792,"status":286,"phases":1837,"primaryCompletion":794,"completion":794,"start":795,"enrollment":268,"conditions":1838,"interventions":1839},[88],[20],[765,780],{"trials":1841,"activeCount":100},[1842,1846],{"nctId":809,"briefTitle":810,"status":286,"phases":1843,"primaryCompletion":812,"completion":813,"start":605,"enrollment":110,"conditions":1844,"interventions":1845},[89],[31],[765,780],{"nctId":817,"briefTitle":818,"status":286,"phases":1847,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":1848,"interventions":1849},[89],[31],[765,780],{"trials":1851,"activeCount":895,"soonestReadout":45},[1852,1856,1860,1864,1868,1872],{"nctId":840,"briefTitle":841,"status":106,"phases":1853,"primaryCompletion":843,"completion":844,"start":845,"enrollment":846,"conditions":1854,"interventions":1855},[90],[848,788],[765,780],{"nctId":851,"briefTitle":852,"status":142,"phases":1857,"primaryCompletion":854,"completion":855,"start":856,"enrollment":607,"conditions":1858,"interventions":1859},[90],[31],[859,765,780,860],{"nctId":862,"briefTitle":863,"status":106,"phases":1861,"primaryCompletion":865,"completion":865,"start":866,"enrollment":607,"conditions":1862,"interventions":1863},[90],[31],[765,780],{"nctId":870,"briefTitle":871,"status":106,"phases":1865,"primaryCompletion":873,"completion":874,"start":875,"enrollment":876,"conditions":1866,"interventions":1867},[90],[31],[765,780],{"nctId":880,"briefTitle":881,"status":414,"phases":1869,"primaryCompletion":883,"completion":883,"start":884,"enrollment":763,"conditions":1870,"interventions":1871},[90],[31],[780,860,765,859],{"nctId":43,"briefTitle":44,"status":142,"phases":1873,"primaryCompletion":45,"completion":889,"start":890,"enrollment":891,"conditions":1874,"interventions":1875},[90],[893],[46,780,765],{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":100},[1880],{"nctId":916,"briefTitle":917,"status":918,"phases":1881,"conditions":1882,"interventions":1883},[],[31],[765,780],{"intervention":127,"totalTrials":258,"cells":1885},{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1894,"PHASE3":1896,"PHASE4":1910,"NA":1912},{"trials":1887,"activeCount":100},[],{"trials":1889,"activeCount":273,"soonestReadout":120},[1890],{"nctId":117,"briefTitle":118,"status":106,"phases":1891,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":1892,"interventions":1893},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":763,"soonestReadout":251},[1898,1902,1906],{"nctId":216,"briefTitle":217,"status":218,"phases":1899,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":1900,"interventions":1901},[89,90],[224],[95,130,129,127,226],{"nctId":228,"briefTitle":229,"status":218,"phases":1903,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":1904,"interventions":1905},[90],[235],[95,127],{"nctId":248,"briefTitle":249,"status":106,"phases":1907,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":1908,"interventions":1909},[90],[256],[95,128,127,226,131,130],{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[],{"intervention":226,"totalTrials":258,"cells":1915},{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1922,"PHASE4":1940,"NA":1942},{"trials":1917,"activeCount":100},[],{"trials":1919,"activeCount":100},[],{"trials":1921,"activeCount":100},[],{"trials":1923,"activeCount":258,"soonestReadout":1614},[1924,1928,1932,1936],{"nctId":216,"briefTitle":217,"status":218,"phases":1925,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":1926,"interventions":1927},[89,90],[224],[95,130,129,127,226],{"nctId":1611,"briefTitle":1612,"status":142,"phases":1929,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":1930,"interventions":1931},[90],[1619],[1538,1621,1071,1622,1594,226,1347,1623,1030],{"nctId":238,"briefTitle":239,"status":106,"phases":1933,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":1934,"interventions":1935},[90],[168],[95,246,131,226],{"nctId":248,"briefTitle":249,"status":106,"phases":1937,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":1938,"interventions":1939},[90],[256],[95,128,127,226,131,130],{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[],{"intervention":1945,"totalTrials":258,"cells":1946},"Mibavademab",{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1964,"PHASE4":1998,"NA":2000},{"trials":1948,"activeCount":100},[],{"trials":1950,"activeCount":100},[],{"trials":1952,"activeCount":273,"soonestReadout":1957},[1953],{"nctId":1954,"briefTitle":1955,"status":106,"phases":1956,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":1961,"interventions":1963},"NCT07235917","A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea",[89],"2027-08-20","2027-12-08","2026-03-11",34,[1962],"Functional Hypothalamic Amenorrhea (FHA)",[1945],{"trials":1965,"activeCount":763,"soonestReadout":1970},[1966,1978,1988],{"nctId":1967,"briefTitle":1968,"status":142,"phases":1969,"primaryCompletion":1970,"completion":1971,"start":1972,"enrollment":1973,"conditions":1974,"interventions":1976},"NCT06548100","A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)",[90],"2026-07-14","2026-11-03","2024-12-16",9,[1975],"Generalized Lipodystrophy",[1977],"mibavademab",{"nctId":1979,"briefTitle":1980,"status":106,"phases":1981,"primaryCompletion":1982,"completion":1983,"start":1984,"enrollment":258,"conditions":1985,"interventions":1987},"NCT07220772","A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults",[90],"2027-06-18","2028-04-21","2026-02-09",[1986],"Monogenic Obesity",[1945],{"nctId":1989,"briefTitle":1990,"status":106,"phases":1991,"primaryCompletion":1992,"completion":1993,"start":1994,"enrollment":1995,"conditions":1996,"interventions":1997},"NCT07220785","Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy",[90],"2028-05-19","2028-09-08","2026-03-13",28,[1975],[1945],{"trials":1999,"activeCount":100},[],{"trials":2001,"activeCount":100},[],{"intervention":1680,"totalTrials":35,"cells":2003},{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2021,"PHASE3":2041,"PHASE4":2051,"NA":2053},{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":100},[2008,2012],{"nctId":1670,"briefTitle":1671,"status":286,"phases":2009,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":1676,"conditions":2010,"interventions":2011},[88],[14],[1679,1680,1663,1681],{"nctId":2013,"briefTitle":2014,"status":286,"phases":2015,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":2019,"interventions":2020},"NCT05102136","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers",[88],"2023-04-04","2021-10-27",56,[14],[1680],{"trials":2022,"activeCount":273,"soonestReadout":1706},[2023,2027,2037],{"nctId":1694,"briefTitle":1695,"status":286,"phases":2024,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1343,"conditions":2025,"interventions":2026},[89],[1700],[1680,1663],{"nctId":2028,"briefTitle":2029,"status":286,"phases":2030,"primaryCompletion":2031,"completion":2031,"start":2032,"enrollment":2033,"conditions":2034,"interventions":2035},"NCT05618808","A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants",[89],"2024-05-27","2023-05-24",373,[1700],[1680,1724,2036],"Apixiban",{"nctId":1703,"briefTitle":1704,"status":106,"phases":2038,"primaryCompletion":1706,"completion":1707,"start":1708,"enrollment":1709,"conditions":2039,"interventions":2040},[89],[1711],[1663,1680,1713],{"trials":2042,"activeCount":136,"soonestReadout":1763},[2043,2047],{"nctId":1749,"briefTitle":1750,"status":106,"phases":2044,"primaryCompletion":1752,"completion":1753,"start":1754,"enrollment":1755,"conditions":2045,"interventions":2046},[90],[1757],[1663,1680,1681],{"nctId":1760,"briefTitle":1761,"status":106,"phases":2048,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":2049,"interventions":2050},[90],[1711],[1663,1680],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"intervention":1031,"totalTrials":110,"cells":2056},{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2069,"PHASE3":2086,"PHASE4":2096,"NA":2098},{"trials":2058,"activeCount":100},[],{"trials":2060,"activeCount":273,"soonestReadout":1022},[2061,2065],{"nctId":1019,"briefTitle":1020,"status":142,"phases":2062,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":2063,"interventions":2064},[88],[1026],[133,1028,1029,1030,1031,1032,66],{"nctId":1060,"briefTitle":1061,"status":286,"phases":2066,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":2067,"interventions":2068},[88],[1067,1026],[133,1069,1070,1071,1072,1032,1031],{"trials":2070,"activeCount":273,"soonestReadout":75},[2071,2082],{"nctId":2072,"briefTitle":2073,"status":414,"phases":2074,"primaryCompletion":2075,"completion":2075,"start":2076,"enrollment":2077,"conditions":2078,"interventions":2080},"NCT00794417","A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma",[88,89],"2011-06-30","2008-11-30",60,[2079,1297],"Advanced Carcinoma",[2081,1031,1347],"Aflibercept",{"nctId":73,"briefTitle":74,"status":142,"phases":2083,"primaryCompletion":75,"completion":1341,"start":1342,"enrollment":1343,"conditions":2084,"interventions":2085},[89],[1345],[66,133,1031,1032,1071,1347],{"trials":2087,"activeCount":273,"soonestReadout":1403},[2088,2092],{"nctId":1400,"briefTitle":1401,"status":142,"phases":2089,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":2090,"interventions":2091},[89,90],[1297],[1302,41,1031,1032,1071,1347],{"nctId":1410,"briefTitle":1411,"status":286,"phases":2093,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":2094,"interventions":2095},[90],[1417,1418,1419,1420],[1031,1032,1030,1347,1071,41],{"trials":2097,"activeCount":100},[],{"trials":2099,"activeCount":100},[],{"intervention":1032,"totalTrials":895,"cells":2101},{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2114,"PHASE3":2120,"PHASE4":2130,"NA":2132},{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":273,"soonestReadout":1022},[2106,2110],{"nctId":1019,"briefTitle":1020,"status":142,"phases":2107,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":2108,"interventions":2109},[88],[1026],[133,1028,1029,1030,1031,1032,66],{"nctId":1060,"briefTitle":1061,"status":286,"phases":2111,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":2112,"interventions":2113},[88],[1067,1026],[133,1069,1070,1071,1072,1032,1031],{"trials":2115,"activeCount":273,"soonestReadout":75},[2116],{"nctId":73,"briefTitle":74,"status":142,"phases":2117,"primaryCompletion":75,"completion":1341,"start":1342,"enrollment":1343,"conditions":2118,"interventions":2119},[89],[1345],[66,133,1031,1032,1071,1347],{"trials":2121,"activeCount":273,"soonestReadout":1403},[2122,2126],{"nctId":1400,"briefTitle":1401,"status":142,"phases":2123,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":2124,"interventions":2125},[89,90],[1297],[1302,41,1031,1032,1071,1347],{"nctId":1410,"briefTitle":1411,"status":286,"phases":2127,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":2128,"interventions":2129},[90],[1417,1418,1419,1420],[1031,1032,1030,1347,1071,41],{"trials":2131,"activeCount":100},[],{"trials":2133,"activeCount":100},[],{"intervention":1347,"totalTrials":895,"cells":2135},{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2150,"PHASE4":2164,"NA":2166},{"trials":2137,"activeCount":100},[],{"trials":2139,"activeCount":100},[],{"trials":2141,"activeCount":273,"soonestReadout":75},[2142,2146],{"nctId":2072,"briefTitle":2073,"status":414,"phases":2143,"primaryCompletion":2075,"completion":2075,"start":2076,"enrollment":2077,"conditions":2144,"interventions":2145},[88,89],[2079,1297],[2081,1031,1347],{"nctId":73,"briefTitle":74,"status":142,"phases":2147,"primaryCompletion":75,"completion":1341,"start":1342,"enrollment":1343,"conditions":2148,"interventions":2149},[89],[1345],[66,133,1031,1032,1071,1347],{"trials":2151,"activeCount":136,"soonestReadout":1614},[2152,2156,2160],{"nctId":1611,"briefTitle":1612,"status":142,"phases":2153,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":2154,"interventions":2155},[90],[1619],[1538,1621,1071,1622,1594,226,1347,1623,1030],{"nctId":1400,"briefTitle":1401,"status":142,"phases":2157,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":2158,"interventions":2159},[89,90],[1297],[1302,41,1031,1032,1071,1347],{"nctId":1410,"briefTitle":1411,"status":286,"phases":2161,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":2162,"interventions":2163},[90],[1417,1418,1419,1420],[1031,1032,1030,1347,1071,41],{"trials":2165,"activeCount":100},[],{"trials":2167,"activeCount":100},[],{"intervention":1071,"totalTrials":895,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2178,"PHASE3":2184,"PHASE4":2198,"NA":2200},{"trials":2171,"activeCount":100},[],{"trials":2173,"activeCount":100},[2174],{"nctId":1060,"briefTitle":1061,"status":286,"phases":2175,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":2176,"interventions":2177},[88],[1067,1026],[133,1069,1070,1071,1072,1032,1031],{"trials":2179,"activeCount":273,"soonestReadout":75},[2180],{"nctId":73,"briefTitle":74,"status":142,"phases":2181,"primaryCompletion":75,"completion":1341,"start":1342,"enrollment":1343,"conditions":2182,"interventions":2183},[89],[1345],[66,133,1031,1032,1071,1347],{"trials":2185,"activeCount":136,"soonestReadout":1614},[2186,2190,2194],{"nctId":1611,"briefTitle":1612,"status":142,"phases":2187,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":2188,"interventions":2189},[90],[1619],[1538,1621,1071,1622,1594,226,1347,1623,1030],{"nctId":1400,"briefTitle":1401,"status":142,"phases":2191,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":2192,"interventions":2193},[89,90],[1297],[1302,41,1031,1032,1071,1347],{"nctId":1410,"briefTitle":1411,"status":286,"phases":2195,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":2196,"interventions":2197},[90],[1417,1418,1419,1420],[1031,1032,1030,1347,1071,41],{"trials":2199,"activeCount":100},[],{"trials":2201,"activeCount":100},[],{"intervention":1069,"totalTrials":258,"cells":2203},{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2212,"PHASE3":2214,"PHASE4":2228,"NA":2230},{"trials":2205,"activeCount":100},[],{"trials":2207,"activeCount":100},[2208],{"nctId":1060,"briefTitle":1061,"status":286,"phases":2209,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":2210,"interventions":2211},[88],[1067,1026],[133,1069,1070,1071,1072,1032,1031],{"trials":2213,"activeCount":100},[],{"trials":2215,"activeCount":763,"soonestReadout":1602},[2216,2220,2224],{"nctId":1585,"briefTitle":1586,"status":142,"phases":2217,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":2218,"interventions":2219},[90],[1592],[1538,1594,1069,1595,1596,1597],{"nctId":1599,"briefTitle":1600,"status":106,"phases":2221,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":1605,"conditions":2222,"interventions":2223},[90],[1592],[1538,1594,1069,1595,1596,1608,1609],{"nctId":1625,"briefTitle":1626,"status":106,"phases":2225,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":1631,"conditions":2226,"interventions":2227},[90],[1633],[1538,1594,1069,1595,1596,1635],{"trials":2229,"activeCount":100},[],{"trials":2231,"activeCount":100},[],{"intervention":1595,"totalTrials":763,"cells":2233},{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2240,"PHASE4":2254,"NA":2256},{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[],{"trials":2239,"activeCount":100},[],{"trials":2241,"activeCount":763,"soonestReadout":1602},[2242,2246,2250],{"nctId":1585,"briefTitle":1586,"status":142,"phases":2243,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":2244,"interventions":2245},[90],[1592],[1538,1594,1069,1595,1596,1597],{"nctId":1599,"briefTitle":1600,"status":106,"phases":2247,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":1605,"conditions":2248,"interventions":2249},[90],[1592],[1538,1594,1069,1595,1596,1608,1609],{"nctId":1625,"briefTitle":1626,"status":106,"phases":2251,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":1631,"conditions":2252,"interventions":2253},[90],[1633],[1538,1594,1069,1595,1596,1635],{"trials":2255,"activeCount":100},[],{"trials":2257,"activeCount":100},[],{"intervention":1596,"totalTrials":763,"cells":2259},{"EARLY_PHASE1":2260,"PHASE1":2262,"PHASE2":2264,"PHASE3":2266,"PHASE4":2280,"NA":2282},{"trials":2261,"activeCount":100},[],{"trials":2263,"activeCount":100},[],{"trials":2265,"activeCount":100},[],{"trials":2267,"activeCount":763,"soonestReadout":1602},[2268,2272,2276],{"nctId":1585,"briefTitle":1586,"status":142,"phases":2269,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":2270,"interventions":2271},[90],[1592],[1538,1594,1069,1595,1596,1597],{"nctId":1599,"briefTitle":1600,"status":106,"phases":2273,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":1605,"conditions":2274,"interventions":2275},[90],[1592],[1538,1594,1069,1595,1596,1608,1609],{"nctId":1625,"briefTitle":1626,"status":106,"phases":2277,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":1631,"conditions":2278,"interventions":2279},[90],[1633],[1538,1594,1069,1595,1596,1635],{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[],{"intervention":130,"totalTrials":763,"cells":2285},{"EARLY_PHASE1":2286,"PHASE1":2288,"PHASE2":2294,"PHASE3":2296,"PHASE4":2306,"NA":2308},{"trials":2287,"activeCount":100},[],{"trials":2289,"activeCount":273,"soonestReadout":120},[2290],{"nctId":117,"briefTitle":118,"status":106,"phases":2291,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":2292,"interventions":2293},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"trials":2295,"activeCount":100},[],{"trials":2297,"activeCount":136,"soonestReadout":251},[2298,2302],{"nctId":216,"briefTitle":217,"status":218,"phases":2299,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":2300,"interventions":2301},[89,90],[224],[95,130,129,127,226],{"nctId":248,"briefTitle":249,"status":106,"phases":2303,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":2304,"interventions":2305},[90],[256],[95,128,127,226,131,130],{"trials":2307,"activeCount":100},[],{"trials":2309,"activeCount":100},[],{"intervention":129,"totalTrials":763,"cells":2311},{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2320,"PHASE3":2322,"PHASE4":2332,"NA":2334},{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":273,"soonestReadout":120},[2316],{"nctId":117,"briefTitle":118,"status":106,"phases":2317,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":2318,"interventions":2319},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"trials":2321,"activeCount":100},[],{"trials":2323,"activeCount":136,"soonestReadout":1640},[2324,2328],{"nctId":216,"briefTitle":217,"status":218,"phases":2325,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":2326,"interventions":2327},[89,90],[224],[95,130,129,127,226],{"nctId":1637,"briefTitle":1638,"status":106,"phases":2329,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":1642,"conditions":2330,"interventions":2331},[90],[1644,1645],[1538,129,1594],{"trials":2333,"activeCount":100},[],{"trials":2335,"activeCount":100},[],{"intervention":1713,"totalTrials":763,"cells":2337},{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2342,"PHASE3":2348,"PHASE4":2358,"NA":2360},{"trials":2339,"activeCount":100},[],{"trials":2341,"activeCount":100},[],{"trials":2343,"activeCount":273,"soonestReadout":1706},[2344],{"nctId":1703,"briefTitle":1704,"status":106,"phases":2345,"primaryCompletion":1706,"completion":1707,"start":1708,"enrollment":1709,"conditions":2346,"interventions":2347},[89],[1711],[1663,1680,1713],{"trials":2349,"activeCount":136,"soonestReadout":1783},[2350,2354],{"nctId":1728,"briefTitle":1729,"status":106,"phases":2351,"primaryCompletion":1731,"completion":1731,"start":638,"enrollment":1732,"conditions":2352,"interventions":2353},[90],[1734],[1663,1713],{"nctId":1780,"briefTitle":1781,"status":106,"phases":2355,"primaryCompletion":1783,"completion":1784,"start":1785,"enrollment":1743,"conditions":2356,"interventions":2357},[90],[1734],[1663,1713,1724],{"trials":2359,"activeCount":100},[],{"trials":2361,"activeCount":100},[],{"intervention":131,"totalTrials":763,"cells":2363},{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2372,"PHASE3":2374,"PHASE4":2384,"NA":2386},{"trials":2365,"activeCount":100},[],{"trials":2367,"activeCount":273,"soonestReadout":120},[2368],{"nctId":117,"briefTitle":118,"status":106,"phases":2369,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":2370,"interventions":2371},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"trials":2373,"activeCount":100},[],{"trials":2375,"activeCount":136,"soonestReadout":251},[2376,2380],{"nctId":238,"briefTitle":239,"status":106,"phases":2377,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":2378,"interventions":2379},[90],[168],[95,246,131,226],{"nctId":248,"briefTitle":249,"status":106,"phases":2381,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":2382,"interventions":2383},[90],[256],[95,128,127,226,131,130],{"trials":2385,"activeCount":100},[],{"trials":2387,"activeCount":100},[],{"intervention":51,"totalTrials":110,"cells":2389},{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2402,"PHASE3":2413,"PHASE4":2445,"NA":2447},{"trials":2391,"activeCount":100},[],{"trials":2393,"activeCount":100},[2394],{"nctId":2395,"briefTitle":2396,"status":655,"phases":2397,"primaryCompletion":1323,"completion":1323,"start":2398,"enrollment":100,"conditions":2399,"interventions":2401},"NCT06970405","Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women",[88],"2025-05-29",[2400],"Obesity",[51],{"trials":2403,"activeCount":273,"soonestReadout":84},[2404],{"nctId":82,"briefTitle":83,"status":142,"phases":2405,"primaryCompletion":84,"completion":2406,"start":2407,"enrollment":2408,"conditions":2409,"interventions":2410},[89],"2026-10-30","2024-03-13",1005,[2400],[85,2411,51,2412],"Trevogrumab-Part B and Part C","Semaglutide",{"trials":2414,"activeCount":136,"soonestReadout":50},[2415,2427,2435],{"nctId":2416,"briefTitle":2417,"status":655,"phases":2418,"primaryCompletion":2419,"completion":2420,"start":2421,"enrollment":100,"conditions":2422,"interventions":2425},"NCT04577820","Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)",[90],"2022-03-01","2022-10-08","2021-10-13",[2423,2424],"Fibrodyplasia Ossificans Progressiva (FOP)","Heterotopic Ossification (HO)",[2426],"garetosmab",{"nctId":48,"briefTitle":49,"status":142,"phases":2428,"primaryCompletion":50,"completion":2429,"start":2430,"enrollment":2431,"conditions":2432,"interventions":2434},[90],"2029-02-27","2022-11-21",63,[2433],"Fibrodysplasia Ossificans Progressiva",[51],{"nctId":2436,"briefTitle":2437,"status":218,"phases":2438,"primaryCompletion":2439,"completion":2440,"start":2441,"enrollment":18,"conditions":2442,"interventions":2444},"NCT07559513","A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)",[90],"2028-12-10","2029-12-21","2026-07-30",[2443],"Fibrodysplasia Ossificans Progressiva (FOP)",[2426],{"trials":2446,"activeCount":100},[],{"trials":2448,"activeCount":100},[2449],{"nctId":2450,"briefTitle":2451,"status":750,"phases":2452,"conditions":2453,"interventions":2454},"NCT07301450","An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)",[],[2443],[51],{"intervention":1358,"totalTrials":110,"cells":2456},{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2481,"PHASE3":2491,"PHASE4":2510,"NA":2512},{"trials":2458,"activeCount":100},[],{"trials":2460,"activeCount":100},[2461,2472],{"nctId":2462,"briefTitle":2463,"status":286,"phases":2464,"primaryCompletion":2465,"completion":2466,"start":2467,"enrollment":268,"conditions":2468,"interventions":2470},"NCT03084640","Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma",[88],"2021-07-02","2021-09-30","2017-05-04",[2469],"Malignant Melanoma",[2471,1358,2471],"CMP-001",{"nctId":2473,"briefTitle":2474,"status":286,"phases":2475,"primaryCompletion":2476,"completion":2476,"start":2477,"enrollment":2478,"conditions":2479,"interventions":2480},"NCT02680184","Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy",[88],"2022-12-06","2016-04-12",199,[29],[2471,1358],{"trials":2482,"activeCount":100},[2483],{"nctId":2484,"briefTitle":2485,"status":414,"phases":2486,"primaryCompletion":2487,"completion":2487,"start":2488,"enrollment":823,"conditions":2489,"interventions":2490},"NCT04633278","CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[89],"2024-01-19","2021-01-21",[1056],[2471,1358],{"trials":2492,"activeCount":136,"soonestReadout":65},[2493,2497,2501],{"nctId":63,"briefTitle":64,"status":142,"phases":2494,"primaryCompletion":65,"completion":1353,"start":1354,"enrollment":1355,"conditions":2495,"interventions":2496},[90],[29],[66,133,1358],{"nctId":1370,"briefTitle":1371,"status":142,"phases":2498,"primaryCompletion":1308,"completion":1373,"start":1374,"enrollment":1375,"conditions":2499,"interventions":2500},[90],[29],[66,133,1358],{"nctId":2502,"briefTitle":2503,"status":414,"phases":2504,"primaryCompletion":822,"completion":822,"start":2505,"enrollment":895,"conditions":2506,"interventions":2507},"NCT03515629","REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer",[90],"2018-07-02",[1297],[2508,2509,1358],"REGN2810\u002Fipi","REGN2810\u002Fchemo\u002Fipi",{"trials":2511,"activeCount":100},[],{"trials":2513,"activeCount":100},[],{"intervention":1030,"totalTrials":763,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2524,"PHASE3":2526,"PHASE4":2536,"NA":2538},{"trials":2517,"activeCount":100},[],{"trials":2519,"activeCount":273,"soonestReadout":1022},[2520],{"nctId":1019,"briefTitle":1020,"status":142,"phases":2521,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":2522,"interventions":2523},[88],[1026],[133,1028,1029,1030,1031,1032,66],{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":273,"soonestReadout":1614},[2528,2532],{"nctId":1611,"briefTitle":1612,"status":142,"phases":2529,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":2530,"interventions":2531},[90],[1619],[1538,1621,1071,1622,1594,226,1347,1623,1030],{"nctId":1410,"briefTitle":1411,"status":286,"phases":2533,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":2534,"interventions":2535},[90],[1417,1418,1419,1420],[1031,1032,1030,1347,1071,41],{"trials":2537,"activeCount":100},[],{"trials":2539,"activeCount":100},[],{"intervention":1608,"totalTrials":136,"cells":2541},{"EARLY_PHASE1":2542,"PHASE1":2544,"PHASE2":2546,"PHASE3":2548,"PHASE4":2558,"NA":2560},{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[],{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":136,"soonestReadout":1602},[2550,2554],{"nctId":1599,"briefTitle":1600,"status":106,"phases":2551,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":1605,"conditions":2552,"interventions":2553},[90],[1592],[1538,1594,1069,1595,1596,1608,1609],{"nctId":1625,"briefTitle":1626,"status":106,"phases":2555,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":1631,"conditions":2556,"interventions":2557},[90],[1633],[1538,1594,1069,1595,1596,1635],{"trials":2559,"activeCount":100},[],{"trials":2561,"activeCount":100},[],{"intervention":128,"totalTrials":136,"cells":2563},{"EARLY_PHASE1":2564,"PHASE1":2566,"PHASE2":2572,"PHASE3":2574,"PHASE4":2580,"NA":2582},{"trials":2565,"activeCount":100},[],{"trials":2567,"activeCount":273,"soonestReadout":120},[2568],{"nctId":117,"briefTitle":118,"status":106,"phases":2569,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":2570,"interventions":2571},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"trials":2573,"activeCount":100},[],{"trials":2575,"activeCount":273,"soonestReadout":251},[2576],{"nctId":248,"briefTitle":249,"status":106,"phases":2577,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":2578,"interventions":2579},[90],[256],[95,128,127,226,131,130],{"trials":2581,"activeCount":100},[],{"trials":2583,"activeCount":100},[],{"intervention":2585,"totalTrials":258,"cells":2586},"REGN5713",{"EARLY_PHASE1":2587,"PHASE1":2589,"PHASE2":2591,"PHASE3":2604,"PHASE4":2633,"NA":2635},{"trials":2588,"activeCount":100},[],{"trials":2590,"activeCount":100},[],{"trials":2592,"activeCount":100},[2593],{"nctId":2594,"briefTitle":2595,"status":286,"phases":2596,"primaryCompletion":2597,"completion":2597,"start":2598,"enrollment":2599,"conditions":2600,"interventions":2601},"NCT05430919","Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants",[89],"2023-07-31","2022-08-15",217,[356,745],[2585,2602,2603],"REGN5714","REGN5715",{"trials":2605,"activeCount":273,"soonestReadout":2610},[2606,2616,2624],{"nctId":2607,"briefTitle":2608,"status":106,"phases":2609,"primaryCompletion":2610,"completion":2611,"start":2612,"enrollment":760,"conditions":2613,"interventions":2615},"NCT07309432","Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy",[90],"2027-02-28","2027-06-15","2026-01-10",[2614],"Allergic Conjunctivitis",[2585,2603],{"nctId":2617,"briefTitle":2618,"status":286,"phases":2619,"primaryCompletion":2620,"completion":2621,"start":1718,"enrollment":378,"conditions":2622,"interventions":2623},"NCT06602739","A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy",[90],"2025-04-23","2025-08-02",[2614],[2585,2603],{"nctId":2625,"briefTitle":2626,"status":286,"phases":2627,"primaryCompletion":2628,"completion":2628,"start":2629,"enrollment":2630,"conditions":2631,"interventions":2632},"NCT04709575","Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis",[90],"2021-08-24","2021-01-14",353,[356,745],[2585,2602,2603],{"trials":2634,"activeCount":100},[],{"trials":2636,"activeCount":100},[],{"intervention":2603,"totalTrials":258,"cells":2638},{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2649,"PHASE4":2663,"NA":2665},{"trials":2640,"activeCount":100},[],{"trials":2642,"activeCount":100},[],{"trials":2644,"activeCount":100},[2645],{"nctId":2594,"briefTitle":2595,"status":286,"phases":2646,"primaryCompletion":2597,"completion":2597,"start":2598,"enrollment":2599,"conditions":2647,"interventions":2648},[89],[356,745],[2585,2602,2603],{"trials":2650,"activeCount":273,"soonestReadout":2610},[2651,2655,2659],{"nctId":2607,"briefTitle":2608,"status":106,"phases":2652,"primaryCompletion":2610,"completion":2611,"start":2612,"enrollment":760,"conditions":2653,"interventions":2654},[90],[2614],[2585,2603],{"nctId":2617,"briefTitle":2618,"status":286,"phases":2656,"primaryCompletion":2620,"completion":2621,"start":1718,"enrollment":378,"conditions":2657,"interventions":2658},[90],[2614],[2585,2603],{"nctId":2625,"briefTitle":2626,"status":286,"phases":2660,"primaryCompletion":2628,"completion":2628,"start":2629,"enrollment":2630,"conditions":2661,"interventions":2662},[90],[356,745],[2585,2602,2603],{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":100},[],{"intervention":1724,"totalTrials":763,"cells":2668},{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2683,"PHASE4":2689,"NA":2691},{"trials":2670,"activeCount":100},[],{"trials":2672,"activeCount":100},[],{"trials":2674,"activeCount":100},[2675,2679],{"nctId":2028,"briefTitle":2029,"status":286,"phases":2676,"primaryCompletion":2031,"completion":2031,"start":2032,"enrollment":2033,"conditions":2677,"interventions":2678},[89],[1700],[1680,1724,2036],{"nctId":1715,"briefTitle":1716,"status":286,"phases":2680,"primaryCompletion":1718,"completion":1719,"start":1720,"enrollment":1721,"conditions":2681,"interventions":2682},[89],[1700],[1663,1724],{"trials":2684,"activeCount":273,"soonestReadout":1783},[2685],{"nctId":1780,"briefTitle":1781,"status":106,"phases":2686,"primaryCompletion":1783,"completion":1784,"start":1785,"enrollment":1743,"conditions":2687,"interventions":2688},[90],[1734],[1663,1713,1724],{"trials":2690,"activeCount":100},[],{"trials":2692,"activeCount":100},[],{"intervention":1681,"totalTrials":136,"cells":2694},{"EARLY_PHASE1":2695,"PHASE1":2697,"PHASE2":2703,"PHASE3":2705,"PHASE4":2711,"NA":2713},{"trials":2696,"activeCount":100},[],{"trials":2698,"activeCount":100},[2699],{"nctId":1670,"briefTitle":1671,"status":286,"phases":2700,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":1676,"conditions":2701,"interventions":2702},[88],[14],[1679,1680,1663,1681],{"trials":2704,"activeCount":100},[],{"trials":2706,"activeCount":273,"soonestReadout":1752},[2707],{"nctId":1749,"briefTitle":1750,"status":106,"phases":2708,"primaryCompletion":1752,"completion":1753,"start":1754,"enrollment":1755,"conditions":2709,"interventions":2710},[90],[1757],[1663,1680,1681],{"trials":2712,"activeCount":100},[],{"trials":2714,"activeCount":100},[],{"intervention":859,"totalTrials":136,"cells":2716},{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2723,"PHASE4":2733,"NA":2735},{"trials":2718,"activeCount":100},[],{"trials":2720,"activeCount":100},[],{"trials":2722,"activeCount":100},[],{"trials":2724,"activeCount":273,"soonestReadout":854},[2725,2729],{"nctId":851,"briefTitle":852,"status":142,"phases":2726,"primaryCompletion":854,"completion":855,"start":856,"enrollment":607,"conditions":2727,"interventions":2728},[90],[31],[859,765,780,860],{"nctId":880,"briefTitle":881,"status":414,"phases":2730,"primaryCompletion":883,"completion":883,"start":884,"enrollment":763,"conditions":2731,"interventions":2732},[90],[31],[780,860,765,859],{"trials":2734,"activeCount":100},[],{"trials":2736,"activeCount":100},[],{"intervention":860,"totalTrials":136,"cells":2738},{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2745,"PHASE4":2755,"NA":2757},{"trials":2740,"activeCount":100},[],{"trials":2742,"activeCount":100},[],{"trials":2744,"activeCount":100},[],{"trials":2746,"activeCount":273,"soonestReadout":854},[2747,2751],{"nctId":851,"briefTitle":852,"status":142,"phases":2748,"primaryCompletion":854,"completion":855,"start":856,"enrollment":607,"conditions":2749,"interventions":2750},[90],[31],[859,765,780,860],{"nctId":880,"briefTitle":881,"status":414,"phases":2752,"primaryCompletion":883,"completion":883,"start":884,"enrollment":763,"conditions":2753,"interventions":2754},[90],[31],[780,860,765,859],{"trials":2756,"activeCount":100},[],{"trials":2758,"activeCount":100},[],{"intervention":1597,"totalTrials":273,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2773,"NA":2775},{"trials":2762,"activeCount":100},[],{"trials":2764,"activeCount":100},[],{"trials":2766,"activeCount":100},[],{"trials":2768,"activeCount":273,"soonestReadout":1588},[2769],{"nctId":1585,"briefTitle":1586,"status":142,"phases":2770,"primaryCompletion":1588,"completion":1588,"start":1589,"enrollment":1590,"conditions":2771,"interventions":2772},[90],[1592],[1538,1594,1069,1595,1596,1597],{"trials":2774,"activeCount":100},[],{"trials":2776,"activeCount":100},[],{"intervention":1609,"totalTrials":273,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2785,"PHASE4":2791,"NA":2793},{"trials":2780,"activeCount":100},[],{"trials":2782,"activeCount":100},[],{"trials":2784,"activeCount":100},[],{"trials":2786,"activeCount":273,"soonestReadout":1602},[2787],{"nctId":1599,"briefTitle":1600,"status":106,"phases":2788,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":1605,"conditions":2789,"interventions":2790},[90],[1592],[1538,1594,1069,1595,1596,1608,1609],{"trials":2792,"activeCount":100},[],{"trials":2794,"activeCount":100},[],{"intervention":1747,"totalTrials":273,"cells":2796},{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2803,"PHASE4":2809,"NA":2811},{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":273,"soonestReadout":1740},[2805],{"nctId":1737,"briefTitle":1738,"status":106,"phases":2806,"primaryCompletion":1740,"completion":1741,"start":1742,"enrollment":1743,"conditions":2807,"interventions":2808},[90],[1745],[1663,1747],{"trials":2810,"activeCount":100},[],{"trials":2812,"activeCount":100},[],{"intervention":1398,"totalTrials":273,"cells":2814},{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2821,"PHASE4":2827,"NA":2829},{"trials":2816,"activeCount":100},[],{"trials":2818,"activeCount":100},[],{"trials":2820,"activeCount":100},[],{"trials":2822,"activeCount":273,"soonestReadout":1392},[2823],{"nctId":1389,"briefTitle":1390,"status":106,"phases":2824,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":2825,"interventions":2826},[90],[29],[1302,41,1398],{"trials":2828,"activeCount":100},[],{"trials":2830,"activeCount":100},[],{"intervention":1621,"totalTrials":273,"cells":2832},{"EARLY_PHASE1":2833,"PHASE1":2835,"PHASE2":2837,"PHASE3":2839,"PHASE4":2845,"NA":2847},{"trials":2834,"activeCount":100},[],{"trials":2836,"activeCount":100},[],{"trials":2838,"activeCount":100},[],{"trials":2840,"activeCount":273,"soonestReadout":1614},[2841],{"nctId":1611,"briefTitle":1612,"status":142,"phases":2842,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":2843,"interventions":2844},[90],[1619],[1538,1621,1071,1622,1594,226,1347,1623,1030],{"trials":2846,"activeCount":100},[],{"trials":2848,"activeCount":100},[],{"intervention":1622,"totalTrials":273,"cells":2850},{"EARLY_PHASE1":2851,"PHASE1":2853,"PHASE2":2855,"PHASE3":2857,"PHASE4":2863,"NA":2865},{"trials":2852,"activeCount":100},[],{"trials":2854,"activeCount":100},[],{"trials":2856,"activeCount":100},[],{"trials":2858,"activeCount":273,"soonestReadout":1614},[2859],{"nctId":1611,"briefTitle":1612,"status":142,"phases":2860,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":2861,"interventions":2862},[90],[1619],[1538,1621,1071,1622,1594,226,1347,1623,1030],{"trials":2864,"activeCount":100},[],{"trials":2866,"activeCount":100},[],{"intervention":1623,"totalTrials":273,"cells":2868},{"EARLY_PHASE1":2869,"PHASE1":2871,"PHASE2":2873,"PHASE3":2875,"PHASE4":2881,"NA":2883},{"trials":2870,"activeCount":100},[],{"trials":2872,"activeCount":100},[],{"trials":2874,"activeCount":100},[],{"trials":2876,"activeCount":273,"soonestReadout":1614},[2877],{"nctId":1611,"briefTitle":1612,"status":142,"phases":2878,"primaryCompletion":1614,"completion":1615,"start":1616,"enrollment":1617,"conditions":2879,"interventions":2880},[90],[1619],[1538,1621,1071,1622,1594,226,1347,1623,1030],{"trials":2882,"activeCount":100},[],{"trials":2884,"activeCount":100},[],{"intervention":246,"totalTrials":273,"cells":2886},{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2893,"PHASE4":2899,"NA":2901},{"trials":2888,"activeCount":100},[],{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[],{"trials":2894,"activeCount":273,"soonestReadout":241},[2895],{"nctId":238,"briefTitle":239,"status":106,"phases":2896,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":2897,"interventions":2898},[90],[168],[95,246,131,226],{"trials":2900,"activeCount":100},[],{"trials":2902,"activeCount":100},[],{"intervention":46,"totalTrials":273,"cells":2904},{"EARLY_PHASE1":2905,"PHASE1":2907,"PHASE2":2909,"PHASE3":2911,"PHASE4":2917,"NA":2919},{"trials":2906,"activeCount":100},[],{"trials":2908,"activeCount":100},[],{"trials":2910,"activeCount":100},[],{"trials":2912,"activeCount":273,"soonestReadout":45},[2913],{"nctId":43,"briefTitle":44,"status":142,"phases":2914,"primaryCompletion":45,"completion":889,"start":890,"enrollment":891,"conditions":2915,"interventions":2916},[90],[893],[46,780,765],{"trials":2918,"activeCount":100},[],{"trials":2920,"activeCount":100},[],{"intervention":56,"totalTrials":136,"cells":2922},{"EARLY_PHASE1":2923,"PHASE1":2925,"PHASE2":2927,"PHASE3":2929,"PHASE4":2940,"NA":2942},{"trials":2924,"activeCount":100},[],{"trials":2926,"activeCount":100},[],{"trials":2928,"activeCount":100},[],{"trials":2930,"activeCount":273,"soonestReadout":55},[2931],{"nctId":53,"briefTitle":54,"status":142,"phases":2932,"primaryCompletion":55,"completion":2933,"start":2934,"enrollment":2935,"conditions":2936,"interventions":2939},[90],"2027-01-07","2024-07-24",1118,[2937,2938],"Neovascular Age-Related Macular Degeneration","Diabetic Macular Edema",[56],{"trials":2941,"activeCount":100},[],{"trials":2943,"activeCount":100},[2944],{"nctId":2945,"briefTitle":2946,"status":655,"phases":2947,"primaryCompletion":2948,"completion":2949,"start":2950,"enrollment":100,"conditions":2951,"interventions":2956},"NCT06398080","An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting",[],"2028-01-03","2029-01-03","2024-12-12",[2952,2953,2954,2955],"Neovascular Age-related Macular Degeneration (nAMD)","Wet Age-related Macular Degeneration (AMD)","Diabetic Macular Edema (DME)","Visual Impairment",[2957],"aflibercept 8 mg",{"intervention":945,"totalTrials":110,"cells":2959},{"EARLY_PHASE1":2960,"PHASE1":2962,"PHASE2":2968,"PHASE3":2992,"PHASE4":3005,"NA":3007},{"trials":2961,"activeCount":100},[],{"trials":2963,"activeCount":100},[2964],{"nctId":936,"briefTitle":937,"status":286,"phases":2965,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":2966,"interventions":2967},[88],[943],[945,272],{"trials":2969,"activeCount":258,"soonestReadout":1249},[2970,2974,2978,2982],{"nctId":1143,"briefTitle":1144,"status":106,"phases":2971,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":197,"conditions":2972,"interventions":2973},[89],[1149,1114,1150],[963,1116,133,66,1152,945],{"nctId":1246,"briefTitle":1247,"status":106,"phases":2975,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":2976,"interventions":2977},[88,89],[1149,1114,1150,960],[1255,133,963,945,1256],{"nctId":949,"briefTitle":950,"status":106,"phases":2979,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":2980,"interventions":2981},[88,89],[956,957,958,959,960,961],[963,133,945,272],{"nctId":2983,"briefTitle":2984,"status":106,"phases":2985,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":2988,"conditions":2989,"interventions":2991},"NCT07154290","A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced\u002FMetastatic Non-Small Cell Lung Cancer (NSCLC)",[89],"2030-06-24","2026-03-18",300,[2990],"Advanced\u002FMetastatic Non-Small Cell Lung Cancer",[963,1130,945],{"trials":2993,"activeCount":100},[2994],{"nctId":2995,"briefTitle":2996,"status":286,"phases":2997,"primaryCompletion":2998,"completion":2999,"start":3000,"enrollment":3001,"conditions":3002,"interventions":3004},"NCT04315298","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19",[89,90],"2020-07-24","2020-09-02","2020-03-18",1912,[3003],"COVID-19",[945],{"trials":3006,"activeCount":100},[],{"trials":3008,"activeCount":100},[],{"intervention":963,"totalTrials":895,"cells":3010},{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3015,"PHASE3":3033,"PHASE4":3035,"NA":3037},{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[],{"trials":3016,"activeCount":258,"soonestReadout":1249},[3017,3021,3025,3029],{"nctId":1143,"briefTitle":1144,"status":106,"phases":3018,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":197,"conditions":3019,"interventions":3020},[89],[1149,1114,1150],[963,1116,133,66,1152,945],{"nctId":1246,"briefTitle":1247,"status":106,"phases":3022,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":3023,"interventions":3024},[88,89],[1149,1114,1150,960],[1255,133,963,945,1256],{"nctId":949,"briefTitle":950,"status":106,"phases":3026,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":3027,"interventions":3028},[88,89],[956,957,958,959,960,961],[963,133,945,272],{"nctId":2983,"briefTitle":2984,"status":106,"phases":3030,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":2988,"conditions":3031,"interventions":3032},[89],[2990],[963,1130,945],{"trials":3034,"activeCount":100},[],{"trials":3036,"activeCount":100},[],{"trials":3038,"activeCount":100},[3039],{"nctId":3040,"briefTitle":3041,"status":1654,"phases":3042,"conditions":3043,"interventions":3046},"NCT07502716","Compassionate Use of Ubamatamab",[],[3044,3045],"Renal Medullary Carcinoma (RMC)","Epithelioid Sarcoma",[3047],"ubamatamab",{"intervention":1130,"totalTrials":763,"cells":3049},{"EARLY_PHASE1":3050,"PHASE1":3052,"PHASE2":3054,"PHASE3":3068,"PHASE4":3070,"NA":3072},{"trials":3051,"activeCount":100},[],{"trials":3053,"activeCount":100},[],{"trials":3055,"activeCount":763,"soonestReadout":1331},[3056,3060,3064],{"nctId":1120,"briefTitle":1121,"status":106,"phases":3057,"primaryCompletion":1123,"completion":1124,"start":1125,"enrollment":679,"conditions":3058,"interventions":3059},[89],[1127],[133,1129,1130],{"nctId":1328,"briefTitle":1329,"status":106,"phases":3061,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":3062,"interventions":3063},[88,89],[1278],[1130,133,1337,1116,1338],{"nctId":2983,"briefTitle":2984,"status":106,"phases":3065,"primaryCompletion":2986,"completion":2986,"start":2987,"enrollment":2988,"conditions":3066,"interventions":3067},[89],[2990],[963,1130,945],{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[],{"intervention":1116,"totalTrials":763,"cells":3075},{"EARLY_PHASE1":3076,"PHASE1":3078,"PHASE2":3084,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3077,"activeCount":100},[],{"trials":3079,"activeCount":273,"soonestReadout":1108},[3080],{"nctId":1105,"briefTitle":1106,"status":106,"phases":3081,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":3082,"interventions":3083},[88],[1112,1113,1114],[133,1116],{"trials":3085,"activeCount":136,"soonestReadout":1331},[3086,3090],{"nctId":1143,"briefTitle":1144,"status":106,"phases":3087,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":197,"conditions":3088,"interventions":3089},[89],[1149,1114,1150],[963,1116,133,66,1152,945],{"nctId":1328,"briefTitle":1329,"status":106,"phases":3091,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":3092,"interventions":3093},[88,89],[1278],[1130,133,1337,1116,1338],{"trials":3095,"activeCount":100},[],{"trials":3097,"activeCount":100},[],{"trials":3099,"activeCount":100},[],{"intervention":3101,"totalTrials":763,"cells":3102},"ALN-PNP",{"EARLY_PHASE1":3103,"PHASE1":3105,"PHASE2":3118,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3104,"activeCount":100},[],{"trials":3106,"activeCount":100},[3107],{"nctId":3108,"briefTitle":3109,"status":286,"phases":3110,"primaryCompletion":3111,"completion":3111,"start":3112,"enrollment":1973,"conditions":3113,"interventions":3117},"NCT06024408","A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor",[88],"2025-07-07","2024-05-21",[3114,3115,3116],"Nonalcoholic Fatty Liver Disease (NAFLD)","Nonalcoholic Steatohepatitis (NASH)","Genetic Risk Factor",[3101],{"trials":3119,"activeCount":136,"soonestReadout":3134},[3120,3130],{"nctId":3121,"briefTitle":3122,"status":218,"phases":3123,"primaryCompletion":3124,"completion":3124,"start":75,"enrollment":3125,"conditions":3126,"interventions":3128},"NCT07527910","A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD",[89],"2029-11-27",204,[3127],"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",[3101,3129],"Tirzepatide",{"nctId":3131,"briefTitle":3132,"status":106,"phases":3133,"primaryCompletion":3134,"completion":3134,"start":3135,"enrollment":3136,"conditions":3137,"interventions":3138},"NCT05648214","A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",[88,89],"2027-08-10","2022-12-27",172,[14,3127],[3101],{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":100},[],{"trials":3144,"activeCount":100},[],{"intervention":1268,"totalTrials":136,"cells":3146},{"EARLY_PHASE1":3147,"PHASE1":3149,"PHASE2":3151,"PHASE3":3167,"PHASE4":3169,"NA":3171},{"trials":3148,"activeCount":100},[],{"trials":3150,"activeCount":100},[],{"trials":3152,"activeCount":136,"soonestReadout":1261},[3153,3163],{"nctId":3154,"briefTitle":3155,"status":106,"phases":3156,"primaryCompletion":3157,"completion":3157,"start":1158,"enrollment":3158,"conditions":3159,"interventions":3161},"NCT05125016","A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer",[88,89],"2030-03-28",228,[3160],"Metastatic Castration-resistant Prostate Cancer",[3162,1268],"REGN4336",{"nctId":1258,"briefTitle":1259,"status":106,"phases":3164,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":1263,"conditions":3165,"interventions":3166},[88,89],[1265,1266],[1268,133],{"trials":3168,"activeCount":100},[],{"trials":3170,"activeCount":100},[],{"trials":3172,"activeCount":100},[],{"intervention":1568,"totalTrials":136,"cells":3174},{"EARLY_PHASE1":3175,"PHASE1":3177,"PHASE2":3183,"PHASE3":3195,"PHASE4":3197,"NA":3199},{"trials":3176,"activeCount":100},[],{"trials":3178,"activeCount":273,"soonestReadout":1563},[3179],{"nctId":1560,"briefTitle":1561,"status":106,"phases":3180,"primaryCompletion":1563,"completion":1563,"start":1564,"enrollment":1110,"conditions":3181,"interventions":3182},[88],[1566],[1568,1538],{"trials":3184,"activeCount":273,"soonestReadout":3189},[3185],{"nctId":3186,"briefTitle":3187,"status":142,"phases":3188,"primaryCompletion":3189,"completion":3189,"start":3190,"enrollment":3191,"conditions":3192,"interventions":3194},"NCT05092347","A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)",[88,89],"2027-11-22","2022-08-02",43,[3193],"Chronic Kidney Disease (CKD)",[1568],{"trials":3196,"activeCount":100},[],{"trials":3198,"activeCount":100},[],{"trials":3200,"activeCount":100},[],{"intervention":3202,"totalTrials":136,"cells":3203},"ALN-ANG3",{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3217,"PHASE3":3232,"PHASE4":3234,"NA":3236},{"trials":3205,"activeCount":100},[],{"trials":3207,"activeCount":273,"soonestReadout":3212},[3208],{"nctId":3209,"briefTitle":3210,"status":142,"phases":3211,"primaryCompletion":3212,"completion":3212,"start":1720,"enrollment":3213,"conditions":3214,"interventions":3216},"NCT06452771","A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults",[88],"2026-12-04",59,[3215],"Healthy Volunteers With Hyperlipidemia",[3202],{"trials":3218,"activeCount":273,"soonestReadout":3223},[3219],{"nctId":3220,"briefTitle":3221,"status":106,"phases":3222,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":233,"conditions":3226,"interventions":3228},"NCT07271186","Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease",[89],"2027-09-24","2028-04-07","2026-01-09",[3227],"Diabetic Kidney Disease (DKD)",[3202,3229,3230,3231],"Evinacumab","ALN-ANG3 placebo","Evinacumab placebo",{"trials":3233,"activeCount":100},[],{"trials":3235,"activeCount":100},[],{"trials":3237,"activeCount":100},[],{"intervention":1129,"totalTrials":136,"cells":3239},{"EARLY_PHASE1":3240,"PHASE1":3242,"PHASE2":3244,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3241,"activeCount":100},[],{"trials":3243,"activeCount":100},[],{"trials":3245,"activeCount":273,"soonestReadout":1123},[3246],{"nctId":1120,"briefTitle":1121,"status":106,"phases":3247,"primaryCompletion":1123,"completion":1124,"start":1125,"enrollment":679,"conditions":3248,"interventions":3249},[89],[1127],[133,1129,1130],{"trials":3251,"activeCount":100},[],{"trials":3253,"activeCount":100},[],{"trials":3255,"activeCount":273,"soonestReadout":1146},[3256],{"nctId":1472,"briefTitle":1473,"status":106,"phases":3257,"primaryCompletion":1146,"completion":1146,"start":1475,"enrollment":1476,"conditions":3258,"interventions":3259},[],[1297],[133,1129],{"intervention":3261,"totalTrials":11,"cells":3262},"Alirocumab",{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3267,"PHASE3":3306,"PHASE4":3376,"NA":3378},{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[],{"trials":3268,"activeCount":273,"soonestReadout":3301},[3269,3277,3287,3297],{"nctId":3270,"briefTitle":3271,"status":286,"phases":3272,"primaryCompletion":3273,"completion":3273,"start":3274,"enrollment":1159,"conditions":3275,"interventions":3276},"NCT01266876","Study of the Safety and Efficacy of REGN727\u002FSAR236553 in Patients With HeFH Hypercholesterolemia",[89],"2011-11","2011-01",[23],[3261],{"nctId":3278,"briefTitle":3279,"status":286,"phases":3280,"primaryCompletion":3281,"completion":3281,"start":3282,"enrollment":3283,"conditions":3284,"interventions":3286},"NCT01576484","Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)",[89],"2016-12-22","2012-02-28",58,[23,3285],"Heterozygous Familial Hypercholesterolemia",[3261],{"nctId":3288,"briefTitle":3289,"status":286,"phases":3290,"primaryCompletion":3291,"completion":3292,"start":3293,"enrollment":3294,"conditions":3295,"interventions":3296},"NCT01604824","A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene",[89],"2014-06-02","2017-07-28","2012-02-22",23,[23],[3261],{"nctId":3298,"briefTitle":3299,"status":218,"phases":3300,"primaryCompletion":3301,"completion":3302,"start":1230,"enrollment":3303,"conditions":3304,"interventions":3305},"NCT07477704","A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia",[89],"2026-10-20","2027-03-09",420,[23],[3261],{"trials":3307,"activeCount":100},[3308,3320,3330,3337,3346,3357,3366],{"nctId":3309,"briefTitle":3310,"status":286,"phases":3311,"primaryCompletion":3312,"completion":427,"start":3313,"enrollment":3314,"conditions":3315,"interventions":3316},"NCT01730040","Study of the Efficacy and Safety of Alirocumab (REGN727\u002FSAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)",[90],"2014-04","2012-10",355,[23],[3261,3317,3318,3319],"Atorvastatin","Ezetimibe","Rosuvastatin",{"nctId":3321,"briefTitle":3322,"status":286,"phases":3323,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":3327,"conditions":3328,"interventions":3329},"NCT01730053","Study of Alirocumab (REGN727\u002FSAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)",[90],"2014-04-30","2014-05-31","2012-11-30",305,[23],[3261,3319,3318],{"nctId":3331,"briefTitle":3332,"status":286,"phases":3333,"primaryCompletion":480,"completion":3334,"start":387,"enrollment":459,"conditions":3335,"interventions":3336},"NCT02326220","Study of Alirocumab (REGN727\u002FSAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy",[90],"2016-04-30",[3285],[3261],{"nctId":3338,"briefTitle":3339,"status":286,"phases":3340,"primaryCompletion":3325,"completion":3341,"start":3342,"enrollment":3343,"conditions":3344,"interventions":3345},"NCT01709513","Study of Alirocumab (REGN727\u002FSAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",[90],"2017-05-31","2012-09-30",314,[23],[3317,3318,3261],{"nctId":3347,"briefTitle":3348,"status":286,"phases":3349,"primaryCompletion":3350,"completion":3351,"start":3352,"enrollment":3353,"conditions":3354,"interventions":3356},"NCT03156621","Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)",[90],"2019-09-27","2020-02-13","2017-10-03",69,[3355],"Homozygous Familial Hypercholesterolemia",[3261],{"nctId":3358,"briefTitle":3359,"status":286,"phases":3360,"primaryCompletion":428,"completion":939,"start":3361,"enrollment":3362,"conditions":3363,"interventions":3364},"NCT01926782","Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727\u002F SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)",[90],"2013-09",803,[23],[3261,3365],"Statin",{"nctId":3367,"briefTitle":3368,"status":286,"phases":3369,"primaryCompletion":427,"completion":3370,"start":467,"enrollment":3371,"conditions":3372,"interventions":3373},"NCT01709500","Study of Alirocumab (REGN727\u002FSAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)",[90],"2015-01",249,[3285],[3374,3375],"LMT","alirocumab",{"trials":3377,"activeCount":100},[],{"trials":3379,"activeCount":100},[],{"intervention":71,"totalTrials":763,"cells":3381},{"EARLY_PHASE1":3382,"PHASE1":3384,"PHASE2":3394,"PHASE3":3415,"PHASE4":3417,"NA":3419},{"trials":3383,"activeCount":100},[],{"trials":3385,"activeCount":100},[3386],{"nctId":3387,"briefTitle":3388,"status":286,"phases":3389,"primaryCompletion":3390,"completion":3390,"start":3391,"enrollment":1688,"conditions":3392,"interventions":3393},"NCT05970718","A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants",[88],"2024-07-22","2023-08-07",[14],[71],{"trials":3395,"activeCount":273,"soonestReadout":70},[3396,3408],{"nctId":3397,"briefTitle":3398,"status":286,"phases":3399,"primaryCompletion":3400,"completion":3401,"start":3402,"enrollment":3403,"conditions":3404,"interventions":3406},"NCT06608901","A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension",[89],"2026-02-01","2026-04-28","2025-05-05",76,[3405],"Sepsis-Induced Hypotension",[71,3407],"PB",{"nctId":68,"briefTitle":69,"status":142,"phases":3409,"primaryCompletion":70,"completion":1575,"start":3410,"enrollment":3411,"conditions":3412,"interventions":3414},[89],"2024-11-13",82,[3413],"Postural Orthostatic Tachycardia Syndrome (POTS)",[71],{"trials":3416,"activeCount":100},[],{"trials":3418,"activeCount":100},[],{"trials":3420,"activeCount":100},[],{"intervention":3422,"totalTrials":136,"cells":3423},"REGN13335",{"EARLY_PHASE1":3424,"PHASE1":3426,"PHASE2":3436,"PHASE3":3449,"PHASE4":3451,"NA":3453},{"trials":3425,"activeCount":100},[],{"trials":3427,"activeCount":100},[3428],{"nctId":3429,"briefTitle":3430,"status":286,"phases":3431,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":2018,"conditions":3434,"interventions":3435},"NCT06137482","A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants",[88],"2025-02-11","2023-12-06",[14],[3422],{"trials":3437,"activeCount":273,"soonestReadout":3442},[3438],{"nctId":3439,"briefTitle":3440,"status":106,"phases":3441,"primaryCompletion":3442,"completion":3443,"start":3444,"enrollment":3445,"conditions":3446,"interventions":3448},"NCT07318597","Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)",[89],"2028-02-27","2028-09-17","2026-05-06",99,[3447],"Pulmonary Arterial Hypertension (PAH)",[3422],{"trials":3450,"activeCount":100},[],{"trials":3452,"activeCount":100},[],{"trials":3454,"activeCount":100},[],{"intervention":3456,"totalTrials":136,"cells":3457},"REGN7999",{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3471,"PHASE3":3482,"PHASE4":3484,"NA":3486},{"trials":3459,"activeCount":100},[],{"trials":3461,"activeCount":100},[3462],{"nctId":3463,"briefTitle":3464,"status":286,"phases":3465,"primaryCompletion":3466,"completion":3466,"start":3467,"enrollment":3468,"conditions":3469,"interventions":3470},"NCT05481333","A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants",[88],"2023-08-29","2022-10-24",64,[20],[3456],{"trials":3472,"activeCount":273,"soonestReadout":3477},[3473],{"nctId":3474,"briefTitle":3475,"status":106,"phases":3476,"primaryCompletion":3477,"completion":3477,"start":1675,"enrollment":3478,"conditions":3479,"interventions":3481},"NCT06421636","A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body",[89],"2028-01-24",95,[3480],"Non-Transfusion Dependent Beta-Thalassemia (NTDT)",[3456],{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"trials":3487,"activeCount":100},[],{"intervention":3489,"totalTrials":273,"cells":3490},"ALN-CFB",{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3495,"PHASE3":3508,"PHASE4":3510,"NA":3512},{"trials":3492,"activeCount":100},[],{"trials":3494,"activeCount":100},[],{"trials":3496,"activeCount":273,"soonestReadout":3501},[3497],{"nctId":3498,"briefTitle":3499,"status":106,"phases":3500,"primaryCompletion":3501,"completion":3502,"start":3503,"enrollment":823,"conditions":3504,"interventions":3507},"NCT07187401","A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor",[88,89],"2029-11-29","2031-07-15","2026-02-11",[3505,3506],"Paroxysmal Nocturnal Hemoglobinuria (PNH)","Persistent Anemia",[3489],{"trials":3509,"activeCount":100},[],{"trials":3511,"activeCount":100},[],{"trials":3513,"activeCount":100},[],{"intervention":1152,"totalTrials":273,"cells":3515},{"EARLY_PHASE1":3516,"PHASE1":3518,"PHASE2":3520,"PHASE3":3526,"PHASE4":3528,"NA":3530},{"trials":3517,"activeCount":100},[],{"trials":3519,"activeCount":100},[],{"trials":3521,"activeCount":273,"soonestReadout":1146},[3522],{"nctId":1143,"briefTitle":1144,"status":106,"phases":3523,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":197,"conditions":3524,"interventions":3525},[89],[1149,1114,1150],[963,1116,133,66,1152,945],{"trials":3527,"activeCount":100},[],{"trials":3529,"activeCount":100},[],{"trials":3531,"activeCount":100},[],{"intervention":1190,"totalTrials":273,"cells":3533},{"EARLY_PHASE1":3534,"PHASE1":3536,"PHASE2":3538,"PHASE3":3544,"PHASE4":3546,"NA":3548},{"trials":3535,"activeCount":100},[],{"trials":3537,"activeCount":100},[],{"trials":3539,"activeCount":273,"soonestReadout":1184},[3540],{"nctId":1181,"briefTitle":1182,"status":142,"phases":3541,"primaryCompletion":1184,"completion":1185,"start":1186,"enrollment":1187,"conditions":3542,"interventions":3543},[89],[29],[41,1190],{"trials":3545,"activeCount":100},[],{"trials":3547,"activeCount":100},[],{"trials":3549,"activeCount":100},[],{"intervention":1202,"totalTrials":273,"cells":3551},{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3556,"PHASE3":3562,"PHASE4":3564,"NA":3566},{"trials":3553,"activeCount":100},[],{"trials":3555,"activeCount":100},[],{"trials":3557,"activeCount":273,"soonestReadout":1195},[3558],{"nctId":1192,"briefTitle":1193,"status":218,"phases":3559,"primaryCompletion":1195,"completion":1196,"start":1197,"enrollment":679,"conditions":3560,"interventions":3561},[88,89],[1199,1200],[133,1202],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[],{"intervention":170,"totalTrials":273,"cells":3569},{"EARLY_PHASE1":3570,"PHASE1":3572,"PHASE2":3574,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3571,"activeCount":100},[],{"trials":3573,"activeCount":100},[],{"trials":3575,"activeCount":273,"soonestReadout":164},[3576],{"nctId":161,"briefTitle":162,"status":106,"phases":3577,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":3578,"interventions":3579},[88,89],[168],[95,170],{"trials":3581,"activeCount":100},[],{"trials":3583,"activeCount":100},[],{"trials":3585,"activeCount":100},[],{"intervention":3587,"totalTrials":273,"cells":3588},"DB-OTO",{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3593,"PHASE3":3604,"PHASE4":3606,"NA":3608},{"trials":3590,"activeCount":100},[],{"trials":3592,"activeCount":100},[],{"trials":3594,"activeCount":273,"soonestReadout":3599},[3595],{"nctId":3596,"briefTitle":3597,"status":106,"phases":3598,"primaryCompletion":3599,"completion":3599,"start":3600,"enrollment":268,"conditions":3601,"interventions":3603},"NCT05788536","A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children\u002FInfants With Hearing Loss Due to Otoferlin Mutations",[88,89],"2032-02-28","2023-06-27",[3602],"Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)",[3587,3587],{"trials":3605,"activeCount":100},[],{"trials":3607,"activeCount":100},[],{"trials":3609,"activeCount":100},[],{"intervention":3611,"totalTrials":273,"cells":3612},"ALN-HSD",{"EARLY_PHASE1":3613,"PHASE1":3615,"PHASE2":3617,"PHASE3":3629,"PHASE4":3631,"NA":3633},{"trials":3614,"activeCount":100},[],{"trials":3616,"activeCount":100},[],{"trials":3618,"activeCount":273,"soonestReadout":3623},[3619],{"nctId":3620,"briefTitle":3621,"status":106,"phases":3622,"primaryCompletion":3623,"completion":3624,"start":3625,"enrollment":679,"conditions":3626,"interventions":3628},"NCT05519475","A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition",[89],"2028-04-27","2028-12-07","2023-02-09",[3627],"Metabolic Dysfunction-Associated SteatoHepatitis (MASH)",[3611],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":100},[],{"trials":3634,"activeCount":100},[],{"intervention":1234,"totalTrials":273,"cells":3636},{"EARLY_PHASE1":3637,"PHASE1":3639,"PHASE2":3641,"PHASE3":3647,"PHASE4":3649,"NA":3651},{"trials":3638,"activeCount":100},[],{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":273,"soonestReadout":1228},[3643],{"nctId":1225,"briefTitle":1226,"status":106,"phases":3644,"primaryCompletion":1228,"completion":1229,"start":1230,"enrollment":679,"conditions":3645,"interventions":3646},[89],[1232],[1234,133],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"intervention":3162,"totalTrials":273,"cells":3654},{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3659,"PHASE3":3665,"PHASE4":3667,"NA":3669},{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[],{"trials":3660,"activeCount":273,"soonestReadout":3157},[3661],{"nctId":3154,"briefTitle":3155,"status":106,"phases":3662,"primaryCompletion":3157,"completion":3157,"start":1158,"enrollment":3158,"conditions":3663,"interventions":3664},[88,89],[3160],[3162,1268],{"trials":3666,"activeCount":100},[],{"trials":3668,"activeCount":100},[],{"trials":3670,"activeCount":100},[],{"intervention":1255,"totalTrials":273,"cells":3672},{"EARLY_PHASE1":3673,"PHASE1":3675,"PHASE2":3677,"PHASE3":3683,"PHASE4":3685,"NA":3687},{"trials":3674,"activeCount":100},[],{"trials":3676,"activeCount":100},[],{"trials":3678,"activeCount":273,"soonestReadout":1249},[3679],{"nctId":1246,"briefTitle":1247,"status":106,"phases":3680,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":3681,"interventions":3682},[88,89],[1149,1114,1150,960],[1255,133,963,945,1256],{"trials":3684,"activeCount":100},[],{"trials":3686,"activeCount":100},[],{"trials":3688,"activeCount":100},[],{"intervention":1256,"totalTrials":273,"cells":3690},{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3701,"PHASE4":3703,"NA":3705},{"trials":3692,"activeCount":100},[],{"trials":3694,"activeCount":100},[],{"trials":3696,"activeCount":273,"soonestReadout":1249},[3697],{"nctId":1246,"briefTitle":1247,"status":106,"phases":3698,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":3699,"interventions":3700},[88,89],[1149,1114,1150,960],[1255,133,963,945,1256],{"trials":3702,"activeCount":100},[],{"trials":3704,"activeCount":100},[],{"trials":3706,"activeCount":100},[],{"intervention":3708,"totalTrials":273,"cells":3709},"ALN-SOD",{"EARLY_PHASE1":3710,"PHASE1":3712,"PHASE2":3714,"PHASE3":3727,"PHASE4":3729,"NA":3731},{"trials":3711,"activeCount":100},[],{"trials":3713,"activeCount":100},[],{"trials":3715,"activeCount":273,"soonestReadout":3720},[3716],{"nctId":3717,"briefTitle":3718,"status":106,"phases":3719,"primaryCompletion":3720,"completion":3720,"start":3721,"enrollment":3722,"conditions":3723,"interventions":3726},"NCT06351592","First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)",[88,89],"2031-06-05","2024-08-28",42,[3724,3725],"Amyotrophic Lateral Sclerosis (ALS)","Mutation in the Superoxide Dismutase-1 (SOD1) Gene",[3708],{"trials":3728,"activeCount":100},[],{"trials":3730,"activeCount":100},[],{"trials":3732,"activeCount":100},[],{"intervention":1280,"totalTrials":273,"cells":3734},{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3739,"PHASE3":3745,"PHASE4":3747,"NA":3749},{"trials":3736,"activeCount":100},[],{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":273,"soonestReadout":1273},[3741],{"nctId":1270,"briefTitle":1271,"status":106,"phases":3742,"primaryCompletion":1273,"completion":1273,"start":1274,"enrollment":1275,"conditions":3743,"interventions":3744},[88,89],[29,1277,1278],[1280,133],{"trials":3746,"activeCount":100},[],{"trials":3748,"activeCount":100},[],{"trials":3750,"activeCount":100},[],{"intervention":3752,"totalTrials":273,"cells":3753},"Fianlimab+cemiplimab",{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":273,"soonestReadout":3765},[3760],{"nctId":3761,"briefTitle":3762,"status":3763,"phases":3764,"primaryCompletion":3765,"completion":3765,"start":3766,"enrollment":3767,"conditions":3768,"interventions":3769},"NCT06848088","A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment","ENROLLING_BY_INVITATION",[89],"2029-10-10","2025-04-14",48,[29],[3752],{"trials":3771,"activeCount":100},[],{"trials":3773,"activeCount":100},[],{"trials":3775,"activeCount":100},[],{"intervention":3777,"totalTrials":273,"cells":3778},"REGV131",{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3797,"PHASE4":3799,"NA":3801},{"trials":3780,"activeCount":100},[],{"trials":3782,"activeCount":100},[],{"trials":3784,"activeCount":273,"soonestReadout":3789},[3785],{"nctId":3786,"briefTitle":3787,"status":106,"phases":3788,"primaryCompletion":3789,"completion":3790,"start":3791,"enrollment":3792,"conditions":3793,"interventions":3795},"NCT06379789","A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B",[88,89],"2034-08-14","2047-08-14","2024-09-11",130,[3794],"Hemophilia B",[3777,3796],"LNP1265",{"trials":3798,"activeCount":100},[],{"trials":3800,"activeCount":100},[],{"trials":3802,"activeCount":100},[],{"intervention":3796,"totalTrials":273,"cells":3804},{"EARLY_PHASE1":3805,"PHASE1":3807,"PHASE2":3809,"PHASE3":3815,"PHASE4":3817,"NA":3819},{"trials":3806,"activeCount":100},[],{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":273,"soonestReadout":3789},[3811],{"nctId":3786,"briefTitle":3787,"status":106,"phases":3812,"primaryCompletion":3789,"completion":3790,"start":3791,"enrollment":3792,"conditions":3813,"interventions":3814},[88,89],[3794],[3777,3796],{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":100},[],{"trials":3820,"activeCount":100},[],{"intervention":3822,"totalTrials":273,"cells":3823},"Olatorepatide",{"EARLY_PHASE1":3824,"PHASE1":3826,"PHASE2":3828,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":273,"soonestReadout":3834},[3830],{"nctId":3831,"briefTitle":3832,"status":106,"phases":3833,"primaryCompletion":3834,"completion":3835,"start":3836,"enrollment":679,"conditions":3837,"interventions":3839},"NCT07431086","Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US",[89],"2026-11-23","2026-12-28","2026-03-16",[3838],"Overweight or Obesity",[3822],{"trials":3841,"activeCount":100},[],{"trials":3843,"activeCount":100},[],{"trials":3845,"activeCount":100},[],{"intervention":3847,"totalTrials":273,"cells":3848},"ALN-CIDEB",{"EARLY_PHASE1":3849,"PHASE1":3851,"PHASE2":3853,"PHASE3":3866,"PHASE4":3868,"NA":3870},{"trials":3850,"activeCount":100},[],{"trials":3852,"activeCount":100},[],{"trials":3854,"activeCount":273,"soonestReadout":3859},[3855],{"nctId":3856,"briefTitle":3857,"status":106,"phases":3858,"primaryCompletion":3859,"completion":3859,"start":3860,"enrollment":3861,"conditions":3862,"interventions":3865},"NCT06836609","A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD\u002FMASH)",[88,89],"2027-05-15","2025-04-28",132,[3863,3864],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis",[3847],{"trials":3867,"activeCount":100},[],{"trials":3869,"activeCount":100},[],{"trials":3871,"activeCount":100},[],{"intervention":1301,"totalTrials":273,"cells":3873},{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3878,"PHASE3":3884,"PHASE4":3886,"NA":3888},{"trials":3875,"activeCount":100},[],{"trials":3877,"activeCount":100},[],{"trials":3879,"activeCount":273,"soonestReadout":40},[3880],{"nctId":38,"briefTitle":39,"status":142,"phases":3881,"primaryCompletion":40,"completion":1293,"start":1294,"enrollment":1295,"conditions":3882,"interventions":3883},[89],[1297,1298,1299],[41,1301,1302],{"trials":3885,"activeCount":100},[],{"trials":3887,"activeCount":100},[],{"trials":3889,"activeCount":100},[],{"intervention":1314,"totalTrials":273,"cells":3891},{"EARLY_PHASE1":3892,"PHASE1":3894,"PHASE2":3896,"PHASE3":3902,"PHASE4":3904,"NA":3906},{"trials":3893,"activeCount":100},[],{"trials":3895,"activeCount":100},[],{"trials":3897,"activeCount":273,"soonestReadout":1307},[3898],{"nctId":1304,"briefTitle":1305,"status":142,"phases":3899,"primaryCompletion":1307,"completion":1308,"start":1309,"enrollment":1310,"conditions":3900,"interventions":3901},[89],[1312],[1314,133],{"trials":3903,"activeCount":100},[],{"trials":3905,"activeCount":100},[],{"trials":3907,"activeCount":100},[],{"intervention":1337,"totalTrials":273,"cells":3909},{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3914,"PHASE3":3920,"PHASE4":3922,"NA":3924},{"trials":3911,"activeCount":100},[],{"trials":3913,"activeCount":100},[],{"trials":3915,"activeCount":273,"soonestReadout":1331},[3916],{"nctId":1328,"briefTitle":1329,"status":106,"phases":3917,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":3918,"interventions":3919},[88,89],[1278],[1130,133,1337,1116,1338],{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"trials":3925,"activeCount":100},[],{"intervention":1338,"totalTrials":273,"cells":3927},{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3932,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3929,"activeCount":100},[],{"trials":3931,"activeCount":100},[],{"trials":3933,"activeCount":273,"soonestReadout":1331},[3934],{"nctId":1328,"briefTitle":1329,"status":106,"phases":3935,"primaryCompletion":1331,"completion":1332,"start":1333,"enrollment":1334,"conditions":3936,"interventions":3937},[88,89],[1278],[1130,133,1337,1116,1338],{"trials":3939,"activeCount":100},[],{"trials":3941,"activeCount":100},[],{"trials":3943,"activeCount":100},[],{"intervention":3945,"totalTrials":273,"cells":3946},"REGN5093",{"EARLY_PHASE1":3947,"PHASE1":3949,"PHASE2":3951,"PHASE3":3963,"PHASE4":3965,"NA":3967},{"trials":3948,"activeCount":100},[],{"trials":3950,"activeCount":100},[],{"trials":3952,"activeCount":273,"soonestReadout":3957},[3953],{"nctId":3954,"briefTitle":3955,"status":106,"phases":3956,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":3959,"conditions":3960,"interventions":3962},"NCT04077099","A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer",[88,89],"2032-04-22","2020-01-07",231,[3961],"NSCLC",[3945],{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[],{"trials":3968,"activeCount":100},[],{"intervention":3970,"totalTrials":273,"cells":3971},"REGN15505",{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3989,"PHASE4":3991,"NA":3993},{"trials":3973,"activeCount":100},[],{"trials":3975,"activeCount":100},[],{"trials":3977,"activeCount":273,"soonestReadout":3982},[3978],{"nctId":3979,"briefTitle":3980,"status":218,"phases":3981,"primaryCompletion":3982,"completion":3982,"start":3983,"enrollment":3984,"conditions":3985,"interventions":3986},"NCT07594106","REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma",[88,89],"2030-09-20","2026-05-25",265,[1265,1266],[3970,3987,3988],"REGN15505+Cemiplimab","REGN15505+REGN4336",{"trials":3990,"activeCount":100},[],{"trials":3992,"activeCount":100},[],{"trials":3994,"activeCount":100},[],{"intervention":3987,"totalTrials":273,"cells":3996},{"EARLY_PHASE1":3997,"PHASE1":3999,"PHASE2":4001,"PHASE3":4007,"PHASE4":4009,"NA":4011},{"trials":3998,"activeCount":100},[],{"trials":4000,"activeCount":100},[],{"trials":4002,"activeCount":273,"soonestReadout":3982},[4003],{"nctId":3979,"briefTitle":3980,"status":218,"phases":4004,"primaryCompletion":3982,"completion":3982,"start":3983,"enrollment":3984,"conditions":4005,"interventions":4006},[88,89],[1265,1266],[3970,3987,3988],{"trials":4008,"activeCount":100},[],{"trials":4010,"activeCount":100},[],{"trials":4012,"activeCount":100},[],{"intervention":3988,"totalTrials":273,"cells":4014},{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4019,"PHASE3":4025,"PHASE4":4027,"NA":4029},{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":273,"soonestReadout":3982},[4021],{"nctId":3979,"briefTitle":3980,"status":218,"phases":4022,"primaryCompletion":3982,"completion":3982,"start":3983,"enrollment":3984,"conditions":4023,"interventions":4024},[88,89],[1265,1266],[3970,3987,3988],{"trials":4026,"activeCount":100},[],{"trials":4028,"activeCount":100},[],{"trials":4030,"activeCount":100},[],{"intervention":4032,"totalTrials":273,"cells":4033},"REGN7041",{"EARLY_PHASE1":4034,"PHASE1":4036,"PHASE2":4038,"PHASE3":4050,"PHASE4":4052,"NA":4054},{"trials":4035,"activeCount":100},[],{"trials":4037,"activeCount":100},[],{"trials":4039,"activeCount":273,"soonestReadout":4044},[4040],{"nctId":4041,"briefTitle":4042,"status":142,"phases":4043,"primaryCompletion":4044,"completion":4044,"start":4045,"enrollment":4046,"conditions":4047,"interventions":4049},"NCT07218770","A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants",[88,89],"2028-06-28","2025-12-17",72,[4048],"Active Noninfectious Uveitis Affecting the Posterior Segment",[4032],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":100},[],{"intervention":212,"totalTrials":273,"cells":4057},{"EARLY_PHASE1":4058,"PHASE1":4060,"PHASE2":4062,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[],{"trials":4063,"activeCount":273,"soonestReadout":205},[4064],{"nctId":202,"briefTitle":203,"status":106,"phases":4065,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":4066,"interventions":4067},[88,89],[210],[95,212],{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":100},[],{"trials":4073,"activeCount":100},[],{"intervention":3129,"totalTrials":273,"cells":4075},{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4086,"PHASE4":4088,"NA":4090},{"trials":4077,"activeCount":100},[],{"trials":4079,"activeCount":100},[],{"trials":4081,"activeCount":273,"soonestReadout":3124},[4082],{"nctId":3121,"briefTitle":3122,"status":218,"phases":4083,"primaryCompletion":3124,"completion":3124,"start":75,"enrollment":3125,"conditions":4084,"interventions":4085},[89],[3127],[3101,3129],{"trials":4087,"activeCount":100},[],{"trials":4089,"activeCount":100},[],{"trials":4091,"activeCount":100},[],{"intervention":85,"totalTrials":273,"cells":4093},{"EARLY_PHASE1":4094,"PHASE1":4096,"PHASE2":4098,"PHASE3":4104,"PHASE4":4106,"NA":4108},{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":273,"soonestReadout":84},[4100],{"nctId":82,"briefTitle":83,"status":142,"phases":4101,"primaryCompletion":84,"completion":2406,"start":2407,"enrollment":2408,"conditions":4102,"interventions":4103},[89],[2400],[85,2411,51,2412],{"trials":4105,"activeCount":100},[],{"trials":4107,"activeCount":100},[],{"trials":4109,"activeCount":100},[],{"intervention":2411,"totalTrials":273,"cells":4111},{"EARLY_PHASE1":4112,"PHASE1":4114,"PHASE2":4116,"PHASE3":4122,"PHASE4":4124,"NA":4126},{"trials":4113,"activeCount":100},[],{"trials":4115,"activeCount":100},[],{"trials":4117,"activeCount":273,"soonestReadout":84},[4118],{"nctId":82,"briefTitle":83,"status":142,"phases":4119,"primaryCompletion":84,"completion":2406,"start":2407,"enrollment":2408,"conditions":4120,"interventions":4121},[89],[2400],[85,2411,51,2412],{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":100},[],{"trials":4127,"activeCount":100},[],{"intervention":2412,"totalTrials":273,"cells":4129},{"EARLY_PHASE1":4130,"PHASE1":4132,"PHASE2":4134,"PHASE3":4140,"PHASE4":4142,"NA":4144},{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":273,"soonestReadout":84},[4136],{"nctId":82,"briefTitle":83,"status":142,"phases":4137,"primaryCompletion":84,"completion":2406,"start":2407,"enrollment":2408,"conditions":4138,"interventions":4139},[89],[2400],[85,2411,51,2412],{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":100},[],{"trials":4145,"activeCount":100},[],{"intervention":3230,"totalTrials":273,"cells":4147},{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4152,"PHASE3":4158,"PHASE4":4160,"NA":4162},{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"trials":4153,"activeCount":273,"soonestReadout":3223},[4154],{"nctId":3220,"briefTitle":3221,"status":106,"phases":4155,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":233,"conditions":4156,"interventions":4157},[89],[3227],[3202,3229,3230,3231],{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":100},[],{"trials":4163,"activeCount":100},[],{"intervention":3231,"totalTrials":273,"cells":4165},{"EARLY_PHASE1":4166,"PHASE1":4168,"PHASE2":4170,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[],{"trials":4171,"activeCount":273,"soonestReadout":3223},[4172],{"nctId":3220,"briefTitle":3221,"status":106,"phases":4173,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":233,"conditions":4174,"interventions":4175},[89],[3227],[3202,3229,3230,3231],{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[],{"intervention":3229,"totalTrials":1973,"cells":4183},{"EARLY_PHASE1":4184,"PHASE1":4186,"PHASE2":4197,"PHASE3":4234,"PHASE4":4262,"NA":4264},{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[4188],{"nctId":4189,"briefTitle":4190,"status":286,"phases":4191,"primaryCompletion":4192,"completion":4192,"start":4193,"enrollment":4194,"conditions":4195,"interventions":4196},"NCT03146416","Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers",[88],"2018-06-14","2017-05-16",96,[14],[3229],{"trials":4198,"activeCount":273,"soonestReadout":3223},[4199,4210,4220,4230],{"nctId":4200,"briefTitle":4201,"status":286,"phases":4202,"primaryCompletion":4203,"completion":4204,"start":353,"enrollment":4205,"conditions":4206,"interventions":4208},"NCT03452228","Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis",[89],"2019-12-17","2020-07-23",52,[4207],"Severe Hypertriglyceridemia (sHTG)",[4209],"evinacumab",{"nctId":4211,"briefTitle":4212,"status":286,"phases":4213,"primaryCompletion":4214,"completion":4215,"start":4216,"enrollment":4217,"conditions":4218,"interventions":4219},"NCT03175367","Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia",[89],"2020-05-22","2020-12-14","2017-11-10",272,[23],[3229],{"nctId":4221,"briefTitle":4222,"status":414,"phases":4223,"primaryCompletion":4224,"completion":4224,"start":4225,"enrollment":4226,"conditions":4227,"interventions":4229},"NCT04863014","Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis",[89],"2023-02-15","2021-07-12",21,[4228],"Hypertriglyceridemia",[4209],{"nctId":3220,"briefTitle":3221,"status":106,"phases":4231,"primaryCompletion":3223,"completion":3224,"start":3225,"enrollment":233,"conditions":4232,"interventions":4233},[89],[3227],[3202,3229,3230,3231],{"trials":4235,"activeCount":100},[4236,4245,4253],{"nctId":4237,"briefTitle":4238,"status":286,"phases":4239,"primaryCompletion":4240,"completion":4241,"start":4242,"enrollment":528,"conditions":4243,"interventions":4244},"NCT04233918","Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia",[90],"2022-01-31","2023-05-30","2020-06-29",[3355],[3229],{"nctId":4246,"briefTitle":4247,"status":286,"phases":4248,"primaryCompletion":4249,"completion":4249,"start":4250,"enrollment":177,"conditions":4251,"interventions":4252},"NCT03409744","Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia",[90],"2023-04-13","2018-03-13",[3355],[4209],{"nctId":4254,"briefTitle":4255,"status":286,"phases":4256,"primaryCompletion":4257,"completion":4258,"start":4259,"enrollment":1295,"conditions":4260,"interventions":4261},"NCT03399786","Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia",[90],"2019-06-10","2020-03-17","2018-01-18",[3355],[4209],{"trials":4263,"activeCount":100},[],{"trials":4265,"activeCount":100},[4266],{"nctId":4267,"briefTitle":4268,"status":688,"phases":4269,"conditions":4270,"interventions":4274},"NCT06500598","Compassionate Use of Evinacumab",[],[4271,4272,4273],"Pediatric Homozygous Familial Hypercholesterolemia (HoFH)","Severe Hypertriglyceridemia (HTG)","Dysbetalipoproteinemia (DBL)",[3229],{"intervention":4276,"totalTrials":136,"cells":4277},"BPX-601",{"EARLY_PHASE1":4278,"PHASE1":4280,"PHASE2":4303,"PHASE3":4305,"PHASE4":4307,"NA":4309},{"trials":4279,"activeCount":100},[],{"trials":4281,"activeCount":273,"soonestReadout":4286},[4282,4293],{"nctId":4283,"briefTitle":4284,"status":218,"phases":4285,"primaryCompletion":4286,"completion":4287,"start":4288,"enrollment":4289,"conditions":4290,"interventions":4292},"NCT07543055","A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread",[88],"2029-12-31","2031-03-20","2026-06-01",36,[4291],"Prostate Cancer",[4276],{"nctId":4294,"briefTitle":4295,"status":414,"phases":4296,"primaryCompletion":4297,"completion":4297,"start":4298,"enrollment":4205,"conditions":4299,"interventions":4301},"NCT02744287","Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors",[88],"2023-03-14","2016-11-30",[3160,4300],"Metastatic Prostate Cancer",[4276,4302],"Rimiducid",{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[],{"trials":4308,"activeCount":100},[],{"trials":4310,"activeCount":100},[],{"intervention":4312,"totalTrials":273,"cells":4313},"REGN22044",{"EARLY_PHASE1":4314,"PHASE1":4316,"PHASE2":4326,"PHASE3":4328,"PHASE4":4330,"NA":4332},{"trials":4315,"activeCount":100},[],{"trials":4317,"activeCount":273,"soonestReadout":4322},[4318],{"nctId":4319,"briefTitle":4320,"status":218,"phases":4321,"primaryCompletion":4322,"completion":4322,"start":4323,"enrollment":3468,"conditions":4324,"interventions":4325},"NCT07526116","A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults",[88],"2027-05-27","2026-05-07",[26],[4312],{"trials":4327,"activeCount":100},[],{"trials":4329,"activeCount":100},[],{"trials":4331,"activeCount":100},[],{"trials":4333,"activeCount":100},[],{"intervention":1028,"totalTrials":273,"cells":4335},{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4344,"PHASE3":4346,"PHASE4":4348,"NA":4350},{"trials":4337,"activeCount":100},[],{"trials":4339,"activeCount":273,"soonestReadout":1022},[4340],{"nctId":1019,"briefTitle":1020,"status":142,"phases":4341,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":4342,"interventions":4343},[88],[1026],[133,1028,1029,1030,1031,1032,66],{"trials":4345,"activeCount":100},[],{"trials":4347,"activeCount":100},[],{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[],{"intervention":1029,"totalTrials":273,"cells":4353},{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4362,"PHASE3":4364,"PHASE4":4366,"NA":4368},{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":273,"soonestReadout":1022},[4358],{"nctId":1019,"briefTitle":1020,"status":142,"phases":4359,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":4360,"interventions":4361},[88],[1026],[133,1028,1029,1030,1031,1032,66],{"trials":4363,"activeCount":100},[],{"trials":4365,"activeCount":100},[],{"trials":4367,"activeCount":100},[],{"trials":4369,"activeCount":100},[],{"intervention":4371,"totalTrials":273,"cells":4372},"REGN20423",{"EARLY_PHASE1":4373,"PHASE1":4375,"PHASE2":4386,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4374,"activeCount":100},[],{"trials":4376,"activeCount":273,"soonestReadout":4381},[4377],{"nctId":4378,"briefTitle":4379,"status":218,"phases":4380,"primaryCompletion":4381,"completion":4381,"start":4382,"enrollment":4383,"conditions":4384,"interventions":4385},"NCT07527923","First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis",[88],"2028-06-09","2026-05-04",136,[26,17],[4371],{"trials":4387,"activeCount":100},[],{"trials":4389,"activeCount":100},[],{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"intervention":132,"totalTrials":273,"cells":4395},{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4404,"PHASE3":4406,"PHASE4":4408,"NA":4410},{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":273,"soonestReadout":120},[4400],{"nctId":117,"briefTitle":118,"status":106,"phases":4401,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":4402,"interventions":4403},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"trials":4405,"activeCount":100},[],{"trials":4407,"activeCount":100},[],{"trials":4409,"activeCount":100},[],{"trials":4411,"activeCount":100},[],{"intervention":134,"totalTrials":273,"cells":4413},{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4422,"PHASE3":4424,"PHASE4":4426,"NA":4428},{"trials":4415,"activeCount":100},[],{"trials":4417,"activeCount":273,"soonestReadout":120},[4418],{"nctId":117,"briefTitle":118,"status":106,"phases":4419,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":4420,"interventions":4421},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"trials":4423,"activeCount":100},[],{"trials":4425,"activeCount":100},[],{"trials":4427,"activeCount":100},[],{"trials":4429,"activeCount":100},[],{"intervention":135,"totalTrials":273,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4446},{"trials":4433,"activeCount":100},[],{"trials":4435,"activeCount":273,"soonestReadout":120},[4436],{"nctId":117,"briefTitle":118,"status":106,"phases":4437,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":4438,"interventions":4439},[88],[125],[95,127,128,129,130,131,132,66,133,134,135],{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[],{"trials":4445,"activeCount":100},[],{"trials":4447,"activeCount":100},[],{"intervention":4449,"totalTrials":273,"cells":4450},"REGN20934",{"EARLY_PHASE1":4451,"PHASE1":4453,"PHASE2":4463,"PHASE3":4465,"PHASE4":4467,"NA":4469},{"trials":4452,"activeCount":100},[],{"trials":4454,"activeCount":273,"soonestReadout":4459},[4455],{"nctId":4456,"briefTitle":4457,"status":218,"phases":4458,"primaryCompletion":4459,"completion":4459,"start":4460,"enrollment":1110,"conditions":4461,"interventions":4462},"NCT07594093","Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity",[88],"2027-02-22","2026-06-15",[3838],[4449],{"trials":4464,"activeCount":100},[],{"trials":4466,"activeCount":100},[],{"trials":4468,"activeCount":100},[],{"trials":4470,"activeCount":100},[],{"intervention":1558,"totalTrials":273,"cells":4472},{"EARLY_PHASE1":4473,"PHASE1":4475,"PHASE2":4481,"PHASE3":4483,"PHASE4":4485,"NA":4487},{"trials":4474,"activeCount":100},[],{"trials":4476,"activeCount":273,"soonestReadout":1552},[4477],{"nctId":1549,"briefTitle":1550,"status":106,"phases":4478,"primaryCompletion":1552,"completion":1553,"start":1427,"enrollment":1554,"conditions":4479,"interventions":4480},[88],[1556],[1538,1558],{"trials":4482,"activeCount":100},[],{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[],{"intervention":4490,"totalTrials":273,"cells":4491},"ALN-F1202",{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4503,"PHASE3":4505,"PHASE4":4507,"NA":4509},{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":273,"soonestReadout":2441},[4496],{"nctId":4497,"briefTitle":4498,"status":142,"phases":4499,"primaryCompletion":2441,"completion":2441,"start":4500,"enrollment":2018,"conditions":4501,"interventions":4502},"NCT06669234","Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults",[88],"2025-03-06",[26],[4490],{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[],{"trials":4508,"activeCount":100},[],{"trials":4510,"activeCount":100},[],{"intervention":1094,"totalTrials":273,"cells":4512},{"EARLY_PHASE1":4513,"PHASE1":4515,"PHASE2":4521,"PHASE3":4523,"PHASE4":4525,"NA":4527},{"trials":4514,"activeCount":100},[],{"trials":4516,"activeCount":273,"soonestReadout":1088},[4517],{"nctId":1085,"briefTitle":1086,"status":106,"phases":4518,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":743,"conditions":4519,"interventions":4520},[88],[1091,1092],[1094,41],{"trials":4522,"activeCount":100},[],{"trials":4524,"activeCount":100},[],{"trials":4526,"activeCount":100},[],{"trials":4528,"activeCount":100},[],{"intervention":4530,"totalTrials":273,"cells":4531},"ALN-SNCA",{"EARLY_PHASE1":4532,"PHASE1":4534,"PHASE2":4546,"PHASE3":4548,"PHASE4":4550,"NA":4552},{"trials":4533,"activeCount":100},[],{"trials":4535,"activeCount":273,"soonestReadout":4540},[4536],{"nctId":4537,"briefTitle":4538,"status":106,"phases":4539,"primaryCompletion":4540,"completion":4540,"start":4541,"enrollment":4542,"conditions":4543,"interventions":4545},"NCT07216066","First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)",[88],"2029-06-07","2025-12-05",46,[4544],"Parkinsons Disease",[4530],{"trials":4547,"activeCount":100},[],{"trials":4549,"activeCount":100},[],{"trials":4551,"activeCount":100},[],{"trials":4553,"activeCount":100},[],{"intervention":80,"totalTrials":136,"cells":4555},{"EARLY_PHASE1":4556,"PHASE1":4558,"PHASE2":4560,"PHASE3":4562,"PHASE4":4564,"NA":4566},{"trials":4557,"activeCount":100},[],{"trials":4559,"activeCount":100},[],{"trials":4561,"activeCount":100},[],{"trials":4563,"activeCount":100},[],{"trials":4565,"activeCount":100},[],{"trials":4567,"activeCount":136,"soonestReadout":79},[4568,4574],{"nctId":77,"briefTitle":78,"status":142,"phases":4569,"primaryCompletion":79,"completion":79,"start":4570,"enrollment":4571,"conditions":4572,"interventions":4573},[],"2020-03-02",718,[650],[80],{"nctId":4575,"briefTitle":4576,"status":142,"phases":4577,"primaryCompletion":1249,"completion":1249,"start":4578,"enrollment":4579,"conditions":4580,"interventions":4582},"NCT04959448","Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)",[],"2021-08-12",717,[4581],"Chronic Rhinosinusitis With Nasal Polyposis",[80],{"intervention":4584,"totalTrials":895,"cells":4585},"REGN2810",{"EARLY_PHASE1":4586,"PHASE1":4588,"PHASE2":4619,"PHASE3":4621,"PHASE4":4632,"NA":4634},{"trials":4587,"activeCount":100},[],{"trials":4589,"activeCount":100},[4590,4603,4612],{"nctId":4591,"briefTitle":4592,"status":286,"phases":4593,"primaryCompletion":1453,"completion":4594,"start":4595,"enrollment":4596,"conditions":4597,"interventions":4602},"NCT03198130","An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)",[88],"2020-02-21","2017-07-03",33,[4598,4599,4600,4601],"Recurrent Squamous Cell Carcinoma of Head","Recurrent Squamous Cell Carcinoma of Neck","Metastatic Squamous Cell Carcinoma of Head","Metastatic Squamous Cell Carcinoma Neck",[4584],{"nctId":4604,"briefTitle":4605,"status":286,"phases":4606,"primaryCompletion":4607,"completion":4608,"start":4609,"enrollment":277,"conditions":4610,"interventions":4611},"NCT03002376","An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)",[88],"2019-03-05","2020-03-19","2017-04-10",[29],[4584],{"nctId":4613,"briefTitle":4614,"status":655,"phases":4615,"primaryCompletion":4616,"completion":4616,"start":575,"enrollment":100,"conditions":4617,"interventions":4618},"NCT02520245","Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study",[88],"2023-11",[1026],[4584],{"trials":4620,"activeCount":100},[],{"trials":4622,"activeCount":100},[4623],{"nctId":4624,"briefTitle":4625,"status":286,"phases":4626,"primaryCompletion":4627,"completion":4627,"start":4628,"enrollment":4629,"conditions":4630,"interventions":4631},"NCT03409614","Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer",[90],"2025-02-27","2018-03-06",789,[1297],[4584,2509],{"trials":4633,"activeCount":100},[],{"trials":4635,"activeCount":273,"soonestReadout":4640},[4636],{"nctId":4637,"briefTitle":4638,"status":142,"phases":4639,"primaryCompletion":4640,"completion":4641,"start":4642,"enrollment":4643,"conditions":4644,"interventions":4646},"NCT06269133","Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients",[],"2027-03-31","2027-06-23","2024-02-21",1000,[4645],"Advanced Non-small Cell Lung Cancer",[4584],{"intervention":4648,"totalTrials":273,"cells":4649},"Non-interventional",{"EARLY_PHASE1":4650,"PHASE1":4652,"PHASE2":4654,"PHASE3":4656,"PHASE4":4658,"NA":4660},{"trials":4651,"activeCount":100},[],{"trials":4653,"activeCount":100},[],{"trials":4655,"activeCount":100},[],{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[],{"trials":4661,"activeCount":273,"soonestReadout":4666},[4662],{"nctId":4663,"briefTitle":4664,"status":106,"phases":4665,"primaryCompletion":4666,"completion":4666,"start":527,"enrollment":743,"conditions":4667,"interventions":4669},"NCT06798298","A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells",[],"2040-06-17",[4668],"Long Term Safety Following GM T Cell Therapy",[4648],{"intervention":4671,"totalTrials":273,"cells":4672},"Noninterventional",{"EARLY_PHASE1":4673,"PHASE1":4675,"PHASE2":4677,"PHASE3":4679,"PHASE4":4681,"NA":4683},{"trials":4674,"activeCount":100},[],{"trials":4676,"activeCount":100},[],{"trials":4678,"activeCount":100},[],{"trials":4680,"activeCount":100},[],{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":273,"soonestReadout":4460},[4685],{"nctId":4686,"briefTitle":4687,"status":106,"phases":4688,"primaryCompletion":4460,"completion":4689,"start":4690,"enrollment":528,"conditions":4691,"interventions":4692},"NCT05106387","An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant",[],"2028-02-23","2023-10-19",[3193],[4671],{"intervention":4694,"totalTrials":1973,"cells":4695},"Intravitreal Aflibercept",{"EARLY_PHASE1":4696,"PHASE1":4698,"PHASE2":4710,"PHASE3":4748,"PHASE4":4768,"NA":4789},{"trials":4697,"activeCount":100},[],{"trials":4699,"activeCount":100},[4700],{"nctId":4701,"briefTitle":4702,"status":286,"phases":4703,"primaryCompletion":4704,"completion":4704,"start":4705,"enrollment":528,"conditions":4706,"interventions":4707},"NCT01997164","Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (\"Wet\") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)",[88],"2015-10","2014-11",[2937,2938],[4708,4709,4694],"REGN910-3","REGN910",{"trials":4711,"activeCount":100},[4712,4722,4729,4737],{"nctId":4713,"briefTitle":4714,"status":286,"phases":4715,"primaryCompletion":4716,"completion":4717,"start":4718,"enrollment":4719,"conditions":4720,"interventions":4721},"NCT00789477","DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact",[89],"2009-12","2010-09","2008-12",221,[2938],[4694],{"nctId":4723,"briefTitle":4724,"status":286,"phases":4725,"primaryCompletion":3352,"completion":3352,"start":386,"enrollment":4726,"conditions":4727,"interventions":4728},"NCT02713204","Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection",[89],365,[2937],[4708,4694],{"nctId":4730,"briefTitle":4731,"status":286,"phases":4732,"primaryCompletion":438,"completion":438,"start":4733,"enrollment":4734,"conditions":4735,"interventions":4736},"NCT02712008","Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema",[89],"2016-03-02",302,[2938],[4708,4694],{"nctId":4738,"briefTitle":4739,"status":414,"phases":4740,"primaryCompletion":4741,"completion":4742,"start":4743,"enrollment":4744,"conditions":4745,"interventions":4746},"NCT02418754","Study of Intravitreal REGN2176-3 in Participants With Neovascular (\"Wet\") Age-Related Macular Degeneration (AMD)",[89],"2016-08-17","2017-04-03","2015-05-05",505,[2937],[4747,4694],"REGN2176-3",{"trials":4749,"activeCount":100},[4750,4759],{"nctId":4751,"briefTitle":4752,"status":286,"phases":4753,"primaryCompletion":4754,"completion":940,"start":343,"enrollment":4755,"conditions":4756,"interventions":4758},"NCT01521559","Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)",[90],"2013-08",183,[4757],"Branch Retinal Vein Occlusion",[4694],{"nctId":4760,"briefTitle":4761,"status":286,"phases":4762,"primaryCompletion":4763,"completion":4705,"start":4764,"enrollment":4765,"conditions":4766,"interventions":4767},"NCT01363440","Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema",[90],"2013-01","2011-05",466,[2938],[4694],{"trials":4769,"activeCount":100},[4770,4779],{"nctId":4771,"briefTitle":4772,"status":286,"phases":4773,"primaryCompletion":4774,"completion":4774,"start":4775,"enrollment":1295,"conditions":4776,"interventions":4778},"NCT03767738","Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe",[91],"2020-08-19","2018-12-19",[4777],"Chorioretinal Vascular Disease",[4694],{"nctId":4780,"briefTitle":4781,"status":286,"phases":4782,"primaryCompletion":4783,"completion":4783,"start":4784,"enrollment":4785,"conditions":4786,"interventions":4788},"NCT01722045","Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)",[91],"2015-09","2012-11",154,[4787],"Age - Related Macular Degeneration (AMD)",[4694],{"trials":4790,"activeCount":100},[],{"intervention":4792,"totalTrials":136,"cells":4793},"Praluent",{"EARLY_PHASE1":4794,"PHASE1":4796,"PHASE2":4798,"PHASE3":4800,"PHASE4":4802,"NA":4823},{"trials":4795,"activeCount":100},[],{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"trials":4803,"activeCount":100},[4804,4814],{"nctId":4805,"briefTitle":4806,"status":414,"phases":4807,"primaryCompletion":4808,"completion":4808,"start":4809,"enrollment":4810,"conditions":4811,"interventions":4813},"NCT03694197","Long Term Safety Study of PRALUENT",[91],"2020-04-08","2018-09-28",1389,[3285,4812],"Non-familial Hypercholesterolemia",[4792],{"nctId":4815,"briefTitle":4816,"status":286,"phases":4817,"primaryCompletion":4818,"completion":4818,"start":4819,"enrollment":4820,"conditions":4821,"interventions":4822},"NCT02957682","Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo",[91],"2020-03-05","2016-11-02",2176,[23],[4792],{"trials":4824,"activeCount":100},[],{"intervention":4826,"totalTrials":136,"cells":4827},"Allopurinol",{"EARLY_PHASE1":4828,"PHASE1":4830,"PHASE2":4832,"PHASE3":4834,"PHASE4":4844,"NA":4858},{"trials":4829,"activeCount":100},[],{"trials":4831,"activeCount":100},[],{"trials":4833,"activeCount":100},[],{"trials":4835,"activeCount":100},[4836],{"nctId":4837,"briefTitle":4838,"status":414,"phases":4839,"primaryCompletion":342,"completion":342,"start":3273,"enrollment":197,"conditions":4840,"interventions":4842},"NCT01459796","Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares",[90],[4841],"Gout",[4843,4826],"Rilonacept",{"trials":4845,"activeCount":100},[4846],{"nctId":4847,"briefTitle":4848,"status":286,"phases":4849,"primaryCompletion":4850,"completion":4851,"start":4852,"enrollment":3411,"conditions":4853,"interventions":4855},"NCT01451645","Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol",[91],"2012-08","2012-09","2011-10",[4854],"Intercritical Gout",[4856,4857],"Colchicine","allopurinol",{"trials":4859,"activeCount":100},[],{"intervention":4856,"totalTrials":273,"cells":4861},{"EARLY_PHASE1":4862,"PHASE1":4864,"PHASE2":4866,"PHASE3":4868,"PHASE4":4870,"NA":4876},{"trials":4863,"activeCount":100},[],{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[],{"trials":4871,"activeCount":100},[4872],{"nctId":4847,"briefTitle":4848,"status":286,"phases":4873,"primaryCompletion":4850,"completion":4851,"start":4852,"enrollment":3411,"conditions":4874,"interventions":4875},[91],[4854],[4856,4857],{"trials":4877,"activeCount":100},[],{"intervention":4879,"totalTrials":32,"cells":4880},"Fasinumab",{"EARLY_PHASE1":4881,"PHASE1":4883,"PHASE2":4892,"PHASE3":4917,"PHASE4":4972,"NA":4974},{"trials":4882,"activeCount":100},[],{"trials":4884,"activeCount":100},[4885],{"nctId":4886,"briefTitle":4887,"status":286,"phases":4888,"primaryCompletion":547,"completion":547,"start":4889,"enrollment":4046,"conditions":4890,"interventions":4891},"NCT02516618","Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects",[88],"2015-07",[14],[4879],{"trials":4893,"activeCount":100},[4894,4907],{"nctId":4895,"briefTitle":4896,"status":414,"phases":4897,"primaryCompletion":4898,"completion":4898,"start":4899,"enrollment":3294,"conditions":4900,"interventions":4903},"NCT03949673","Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip",[89],"2020-08-25","2019-04-08",[4901,4902],"Osteoarthritis, Knee","Osteoarthritis, Hip",[4879,4904,4905,4906],"Naproxen","Diclofenac","Celecoxib",{"nctId":4908,"briefTitle":4909,"status":286,"phases":4910,"primaryCompletion":4911,"completion":4912,"start":4913,"enrollment":4914,"conditions":4915,"interventions":4916},"NCT03691974","Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee",[89],"2020-01-30","2021-01-07","2018-10-15",180,[4901,4902],[4879],{"trials":4918,"activeCount":100},[4919,4929,4940,4951,4961],{"nctId":4920,"briefTitle":4921,"status":286,"phases":4922,"primaryCompletion":4923,"completion":4924,"start":4925,"enrollment":4926,"conditions":4927,"interventions":4928},"NCT03304379","Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip",[90],"2019-12-13","2020-11-09","2017-10-26",1650,[4901,4902],[4879],{"nctId":4930,"briefTitle":4931,"status":414,"phases":4932,"primaryCompletion":4933,"completion":4934,"start":4935,"enrollment":2431,"conditions":4936,"interventions":4939},"NCT03285646","Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee",[90],"2018-05-05","2019-05-02","2017-10-30",[4937,4938],"Chronic Low Back Pain","Osteoarthritis",[4879],{"nctId":4941,"briefTitle":4942,"status":286,"phases":4943,"primaryCompletion":4944,"completion":4945,"start":4946,"enrollment":4947,"conditions":4948,"interventions":4950},"NCT02620020","A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain",[89,90],"2017-02-03","2017-09-13","2016-01-26",563,[4949],"Low Back Pain",[4879],{"nctId":4952,"briefTitle":4953,"status":286,"phases":4954,"primaryCompletion":4955,"completion":4956,"start":4957,"enrollment":4958,"conditions":4959,"interventions":4960},"NCT03161093","A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip",[90],"2019-09-09","2021-08-27","2017-08-17",3307,[4901,4902],[4879,4904],{"nctId":4962,"briefTitle":4963,"status":286,"phases":4964,"primaryCompletion":4965,"completion":4966,"start":4967,"enrollment":4968,"conditions":4969,"interventions":4971},"NCT02683239","Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip",[90],"2020-12-01","2021-06-15","2016-02-17",5331,[4970],"Osteoarthritis of the Knee or Hip",[4879],{"trials":4973,"activeCount":100},[],{"trials":4975,"activeCount":100},[],{"intervention":4843,"totalTrials":35,"cells":4977},{"EARLY_PHASE1":4978,"PHASE1":4980,"PHASE2":4992,"PHASE3":5011,"PHASE4":5044,"NA":5046},{"trials":4979,"activeCount":100},[],{"trials":4981,"activeCount":100},[4982],{"nctId":4983,"briefTitle":4984,"status":286,"phases":4985,"primaryCompletion":4986,"completion":4986,"start":4987,"enrollment":823,"conditions":4988,"interventions":4990},"NCT01803321","Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)",[88],"2008-06","2005-11",[4989],"Systemic Juvenile Idiopathic Arthritis",[4991],"rilonacept",{"trials":4993,"activeCount":100},[4994,5003],{"nctId":4995,"briefTitle":4996,"status":286,"phases":4997,"primaryCompletion":4998,"completion":4998,"start":4999,"enrollment":5000,"conditions":5001,"interventions":5002},"NCT00610363","Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares",[89],"2008-10","2007-11",83,[4841],[4843],{"nctId":5004,"briefTitle":5005,"status":655,"phases":5006,"enrollment":100,"conditions":5007,"interventions":5010},"NCT00609544","Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia",[89],[5008,5009],"Chronic Kidney Disease","Anemia",[4843],{"trials":5012,"activeCount":100},[5013,5024,5031,5035],{"nctId":5014,"briefTitle":5015,"status":286,"phases":5016,"primaryCompletion":5017,"completion":5017,"start":5018,"enrollment":5019,"conditions":5020,"interventions":5022},"NCT00855920","Study Utilizing Rilonacept in Gout Exacerbations",[90],"2010-02","2009-03",225,[5021],"Acute Gout Flare",[4843,5023],"Indomethacin",{"nctId":5025,"briefTitle":5026,"status":286,"phases":5027,"primaryCompletion":3274,"completion":3274,"start":5018,"enrollment":5028,"conditions":5029,"interventions":5030},"NCT00856206","Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)",[90],1315,[4841],[4843],{"nctId":4837,"briefTitle":4838,"status":414,"phases":5032,"primaryCompletion":342,"completion":342,"start":3273,"enrollment":197,"conditions":5033,"interventions":5034},[90],[4841],[4843,4826],{"nctId":5036,"briefTitle":5037,"status":286,"phases":5038,"primaryCompletion":5039,"completion":5039,"start":5040,"enrollment":5041,"conditions":5042,"interventions":5043},"NCT00958438","PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)",[90],"2010-12","2009-07",248,[4841],[4843,4843],{"trials":5045,"activeCount":100},[],{"trials":5047,"activeCount":100},[],{"intervention":5049,"totalTrials":35,"cells":5050},"aflibercept",{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5063,"PHASE3":5089,"PHASE4":5122,"NA":5124},{"trials":5052,"activeCount":100},[],{"trials":5054,"activeCount":100},[5055],{"nctId":5056,"briefTitle":5057,"status":286,"phases":5058,"primaryCompletion":4705,"completion":4705,"start":3313,"enrollment":3767,"conditions":5059,"interventions":5061},"NCT01688960","Nesvacumab (REGN910\u002F SAR307746) and Aflibercept (\"Ziv-aflibercept\" in the U.S.) in Patients With Advanced Solid Malignancies",[88],[5060],"Solid Tumors",[5062,5062,5062,5049,5049],"nesvacumab",{"trials":5064,"activeCount":100},[5065,5075,5079],{"nctId":5066,"briefTitle":5067,"status":286,"phases":5068,"primaryCompletion":5069,"completion":1158,"start":5070,"enrollment":617,"conditions":5071,"interventions":5073},"NCT04126317","Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration",[89],"2021-05-14","2019-11-04",[5072],"Neovascular (Wet) Age-Related Macular Degeneration",[5049,5074],"High-dose aflibercept",{"nctId":2072,"briefTitle":2073,"status":414,"phases":5076,"primaryCompletion":2075,"completion":2075,"start":2076,"enrollment":2077,"conditions":5077,"interventions":5078},[88,89],[2079,1297],[2081,1031,1347],{"nctId":5080,"briefTitle":5081,"status":286,"phases":5082,"primaryCompletion":4986,"completion":5083,"start":5084,"enrollment":5085,"conditions":5086,"interventions":5088},"NCT00320788","Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)",[89],"2008-08","2006-04",159,[5087],"Macular Degeneration",[5049,5049,5049,5049,5049],{"trials":5090,"activeCount":100},[5091,5102,5112],{"nctId":5092,"briefTitle":5093,"status":286,"phases":5094,"primaryCompletion":5095,"completion":5096,"start":4242,"enrollment":5097,"conditions":5098,"interventions":5101},"NCT04429503","Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease",[89,90],"2022-05-30","2024-06-18",660,[2938,5099,5100],"Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus",[5049,5074],{"nctId":5103,"briefTitle":5104,"status":286,"phases":5105,"primaryCompletion":4717,"completion":5106,"start":5107,"enrollment":5108,"conditions":5109,"interventions":5110},"NCT00509795","Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)",[90],"2011-07","2007-08",1217,[5087],[5111,5049,5049,5049],"ranibizumab",{"nctId":5113,"briefTitle":5114,"status":286,"phases":5115,"primaryCompletion":5116,"completion":5116,"start":5117,"enrollment":5118,"conditions":5119,"interventions":5121},"NCT04101721","Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity",[90],"2022-08-18","2019-10-30",127,[5120],"Retinopathy of Prematurity",[5049],{"trials":5123,"activeCount":100},[],{"trials":5125,"activeCount":100},[],{"intervention":2471,"totalTrials":110,"cells":5127},{"EARLY_PHASE1":5128,"PHASE1":5130,"PHASE2":5151,"PHASE3":5170,"PHASE4":5179,"NA":5181},{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":100},[5132,5136,5140],{"nctId":2462,"briefTitle":2463,"status":286,"phases":5133,"primaryCompletion":2465,"completion":2466,"start":2467,"enrollment":268,"conditions":5134,"interventions":5135},[88],[2469],[2471,1358,2471],{"nctId":2473,"briefTitle":2474,"status":286,"phases":5137,"primaryCompletion":2476,"completion":2476,"start":2477,"enrollment":2478,"conditions":5138,"interventions":5139},[88],[29],[2471,1358],{"nctId":5141,"briefTitle":5142,"status":286,"phases":5143,"primaryCompletion":5144,"completion":5144,"start":5145,"enrollment":5146,"conditions":5147,"interventions":5149},"NCT03438318","Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer",[88],"2019-12-11","2018-03-15",29,[5148],"Non Small Cell Lung Cancer",[2471,5150],"Atezolizumab",{"trials":5152,"activeCount":100},[5153,5157],{"nctId":2484,"briefTitle":2485,"status":414,"phases":5154,"primaryCompletion":2487,"completion":2487,"start":2488,"enrollment":823,"conditions":5155,"interventions":5156},[89],[1056],[2471,1358],{"nctId":5158,"briefTitle":5159,"status":414,"phases":5160,"primaryCompletion":5161,"completion":5161,"start":5162,"enrollment":5163,"conditions":5164,"interventions":5168},"NCT04698187","CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma",[89],"2024-02-05","2021-03-11",44,[29,5165,5166,5167],"Advanced Melanoma","Metastatic Melanoma","Unresectable Melanoma",[2471,5169],"Nivolumab",{"trials":5171,"activeCount":100},[5172],{"nctId":5173,"briefTitle":5174,"status":414,"phases":5175,"primaryCompletion":3390,"completion":3390,"start":5176,"enrollment":528,"conditions":5177,"interventions":5178},"NCT04695977","CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma",[89,90],"2021-02-24",[29,5165,5166,5167],[2471,5169],{"trials":5180,"activeCount":100},[],{"trials":5182,"activeCount":100},[],{"intervention":5184,"totalTrials":895,"cells":5185},"REGN475",{"EARLY_PHASE1":5186,"PHASE1":5188,"PHASE2":5198,"PHASE3":5223,"PHASE4":5235,"NA":5237},{"trials":5187,"activeCount":100},[],{"trials":5189,"activeCount":100},[5190],{"nctId":5191,"briefTitle":5192,"status":286,"phases":5193,"primaryCompletion":5194,"completion":5194,"start":5195,"enrollment":2018,"conditions":5196,"interventions":5197},"NCT00856310","A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects",[88],"2009-11","2009-02",[20],[5184],{"trials":5199,"activeCount":100},[5200,5210,5216],{"nctId":5201,"briefTitle":5202,"status":286,"phases":5203,"primaryCompletion":5204,"completion":5204,"start":5205,"enrollment":5206,"conditions":5207,"interventions":5209},"NCT00944892","A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee",[88,89],"2010-05","2009-08",200,[5208],"Osteoarthritis of the Knee",[5184],{"nctId":5211,"briefTitle":5212,"status":655,"phases":5213,"enrollment":100,"conditions":5214,"interventions":5215},"NCT01239017","A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee",[89],[4938],[5184],{"nctId":5217,"briefTitle":5218,"status":286,"phases":5219,"primaryCompletion":5204,"completion":5204,"start":5194,"enrollment":5085,"conditions":5220,"interventions":5222},"NCT00991172","A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain",[89],[5221],"Sciatica",[5184,5184],{"trials":5224,"activeCount":100},[5225],{"nctId":5226,"briefTitle":5227,"status":286,"phases":5228,"primaryCompletion":5229,"completion":5230,"start":5231,"enrollment":5232,"conditions":5233,"interventions":5234},"NCT02447276","Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip",[89,90],"2016-03","2016-11","2015-05",421,[4901,4902],[5184],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"intervention":5240,"totalTrials":895,"cells":5241},"casirivimab+imdevimab",{"EARLY_PHASE1":5242,"PHASE1":5244,"PHASE2":5264,"PHASE3":5283,"PHASE4":5295,"NA":5297},{"trials":5243,"activeCount":100},[],{"trials":5245,"activeCount":100},[5246,5254],{"nctId":5247,"briefTitle":5248,"status":414,"phases":5249,"primaryCompletion":5250,"completion":5250,"start":5251,"enrollment":136,"conditions":5252,"interventions":5253},"NCT05092581","COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19",[88],"2022-06-09","2021-12-16",[3003],[5240],{"nctId":5255,"briefTitle":5256,"status":286,"phases":5257,"primaryCompletion":5258,"completion":5258,"start":5259,"enrollment":698,"conditions":5260,"interventions":5262},"NCT05181683","COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers",[88],"2022-06-03","2022-01-07",[20,5261],"Chronic Stable Illness",[5263],"Casirivimab+Imdevimab",{"trials":5265,"activeCount":100},[5266,5274],{"nctId":5267,"briefTitle":5268,"status":414,"phases":5269,"primaryCompletion":5270,"completion":5270,"start":5271,"enrollment":35,"conditions":5272,"interventions":5273},"NCT04992273","COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age",[89],"2022-06-01","2021-09-13",[3003],[5240],{"nctId":5275,"briefTitle":5276,"status":286,"phases":5277,"primaryCompletion":2430,"completion":2430,"start":5278,"enrollment":5279,"conditions":5280,"interventions":5281},"NCT04852978","COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers",[89],"2021-04-29",295,[20,5261],[5240,5282],"Moderna mRNA-1273 vaccine",{"trials":5284,"activeCount":100},[5285],{"nctId":5286,"briefTitle":5287,"status":414,"phases":5288,"primaryCompletion":5289,"completion":5289,"start":5290,"enrollment":5291,"conditions":5292,"interventions":5294},"NCT05074433","A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults",[90],"2022-05-18","2021-10-25",66,[5293],"Immunocompromised",[5240],{"trials":5296,"activeCount":100},[],{"trials":5298,"activeCount":100},[],{"intervention":5300,"totalTrials":258,"cells":5301},"REGN1908-1909",{"EARLY_PHASE1":5302,"PHASE1":5304,"PHASE2":5322,"PHASE3":5335,"PHASE4":5348,"NA":5350},{"trials":5303,"activeCount":100},[],{"trials":5305,"activeCount":100},[5306,5313],{"nctId":5307,"briefTitle":5308,"status":286,"phases":5309,"primaryCompletion":427,"completion":427,"start":4754,"enrollment":823,"conditions":5310,"interventions":5312},"NCT01922661","Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects",[88],[5311],"Allergy",[5300],{"nctId":5314,"briefTitle":5315,"status":286,"phases":5316,"primaryCompletion":5317,"completion":5317,"start":5318,"enrollment":5319,"conditions":5320,"interventions":5321},"NCT02127801","Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants",[88],"2015-12-31","2014-10-31",74,[5311],[5300],{"trials":5323,"activeCount":100},[5324],{"nctId":5325,"briefTitle":5326,"status":286,"phases":5327,"primaryCompletion":5328,"completion":5329,"start":5330,"enrollment":2018,"conditions":5331,"interventions":5334},"NCT03838731","Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge",[89],"2019-12-21","2020-04-06","2019-02-12",[5332,5333],"Cat Allergy","Mild Asthma",[5300],{"trials":5336,"activeCount":100},[5337],{"nctId":5338,"briefTitle":5339,"status":414,"phases":5340,"primaryCompletion":5341,"completion":5342,"start":5343,"enrollment":5344,"conditions":5345,"interventions":5347},"NCT04981717","A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat",[90],"2023-01-04","2023-04-24","2021-07-30",446,[5346],"Allergic Rhinitis Due to Cat Allergy",[5300],{"trials":5349,"activeCount":100},[],{"trials":5351,"activeCount":100},[],{"intervention":3318,"totalTrials":763,"cells":5353},{"EARLY_PHASE1":5354,"PHASE1":5356,"PHASE2":5358,"PHASE3":5360,"PHASE4":5374,"NA":5376},{"trials":5355,"activeCount":100},[],{"trials":5357,"activeCount":100},[],{"trials":5359,"activeCount":100},[],{"trials":5361,"activeCount":100},[5362,5366,5370],{"nctId":3309,"briefTitle":3310,"status":286,"phases":5363,"primaryCompletion":3312,"completion":427,"start":3313,"enrollment":3314,"conditions":5364,"interventions":5365},[90],[23],[3261,3317,3318,3319],{"nctId":3321,"briefTitle":3322,"status":286,"phases":5367,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":3327,"conditions":5368,"interventions":5369},[90],[23],[3261,3319,3318],{"nctId":3338,"briefTitle":3339,"status":286,"phases":5371,"primaryCompletion":3325,"completion":3341,"start":3342,"enrollment":3343,"conditions":5372,"interventions":5373},[90],[23],[3317,3318,3261],{"trials":5375,"activeCount":100},[],{"trials":5377,"activeCount":100},[],{"intervention":5379,"totalTrials":763,"cells":5380},"REGN3918",{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5393,"PHASE3":5404,"PHASE4":5414,"NA":5416},{"trials":5382,"activeCount":100},[],{"trials":5384,"activeCount":100},[5385],{"nctId":5386,"briefTitle":5387,"status":286,"phases":5388,"primaryCompletion":5389,"completion":5389,"start":5390,"enrollment":2018,"conditions":5391,"interventions":5392},"NCT03115996","Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers",[88],"2018-08-31","2017-05-10",[14],[5379],{"trials":5394,"activeCount":100},[5395],{"nctId":5396,"briefTitle":5397,"status":286,"phases":5398,"primaryCompletion":5399,"completion":5400,"start":5401,"enrollment":823,"conditions":5402,"interventions":5403},"NCT03946748","Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",[89],"2021-06-09","2021-06-10","2019-05-16",[3505],[5379],{"trials":5405,"activeCount":100},[5406],{"nctId":5407,"briefTitle":5408,"status":414,"phases":5409,"primaryCompletion":5410,"completion":5410,"start":5411,"enrollment":823,"conditions":5412,"interventions":5413},"NCT04162470","REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.",[90],"2022-04-07","2019-12-03",[31],[5379],{"trials":5415,"activeCount":100},[],{"trials":5417,"activeCount":100},[],{"intervention":3317,"totalTrials":136,"cells":5419},{"EARLY_PHASE1":5420,"PHASE1":5422,"PHASE2":5424,"PHASE3":5426,"PHASE4":5436,"NA":5438},{"trials":5421,"activeCount":100},[],{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[5428,5432],{"nctId":3309,"briefTitle":3310,"status":286,"phases":5429,"primaryCompletion":3312,"completion":427,"start":3313,"enrollment":3314,"conditions":5430,"interventions":5431},[90],[23],[3261,3317,3318,3319],{"nctId":3338,"briefTitle":3339,"status":286,"phases":5433,"primaryCompletion":3325,"completion":3341,"start":3342,"enrollment":3343,"conditions":5434,"interventions":5435},[90],[23],[3317,3318,3261],{"trials":5437,"activeCount":100},[],{"trials":5439,"activeCount":100},[],{"intervention":3319,"totalTrials":136,"cells":5441},{"EARLY_PHASE1":5442,"PHASE1":5444,"PHASE2":5446,"PHASE3":5448,"PHASE4":5458,"NA":5460},{"trials":5443,"activeCount":100},[],{"trials":5445,"activeCount":100},[],{"trials":5447,"activeCount":100},[],{"trials":5449,"activeCount":100},[5450,5454],{"nctId":3309,"briefTitle":3310,"status":286,"phases":5451,"primaryCompletion":3312,"completion":427,"start":3313,"enrollment":3314,"conditions":5452,"interventions":5453},[90],[23],[3261,3317,3318,3319],{"nctId":3321,"briefTitle":3322,"status":286,"phases":5455,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":3327,"conditions":5456,"interventions":5457},[90],[23],[3261,3319,3318],{"trials":5459,"activeCount":100},[],{"trials":5461,"activeCount":100},[],{"intervention":4904,"totalTrials":136,"cells":5463},{"EARLY_PHASE1":5464,"PHASE1":5466,"PHASE2":5468,"PHASE3":5474,"PHASE4":5480,"NA":5482},{"trials":5465,"activeCount":100},[],{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[5470],{"nctId":4895,"briefTitle":4896,"status":414,"phases":5471,"primaryCompletion":4898,"completion":4898,"start":4899,"enrollment":3294,"conditions":5472,"interventions":5473},[89],[4901,4902],[4879,4904,4905,4906],{"trials":5475,"activeCount":100},[5476],{"nctId":4952,"briefTitle":4953,"status":286,"phases":5477,"primaryCompletion":4955,"completion":4956,"start":4957,"enrollment":4958,"conditions":5478,"interventions":5479},[90],[4901,4902],[4879,4904],{"trials":5481,"activeCount":100},[],{"trials":5483,"activeCount":100},[],{"intervention":5074,"totalTrials":136,"cells":5485},{"EARLY_PHASE1":5486,"PHASE1":5488,"PHASE2":5490,"PHASE3":5496,"PHASE4":5502,"NA":5504},{"trials":5487,"activeCount":100},[],{"trials":5489,"activeCount":100},[],{"trials":5491,"activeCount":100},[5492],{"nctId":5066,"briefTitle":5067,"status":286,"phases":5493,"primaryCompletion":5069,"completion":1158,"start":5070,"enrollment":617,"conditions":5494,"interventions":5495},[89],[5072],[5049,5074],{"trials":5497,"activeCount":100},[5498],{"nctId":5092,"briefTitle":5093,"status":286,"phases":5499,"primaryCompletion":5095,"completion":5096,"start":4242,"enrollment":5097,"conditions":5500,"interventions":5501},[89,90],[2938,5099,5100],[5049,5074],{"trials":5503,"activeCount":100},[],{"trials":5505,"activeCount":100},[],{"intervention":5169,"totalTrials":136,"cells":5507},{"EARLY_PHASE1":5508,"PHASE1":5510,"PHASE2":5512,"PHASE3":5518,"PHASE4":5524,"NA":5526},{"trials":5509,"activeCount":100},[],{"trials":5511,"activeCount":100},[],{"trials":5513,"activeCount":100},[5514],{"nctId":5158,"briefTitle":5159,"status":414,"phases":5515,"primaryCompletion":5161,"completion":5161,"start":5162,"enrollment":5163,"conditions":5516,"interventions":5517},[89],[29,5165,5166,5167],[2471,5169],{"trials":5519,"activeCount":100},[5520],{"nctId":5173,"briefTitle":5174,"status":414,"phases":5521,"primaryCompletion":3390,"completion":3390,"start":5176,"enrollment":528,"conditions":5522,"interventions":5523},[89,90],[29,5165,5166,5167],[2471,5169],{"trials":5525,"activeCount":100},[],{"trials":5527,"activeCount":100},[],{"intervention":2509,"totalTrials":136,"cells":5529},{"EARLY_PHASE1":5530,"PHASE1":5532,"PHASE2":5534,"PHASE3":5536,"PHASE4":5546,"NA":5548},{"trials":5531,"activeCount":100},[],{"trials":5533,"activeCount":100},[],{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[5538,5542],{"nctId":4624,"briefTitle":4625,"status":286,"phases":5539,"primaryCompletion":4627,"completion":4627,"start":4628,"enrollment":4629,"conditions":5540,"interventions":5541},[90],[1297],[4584,2509],{"nctId":2502,"briefTitle":2503,"status":414,"phases":5543,"primaryCompletion":822,"completion":822,"start":2505,"enrollment":895,"conditions":5544,"interventions":5545},[90],[1297],[2508,2509,1358],{"trials":5547,"activeCount":100},[],{"trials":5549,"activeCount":100},[],{"intervention":2602,"totalTrials":136,"cells":5551},{"EARLY_PHASE1":5552,"PHASE1":5554,"PHASE2":5556,"PHASE3":5562,"PHASE4":5568,"NA":5570},{"trials":5553,"activeCount":100},[],{"trials":5555,"activeCount":100},[],{"trials":5557,"activeCount":100},[5558],{"nctId":2594,"briefTitle":2595,"status":286,"phases":5559,"primaryCompletion":2597,"completion":2597,"start":2598,"enrollment":2599,"conditions":5560,"interventions":5561},[89],[356,745],[2585,2602,2603],{"trials":5563,"activeCount":100},[5564],{"nctId":2625,"briefTitle":2626,"status":286,"phases":5565,"primaryCompletion":2628,"completion":2628,"start":2629,"enrollment":2630,"conditions":5566,"interventions":5567},[90],[356,745],[2585,2602,2603],{"trials":5569,"activeCount":100},[],{"trials":5571,"activeCount":100},[],{"intervention":5573,"totalTrials":136,"cells":5574},"rilonacept 160 mg",{"EARLY_PHASE1":5575,"PHASE1":5577,"PHASE2":5579,"PHASE3":5581,"PHASE4":5605,"NA":5607},{"trials":5576,"activeCount":100},[],{"trials":5578,"activeCount":100},[],{"trials":5580,"activeCount":100},[],{"trials":5582,"activeCount":100},[5583,5595],{"nctId":5584,"briefTitle":5585,"status":286,"phases":5586,"primaryCompletion":4986,"completion":5083,"start":5587,"enrollment":5588,"conditions":5589,"interventions":5594},"NCT00288704","Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)",[90],"2005-12",104,[5590,5591,5592,5593],"Familial Cold Autoinflammatory Syndrome (FCAS)","Familial Cold Urticaria","Muckle-Wells Syndrome (MWS)","Genetic Diseases, Inborn",[5573,5573],{"nctId":5596,"briefTitle":5597,"status":286,"phases":5598,"primaryCompletion":5204,"completion":5599,"start":5195,"enrollment":5600,"conditions":5601,"interventions":5602},"NCT00829829","PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1",[90],"2010-06",241,[4854],[5603,5604],"Rilonacept 80 mg","Rilonacept 160 mg",{"trials":5606,"activeCount":100},[],{"trials":5608,"activeCount":100},[],{"intervention":5610,"totalTrials":273,"cells":5611},"casirivimab+imdevimab combination therapy",{"EARLY_PHASE1":5612,"PHASE1":5614,"PHASE2":5616,"PHASE3":5618,"PHASE4":5629,"NA":5631},{"trials":5613,"activeCount":100},[],{"trials":5615,"activeCount":100},[],{"trials":5617,"activeCount":100},[],{"trials":5619,"activeCount":100},[5620],{"nctId":5621,"briefTitle":5622,"status":414,"phases":5623,"primaryCompletion":5624,"completion":5250,"start":5625,"enrollment":5626,"conditions":5627,"interventions":5628},"NCT04425629","Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",[90],"2022-01-21","2020-06-16",10078,[3003],[5610],{"trials":5630,"activeCount":100},[],{"trials":5632,"activeCount":100},[],{"intervention":5023,"totalTrials":273,"cells":5634},{"EARLY_PHASE1":5635,"PHASE1":5637,"PHASE2":5639,"PHASE3":5641,"PHASE4":5647,"NA":5649},{"trials":5636,"activeCount":100},[],{"trials":5638,"activeCount":100},[],{"trials":5640,"activeCount":100},[],{"trials":5642,"activeCount":100},[5643],{"nctId":5014,"briefTitle":5015,"status":286,"phases":5644,"primaryCompletion":5017,"completion":5017,"start":5018,"enrollment":5019,"conditions":5645,"interventions":5646},[90],[5021],[4843,5023],{"trials":5648,"activeCount":100},[],{"trials":5650,"activeCount":100},[],{"intervention":5652,"totalTrials":273,"cells":5653},"Intravitreal aflibercept injection [IAI]",{"EARLY_PHASE1":5654,"PHASE1":5656,"PHASE2":5658,"PHASE3":5660,"PHASE4":5673,"NA":5675},{"trials":5655,"activeCount":100},[],{"trials":5657,"activeCount":100},[],{"trials":5659,"activeCount":100},[],{"trials":5661,"activeCount":100},[5662],{"nctId":5663,"briefTitle":5664,"status":286,"phases":5665,"primaryCompletion":5666,"completion":5667,"start":5668,"enrollment":5669,"conditions":5670,"interventions":5672},"NCT02718326","Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)",[90],"2018-08-06","2019-07-16","2016-03-29",402,[5671],"Nonproliferative Diabetic Retinopathy",[5652],{"trials":5674,"activeCount":100},[],{"trials":5676,"activeCount":100},[],{"intervention":5678,"totalTrials":273,"cells":5679},"Suptavumab 30 mg\u002Fkg",{"EARLY_PHASE1":5680,"PHASE1":5682,"PHASE2":5684,"PHASE3":5686,"PHASE4":5701,"NA":5703},{"trials":5681,"activeCount":100},[],{"trials":5683,"activeCount":100},[],{"trials":5685,"activeCount":100},[],{"trials":5687,"activeCount":100},[5688],{"nctId":5689,"briefTitle":5690,"status":286,"phases":5691,"primaryCompletion":5692,"completion":5693,"start":5694,"enrollment":5695,"conditions":5696,"interventions":5698},"NCT02325791","Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants",[90],"2017-07-05","2017-09-26","2015-07-21",1177,[5697],"Respiratory Syncytial Virus Infections",[5678,5699,5700],"Suptavumab 30 mg\u002Fkg- 1 Dose","Suptavumab 30 mg\u002Fkg - 2 Doses",{"trials":5702,"activeCount":100},[],{"trials":5704,"activeCount":100},[],{"intervention":5699,"totalTrials":273,"cells":5706},{"EARLY_PHASE1":5707,"PHASE1":5709,"PHASE2":5711,"PHASE3":5713,"PHASE4":5719,"NA":5721},{"trials":5708,"activeCount":100},[],{"trials":5710,"activeCount":100},[],{"trials":5712,"activeCount":100},[],{"trials":5714,"activeCount":100},[5715],{"nctId":5689,"briefTitle":5690,"status":286,"phases":5716,"primaryCompletion":5692,"completion":5693,"start":5694,"enrollment":5695,"conditions":5717,"interventions":5718},[90],[5697],[5678,5699,5700],{"trials":5720,"activeCount":100},[],{"trials":5722,"activeCount":100},[],{"intervention":5700,"totalTrials":273,"cells":5724},{"EARLY_PHASE1":5725,"PHASE1":5727,"PHASE2":5729,"PHASE3":5731,"PHASE4":5737,"NA":5739},{"trials":5726,"activeCount":100},[],{"trials":5728,"activeCount":100},[],{"trials":5730,"activeCount":100},[],{"trials":5732,"activeCount":100},[5733],{"nctId":5689,"briefTitle":5690,"status":286,"phases":5734,"primaryCompletion":5692,"completion":5693,"start":5694,"enrollment":5695,"conditions":5735,"interventions":5736},[90],[5697],[5678,5699,5700],{"trials":5738,"activeCount":100},[],{"trials":5740,"activeCount":100},[],{"intervention":5742,"totalTrials":273,"cells":5743},"Intravitreal Aflibercept Injection 2mg",{"EARLY_PHASE1":5744,"PHASE1":5746,"PHASE2":5748,"PHASE3":5750,"PHASE4":5760,"NA":5762},{"trials":5745,"activeCount":100},[],{"trials":5747,"activeCount":100},[],{"trials":5749,"activeCount":100},[],{"trials":5751,"activeCount":100},[5752],{"nctId":5753,"briefTitle":5754,"status":286,"phases":5755,"primaryCompletion":4754,"completion":4754,"start":4716,"enrollment":5756,"conditions":5757,"interventions":5759},"NCT00964795","Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (\"Wet\") Age-related Macular Degeneration (AMD)",[90],323,[5758],"Neovascular Age-related Macular Degeneration",[5742],{"trials":5761,"activeCount":100},[],{"trials":5763,"activeCount":100},[],{"intervention":5111,"totalTrials":273,"cells":5765},{"EARLY_PHASE1":5766,"PHASE1":5768,"PHASE2":5770,"PHASE3":5772,"PHASE4":5778,"NA":5780},{"trials":5767,"activeCount":100},[],{"trials":5769,"activeCount":100},[],{"trials":5771,"activeCount":100},[],{"trials":5773,"activeCount":100},[5774],{"nctId":5103,"briefTitle":5104,"status":286,"phases":5775,"primaryCompletion":4717,"completion":5106,"start":5107,"enrollment":5108,"conditions":5776,"interventions":5777},[90],[5087],[5111,5049,5049,5049],{"trials":5779,"activeCount":100},[],{"trials":5781,"activeCount":100},[],{"intervention":5783,"totalTrials":273,"cells":5784},"REGN10933 + REGN10987",{"EARLY_PHASE1":5785,"PHASE1":5787,"PHASE2":5789,"PHASE3":5791,"PHASE4":5803,"NA":5805},{"trials":5786,"activeCount":100},[],{"trials":5788,"activeCount":100},[],{"trials":5790,"activeCount":100},[],{"trials":5792,"activeCount":100},[5793],{"nctId":5794,"briefTitle":5795,"status":286,"phases":5796,"primaryCompletion":5797,"completion":5797,"start":5798,"enrollment":5799,"conditions":5800,"interventions":5802},"NCT04452318","COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay",[90],"2021-10-04","2020-07-13",3303,[5801],"Healthy Participants",[5783],{"trials":5804,"activeCount":100},[],{"trials":5806,"activeCount":100},[],{"intervention":3365,"totalTrials":273,"cells":5808},{"EARLY_PHASE1":5809,"PHASE1":5811,"PHASE2":5813,"PHASE3":5815,"PHASE4":5821,"NA":5823},{"trials":5810,"activeCount":100},[],{"trials":5812,"activeCount":100},[],{"trials":5814,"activeCount":100},[],{"trials":5816,"activeCount":100},[5817],{"nctId":3358,"briefTitle":3359,"status":286,"phases":5818,"primaryCompletion":428,"completion":939,"start":3361,"enrollment":3362,"conditions":5819,"interventions":5820},[90],[23],[3261,3365],{"trials":5822,"activeCount":100},[],{"trials":5824,"activeCount":100},[],{"intervention":1434,"totalTrials":273,"cells":5826},{"EARLY_PHASE1":5827,"PHASE1":5829,"PHASE2":5831,"PHASE3":5833,"PHASE4":5839,"NA":5841},{"trials":5828,"activeCount":100},[],{"trials":5830,"activeCount":100},[],{"trials":5832,"activeCount":100},[],{"trials":5834,"activeCount":100},[5835],{"nctId":1423,"briefTitle":1424,"status":286,"phases":5836,"primaryCompletion":1426,"completion":1427,"start":1428,"enrollment":1429,"conditions":5837,"interventions":5838},[90],[1431,1432],[133,1434],{"trials":5840,"activeCount":100},[],{"trials":5842,"activeCount":100},[],{"intervention":621,"totalTrials":273,"cells":5844},{"EARLY_PHASE1":5845,"PHASE1":5847,"PHASE2":5849,"PHASE3":5851,"PHASE4":5857,"NA":5859},{"trials":5846,"activeCount":100},[],{"trials":5848,"activeCount":100},[],{"trials":5850,"activeCount":100},[],{"trials":5852,"activeCount":100},[5853],{"nctId":611,"briefTitle":612,"status":286,"phases":5854,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":5855,"interventions":5856},[89,90],[619],[115,621],{"trials":5858,"activeCount":100},[],{"trials":5860,"activeCount":100},[],{"intervention":5862,"totalTrials":273,"cells":5863},"VEGF Trap-Eye 2.0mg",{"EARLY_PHASE1":5864,"PHASE1":5866,"PHASE2":5868,"PHASE3":5870,"PHASE4":5881,"NA":5883},{"trials":5865,"activeCount":100},[],{"trials":5867,"activeCount":100},[],{"trials":5869,"activeCount":100},[],{"trials":5871,"activeCount":100},[5872],{"nctId":5873,"briefTitle":5874,"status":286,"phases":5875,"primaryCompletion":5876,"completion":343,"start":5040,"enrollment":5877,"conditions":5878,"interventions":5880},"NCT00943072","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)",[90],"2010-10",189,[5879],"Macular Edema Secondary to Central Retinal Vein Occlusion",[5862],{"trials":5882,"activeCount":100},[],{"trials":5884,"activeCount":100},[],{"intervention":5886,"totalTrials":273,"cells":5887},"aflibercept 8 mg PFS",{"EARLY_PHASE1":5888,"PHASE1":5890,"PHASE2":5892,"PHASE3":5894,"PHASE4":5905,"NA":5907},{"trials":5889,"activeCount":100},[],{"trials":5891,"activeCount":100},[],{"trials":5893,"activeCount":100},[],{"trials":5895,"activeCount":100},[5896],{"nctId":5897,"briefTitle":5898,"status":286,"phases":5899,"primaryCompletion":5900,"completion":5900,"start":5901,"enrollment":876,"conditions":5902,"interventions":5904},"NCT05989126","Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)",[90],"2024-05-31","2024-04-15",[2954,5903],"Neovascular Age-Related Macular Degeneration (nAMD)",[5886],{"trials":5906,"activeCount":100},[],{"trials":5908,"activeCount":100},[],{"intervention":5910,"totalTrials":273,"cells":5911},"REGN1908",{"EARLY_PHASE1":5912,"PHASE1":5914,"PHASE2":5916,"PHASE3":5918,"PHASE4":5929,"NA":5931},{"trials":5913,"activeCount":100},[],{"trials":5915,"activeCount":100},[],{"trials":5917,"activeCount":100},[],{"trials":5919,"activeCount":100},[5920],{"nctId":5921,"briefTitle":5922,"status":286,"phases":5923,"primaryCompletion":5924,"completion":2621,"start":5925,"enrollment":3468,"conditions":5926,"interventions":5927},"NCT06602726","A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy",[90],"2025-05-10","2024-11-06",[2614],[5910,5928],"REGN1909",{"trials":5930,"activeCount":100},[],{"trials":5932,"activeCount":100},[],{"intervention":5928,"totalTrials":273,"cells":5934},{"EARLY_PHASE1":5935,"PHASE1":5937,"PHASE2":5939,"PHASE3":5941,"PHASE4":5947,"NA":5949},{"trials":5936,"activeCount":100},[],{"trials":5938,"activeCount":100},[],{"trials":5940,"activeCount":100},[],{"trials":5942,"activeCount":100},[5943],{"nctId":5921,"briefTitle":5922,"status":286,"phases":5944,"primaryCompletion":5924,"completion":2621,"start":5925,"enrollment":3468,"conditions":5945,"interventions":5946},[90],[2614],[5910,5928],{"trials":5948,"activeCount":100},[],{"trials":5950,"activeCount":100},[],{"intervention":3374,"totalTrials":273,"cells":5952},{"EARLY_PHASE1":5953,"PHASE1":5955,"PHASE2":5957,"PHASE3":5959,"PHASE4":5965,"NA":5967},{"trials":5954,"activeCount":100},[],{"trials":5956,"activeCount":100},[],{"trials":5958,"activeCount":100},[],{"trials":5960,"activeCount":100},[5961],{"nctId":3367,"briefTitle":3368,"status":286,"phases":5962,"primaryCompletion":427,"completion":3370,"start":467,"enrollment":3371,"conditions":5963,"interventions":5964},[90],[3285],[3374,3375],{"trials":5966,"activeCount":100},[],{"trials":5968,"activeCount":100},[],{"intervention":2508,"totalTrials":273,"cells":5970},{"EARLY_PHASE1":5971,"PHASE1":5973,"PHASE2":5975,"PHASE3":5977,"PHASE4":5983,"NA":5985},{"trials":5972,"activeCount":100},[],{"trials":5974,"activeCount":100},[],{"trials":5976,"activeCount":100},[],{"trials":5978,"activeCount":100},[5979],{"nctId":2502,"briefTitle":2503,"status":414,"phases":5980,"primaryCompletion":822,"completion":822,"start":2505,"enrollment":895,"conditions":5981,"interventions":5982},[90],[1297],[2508,2509,1358],{"trials":5984,"activeCount":100},[],{"trials":5986,"activeCount":100},[],{"intervention":5603,"totalTrials":273,"cells":5988},{"EARLY_PHASE1":5989,"PHASE1":5991,"PHASE2":5993,"PHASE3":5995,"PHASE4":6001,"NA":6003},{"trials":5990,"activeCount":100},[],{"trials":5992,"activeCount":100},[],{"trials":5994,"activeCount":100},[],{"trials":5996,"activeCount":100},[5997],{"nctId":5596,"briefTitle":5597,"status":286,"phases":5998,"primaryCompletion":5204,"completion":5599,"start":5195,"enrollment":5600,"conditions":5999,"interventions":6000},[90],[4854],[5603,5604],{"trials":6002,"activeCount":100},[],{"trials":6004,"activeCount":100},[],{"intervention":6006,"totalTrials":110,"cells":6007},"REGN1033",{"EARLY_PHASE1":6008,"PHASE1":6010,"PHASE2":6050,"PHASE3":6062,"PHASE4":6064,"NA":6066},{"trials":6009,"activeCount":100},[],{"trials":6011,"activeCount":100},[6012,6020,6027,6035,6044],{"nctId":6013,"briefTitle":6014,"status":286,"phases":6015,"primaryCompletion":6016,"completion":6017,"start":5229,"enrollment":1995,"conditions":6018,"interventions":6019},"NCT02741739","Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects",[88],"2016-04","2016-05",[20],[6006],{"nctId":6021,"briefTitle":6022,"status":286,"phases":6023,"primaryCompletion":4784,"completion":4784,"start":6024,"enrollment":3403,"conditions":6025,"interventions":6026},"NCT01507402","A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)",[88],"2012-01",[14],[6006,6006],{"nctId":6028,"briefTitle":6029,"status":286,"phases":6030,"primaryCompletion":6031,"completion":548,"start":4754,"enrollment":6032,"conditions":6033,"interventions":6034},"NCT01910220","Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)",[88],"2014-06",125,[14],[6006],{"nctId":6036,"briefTitle":6037,"status":286,"phases":6038,"primaryCompletion":6039,"completion":6039,"start":6040,"enrollment":3411,"conditions":6041,"interventions":6042},"NCT02943239","Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men",[88],"2019-04-30","2016-12-08",[14],[6006,6043],"REGN2477",{"nctId":6045,"briefTitle":6046,"status":286,"phases":6047,"primaryCompletion":342,"completion":342,"start":3313,"enrollment":2077,"conditions":6048,"interventions":6049},"NCT01720576","Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)",[88],[14],[6006],{"trials":6051,"activeCount":100},[6052],{"nctId":6053,"briefTitle":6054,"status":286,"phases":6055,"primaryCompletion":3370,"completion":6056,"start":6057,"enrollment":6058,"conditions":6059,"interventions":6061},"NCT01963598","Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia",[89],"2015-02","2013-11",253,[6060],"Sarcopenia",[6006],{"trials":6063,"activeCount":100},[],{"trials":6065,"activeCount":100},[],{"trials":6067,"activeCount":100},[],{"intervention":6069,"totalTrials":895,"cells":6070},"REGN5381",{"EARLY_PHASE1":6071,"PHASE1":6073,"PHASE2":6091,"PHASE3":6120,"PHASE4":6122,"NA":6124},{"trials":6072,"activeCount":100},[],{"trials":6074,"activeCount":100},[6075,6082],{"nctId":6076,"briefTitle":6077,"status":286,"phases":6078,"primaryCompletion":6079,"completion":6079,"start":586,"enrollment":1110,"conditions":6080,"interventions":6081},"NCT04506645","Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans",[88],"2022-12-14",[20],[6069],{"nctId":6083,"briefTitle":6084,"status":286,"phases":6085,"primaryCompletion":1041,"completion":1041,"start":6086,"enrollment":6087,"conditions":6088,"interventions":6089},"NCT05291546","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants",[88],"2022-04-13",93,[14],[6090,6069],"REGN9035",{"trials":6092,"activeCount":100},[6093,6101,6112],{"nctId":6094,"briefTitle":6095,"status":414,"phases":6096,"primaryCompletion":1099,"completion":1099,"start":6097,"enrollment":1960,"conditions":6098,"interventions":6100},"NCT06833190","REGN5381 in Adult Participants With Uncontrolled Hypertension",[89],"2025-04-16",[6099],"Uncontrolled Hypertension",[6069],{"nctId":6102,"briefTitle":6103,"status":414,"phases":6104,"primaryCompletion":6105,"completion":6106,"start":6107,"enrollment":6108,"conditions":6109,"interventions":6111},"NCT06237309","REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction",[89],"2025-09-17","2025-12-29","2024-04-11",89,[6110],"Heart Failure",[6069],{"nctId":6113,"briefTitle":6114,"status":286,"phases":6115,"primaryCompletion":6116,"completion":6116,"start":6117,"enrollment":3213,"conditions":6118,"interventions":6119},"NCT05353166","REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure",[89],"2025-06-02","2022-06-30",[6110],[6069],{"trials":6121,"activeCount":100},[],{"trials":6123,"activeCount":100},[],{"trials":6125,"activeCount":100},[],{"intervention":312,"totalTrials":895,"cells":6127},{"EARLY_PHASE1":6128,"PHASE1":6130,"PHASE2":6153,"PHASE3":6167,"PHASE4":6169,"NA":6171},{"trials":6129,"activeCount":100},[],{"trials":6131,"activeCount":100},[6132,6141,6145],{"nctId":6133,"briefTitle":6134,"status":286,"phases":6135,"primaryCompletion":6136,"completion":6137,"start":4944,"enrollment":3294,"conditions":6138,"interventions":6140},"NCT02999711","Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma",[88],"2018-08-30","2018-09-10",[650,6139],"Moderate Asthma",[312],{"nctId":302,"briefTitle":303,"status":286,"phases":6142,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":6143,"interventions":6144},[88],[310],[312,61,313],{"nctId":6146,"briefTitle":6147,"status":286,"phases":6148,"primaryCompletion":6149,"completion":3352,"start":6150,"enrollment":146,"conditions":6151,"interventions":6152},"NCT02958436","A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects",[88],"2017-06-18","2016-08",[14],[312],{"trials":6154,"activeCount":100},[6155,6159],{"nctId":412,"briefTitle":413,"status":414,"phases":6156,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":6157,"interventions":6158},[89],[17],[312,61,422],{"nctId":6160,"briefTitle":6161,"status":414,"phases":6162,"primaryCompletion":416,"completion":2998,"start":6163,"enrollment":6164,"conditions":6165,"interventions":6166},"NCT03738423","Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis",[89],"2018-11-13",129,[17],[312],{"trials":6168,"activeCount":100},[],{"trials":6170,"activeCount":100},[],{"trials":6172,"activeCount":100},[],{"intervention":4708,"totalTrials":763,"cells":6174},{"EARLY_PHASE1":6175,"PHASE1":6177,"PHASE2":6183,"PHASE3":6193,"PHASE4":6195,"NA":6197},{"trials":6176,"activeCount":100},[],{"trials":6178,"activeCount":100},[6179],{"nctId":4701,"briefTitle":4702,"status":286,"phases":6180,"primaryCompletion":4704,"completion":4704,"start":4705,"enrollment":528,"conditions":6181,"interventions":6182},[88],[2937,2938],[4708,4709,4694],{"trials":6184,"activeCount":100},[6185,6189],{"nctId":4723,"briefTitle":4724,"status":286,"phases":6186,"primaryCompletion":3352,"completion":3352,"start":386,"enrollment":4726,"conditions":6187,"interventions":6188},[89],[2937],[4708,4694],{"nctId":4730,"briefTitle":4731,"status":286,"phases":6190,"primaryCompletion":438,"completion":438,"start":4733,"enrollment":4734,"conditions":6191,"interventions":6192},[89],[2938],[4708,4694],{"trials":6194,"activeCount":100},[],{"trials":6196,"activeCount":100},[],{"trials":6198,"activeCount":100},[],{"intervention":6043,"totalTrials":763,"cells":6200},{"EARLY_PHASE1":6201,"PHASE1":6203,"PHASE2":6217,"PHASE3":6228,"PHASE4":6230,"NA":6232},{"trials":6202,"activeCount":100},[],{"trials":6204,"activeCount":100},[6205,6209],{"nctId":6036,"briefTitle":6037,"status":286,"phases":6206,"primaryCompletion":6039,"completion":6039,"start":6040,"enrollment":3411,"conditions":6207,"interventions":6208},[88],[14],[6006,6043],{"nctId":6210,"briefTitle":6211,"status":286,"phases":6212,"primaryCompletion":6213,"completion":6213,"start":288,"enrollment":6214,"conditions":6215,"interventions":6216},"NCT02870400","A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477",[88],"2017-01-12",41,[14],[6043],{"trials":6218,"activeCount":100},[6219],{"nctId":6220,"briefTitle":6221,"status":286,"phases":6222,"primaryCompletion":6223,"completion":6224,"start":6225,"enrollment":5163,"conditions":6226,"interventions":6227},"NCT03188666","A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva",[89],"2019-09-16","2021-09-16","2018-02-26",[2433],[6043],{"trials":6229,"activeCount":100},[],{"trials":6231,"activeCount":100},[],{"trials":6233,"activeCount":100},[],{"intervention":6235,"totalTrials":136,"cells":6236},"REGN5069",{"EARLY_PHASE1":6237,"PHASE1":6239,"PHASE2":6248,"PHASE3":6261,"PHASE4":6263,"NA":6265},{"trials":6238,"activeCount":100},[],{"trials":6240,"activeCount":100},[6241],{"nctId":6242,"briefTitle":6243,"status":286,"phases":6244,"primaryCompletion":716,"completion":716,"start":6245,"enrollment":2018,"conditions":6246,"interventions":6247},"NCT03645746","Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers",[88],"2018-08-23",[26],[6235],{"trials":6249,"activeCount":100},[6250],{"nctId":6251,"briefTitle":6252,"status":414,"phases":6253,"primaryCompletion":6254,"completion":6255,"start":6256,"enrollment":6257,"conditions":6258,"interventions":6260},"NCT03956550","A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee",[89],"2020-05-01","2020-10-29","2019-05-21",259,[5208,6259],"Pain",[6235],{"trials":6262,"activeCount":100},[],{"trials":6264,"activeCount":100},[],{"trials":6266,"activeCount":100},[],{"intervention":6268,"totalTrials":136,"cells":6269},"REGN846",{"EARLY_PHASE1":6270,"PHASE1":6272,"PHASE2":6282,"PHASE3":6293,"PHASE4":6295,"NA":6297},{"trials":6271,"activeCount":100},[],{"trials":6273,"activeCount":100},[6274],{"nctId":6275,"briefTitle":6276,"status":286,"phases":6277,"primaryCompletion":6278,"completion":6278,"start":6279,"enrollment":146,"conditions":6280,"interventions":6281},"NCT01209793","Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers",[88],"2011-09","2010-11",[20],[6268],{"trials":6283,"activeCount":100},[6284],{"nctId":6285,"briefTitle":6286,"status":414,"phases":6287,"primaryCompletion":6288,"completion":6288,"start":6289,"enrollment":777,"conditions":6290,"interventions":6292},"NCT01605708","Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis",[88,89],"2013-04","2012-06",[6291,17],"Pruritus",[6268],{"trials":6294,"activeCount":100},[],{"trials":6296,"activeCount":100},[],{"trials":6298,"activeCount":100},[],{"intervention":6300,"totalTrials":136,"cells":6301},"REGN475\u002FSAR164877",{"EARLY_PHASE1":6302,"PHASE1":6304,"PHASE2":6306,"PHASE3":6323,"PHASE4":6325,"NA":6327},{"trials":6303,"activeCount":100},[],{"trials":6305,"activeCount":100},[],{"trials":6307,"activeCount":100},[6308,6315],{"nctId":6309,"briefTitle":6310,"status":414,"phases":6311,"primaryCompletion":3274,"completion":3274,"start":5194,"enrollment":6214,"conditions":6312,"interventions":6314},"NCT01001715","Single Injection of REGN475\u002FSAR164877 in Treatment of Vertebral Fracture Pain",[89],[6313],"Back Pain",[6300],{"nctId":6316,"briefTitle":6317,"status":414,"phases":6318,"primaryCompletion":3274,"completion":3274,"start":4716,"enrollment":6319,"conditions":6320,"interventions":6322},"NCT01001923","Single Injection of REGN475\u002FSAR164877 in the Treatment of Chronic Pancreatitis Pain",[89],15,[6321],"Abdominal Pain Upper",[6300],{"trials":6324,"activeCount":100},[],{"trials":6326,"activeCount":100},[],{"trials":6328,"activeCount":100},[],{"intervention":4747,"totalTrials":136,"cells":6330},{"EARLY_PHASE1":6331,"PHASE1":6333,"PHASE2":6344,"PHASE3":6350,"PHASE4":6352,"NA":6354},{"trials":6332,"activeCount":100},[],{"trials":6334,"activeCount":100},[6335],{"nctId":6336,"briefTitle":6337,"status":286,"phases":6338,"primaryCompletion":6339,"completion":6339,"start":6340,"enrollment":24,"conditions":6341,"interventions":6343},"NCT02061865","Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD",[88],"2014-12","2014-02",[6342],"Neovascular Wet Age-related Macular Degeneration (AMD)",[4747],{"trials":6345,"activeCount":100},[6346],{"nctId":4738,"briefTitle":4739,"status":414,"phases":6347,"primaryCompletion":4741,"completion":4742,"start":4743,"enrollment":4744,"conditions":6348,"interventions":6349},[89],[2937],[4747,4694],{"trials":6351,"activeCount":100},[],{"trials":6353,"activeCount":100},[],{"trials":6355,"activeCount":100},[],{"intervention":4905,"totalTrials":273,"cells":6357},{"EARLY_PHASE1":6358,"PHASE1":6360,"PHASE2":6362,"PHASE3":6368,"PHASE4":6370,"NA":6372},{"trials":6359,"activeCount":100},[],{"trials":6361,"activeCount":100},[],{"trials":6363,"activeCount":100},[6364],{"nctId":4895,"briefTitle":4896,"status":414,"phases":6365,"primaryCompletion":4898,"completion":4898,"start":4899,"enrollment":3294,"conditions":6366,"interventions":6367},[89],[4901,4902],[4879,4904,4905,4906],{"trials":6369,"activeCount":100},[],{"trials":6371,"activeCount":100},[],{"trials":6373,"activeCount":100},[],{"intervention":4906,"totalTrials":273,"cells":6375},{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6380,"PHASE3":6386,"PHASE4":6388,"NA":6390},{"trials":6377,"activeCount":100},[],{"trials":6379,"activeCount":100},[],{"trials":6381,"activeCount":100},[6382],{"nctId":4895,"briefTitle":4896,"status":414,"phases":6383,"primaryCompletion":4898,"completion":4898,"start":4899,"enrollment":3294,"conditions":6384,"interventions":6385},[89],[4901,4902],[4879,4904,4905,4906],{"trials":6387,"activeCount":100},[],{"trials":6389,"activeCount":100},[],{"trials":6391,"activeCount":100},[],{"intervention":5282,"totalTrials":273,"cells":6393},{"EARLY_PHASE1":6394,"PHASE1":6396,"PHASE2":6398,"PHASE3":6404,"PHASE4":6406,"NA":6408},{"trials":6395,"activeCount":100},[],{"trials":6397,"activeCount":100},[],{"trials":6399,"activeCount":100},[6400],{"nctId":5275,"briefTitle":5276,"status":286,"phases":6401,"primaryCompletion":2430,"completion":2430,"start":5278,"enrollment":5279,"conditions":6402,"interventions":6403},[89],[20,5261],[5240,5282],{"trials":6405,"activeCount":100},[],{"trials":6407,"activeCount":100},[],{"trials":6409,"activeCount":100},[],{"intervention":6411,"totalTrials":273,"cells":6412},"REGN2477+REGN1033",{"EARLY_PHASE1":6413,"PHASE1":6415,"PHASE2":6417,"PHASE3":6429,"PHASE4":6431,"NA":6433},{"trials":6414,"activeCount":100},[],{"trials":6416,"activeCount":100},[],{"trials":6418,"activeCount":100},[6419],{"nctId":6420,"briefTitle":6421,"status":655,"phases":6422,"primaryCompletion":6423,"completion":6424,"start":6425,"enrollment":100,"conditions":6426,"interventions":6428},"NCT03710941","Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis",[89],"2020-08-27","2020-11-05","2019-02-19",[6427],"Sporadic Inclusion Body Myositis",[6411],{"trials":6430,"activeCount":100},[],{"trials":6432,"activeCount":100},[],{"trials":6434,"activeCount":100},[],{"intervention":6436,"totalTrials":273,"cells":6437},"Low-Dose REGN4461",{"EARLY_PHASE1":6438,"PHASE1":6440,"PHASE2":6442,"PHASE3":6453,"PHASE4":6455,"NA":6457},{"trials":6439,"activeCount":100},[],{"trials":6441,"activeCount":100},[],{"trials":6443,"activeCount":100},[6444],{"nctId":6445,"briefTitle":6446,"status":286,"phases":6447,"primaryCompletion":6448,"completion":6449,"start":3958,"enrollment":21,"conditions":6450,"interventions":6451},"NCT04159415","Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy",[89],"2022-01-05","2024-09-24",[1975],[6436,6452],"High-dose REGN4461",{"trials":6454,"activeCount":100},[],{"trials":6456,"activeCount":100},[],{"trials":6458,"activeCount":100},[],{"intervention":6452,"totalTrials":273,"cells":6460},{"EARLY_PHASE1":6461,"PHASE1":6463,"PHASE2":6465,"PHASE3":6471,"PHASE4":6473,"NA":6475},{"trials":6462,"activeCount":100},[],{"trials":6464,"activeCount":100},[],{"trials":6466,"activeCount":100},[6467],{"nctId":6445,"briefTitle":6446,"status":286,"phases":6468,"primaryCompletion":6448,"completion":6449,"start":3958,"enrollment":21,"conditions":6469,"interventions":6470},[89],[1975],[6436,6452],{"trials":6472,"activeCount":100},[],{"trials":6474,"activeCount":100},[],{"trials":6476,"activeCount":100},[],{"intervention":3407,"totalTrials":273,"cells":6478},{"EARLY_PHASE1":6479,"PHASE1":6481,"PHASE2":6483,"PHASE3":6489,"PHASE4":6491,"NA":6493},{"trials":6480,"activeCount":100},[],{"trials":6482,"activeCount":100},[],{"trials":6484,"activeCount":100},[6485],{"nctId":3397,"briefTitle":3398,"status":286,"phases":6486,"primaryCompletion":3400,"completion":3401,"start":3402,"enrollment":3403,"conditions":6487,"interventions":6488},[89],[3405],[71,3407],{"trials":6490,"activeCount":100},[],{"trials":6492,"activeCount":100},[],{"trials":6494,"activeCount":100},[],{"intervention":358,"totalTrials":273,"cells":6496},{"EARLY_PHASE1":6497,"PHASE1":6499,"PHASE2":6501,"PHASE3":6507,"PHASE4":6509,"NA":6511},{"trials":6498,"activeCount":100},[],{"trials":6500,"activeCount":100},[],{"trials":6502,"activeCount":100},[6503],{"nctId":348,"briefTitle":349,"status":286,"phases":6504,"primaryCompletion":351,"completion":352,"start":353,"enrollment":354,"conditions":6505,"interventions":6506},[89],[356],[61,358],{"trials":6508,"activeCount":100},[],{"trials":6510,"activeCount":100},[],{"trials":6512,"activeCount":100},[],{"intervention":1214,"totalTrials":273,"cells":6514},{"EARLY_PHASE1":6515,"PHASE1":6517,"PHASE2":6519,"PHASE3":6525,"PHASE4":6527,"NA":6529},{"trials":6516,"activeCount":100},[],{"trials":6518,"activeCount":100},[],{"trials":6520,"activeCount":100},[6521],{"nctId":1204,"briefTitle":1205,"status":286,"phases":6522,"primaryCompletion":1207,"completion":1208,"start":1209,"enrollment":1210,"conditions":6523,"interventions":6524},[89],[1212],[133,1214],{"trials":6526,"activeCount":100},[],{"trials":6528,"activeCount":100},[],{"trials":6530,"activeCount":100},[],{"intervention":2036,"totalTrials":273,"cells":6532},{"EARLY_PHASE1":6533,"PHASE1":6535,"PHASE2":6537,"PHASE3":6543,"PHASE4":6545,"NA":6547},{"trials":6534,"activeCount":100},[],{"trials":6536,"activeCount":100},[],{"trials":6538,"activeCount":100},[6539],{"nctId":2028,"briefTitle":2029,"status":286,"phases":6540,"primaryCompletion":2031,"completion":2031,"start":2032,"enrollment":2033,"conditions":6541,"interventions":6542},[89],[1700],[1680,1724,2036],{"trials":6544,"activeCount":100},[],{"trials":6546,"activeCount":100},[],{"trials":6548,"activeCount":100},[],{"intervention":370,"totalTrials":273,"cells":6550},{"EARLY_PHASE1":6551,"PHASE1":6553,"PHASE2":6555,"PHASE3":6561,"PHASE4":6563,"NA":6565},{"trials":6552,"activeCount":100},[],{"trials":6554,"activeCount":100},[],{"trials":6556,"activeCount":100},[6557],{"nctId":360,"briefTitle":361,"status":286,"phases":6558,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":6559,"interventions":6560},[89],[368],[61,370],{"trials":6562,"activeCount":100},[],{"trials":6564,"activeCount":100},[],{"trials":6566,"activeCount":100},[],{"intervention":6568,"totalTrials":273,"cells":6569},"VEGF Trap Eye",{"EARLY_PHASE1":6570,"PHASE1":6572,"PHASE2":6574,"PHASE3":6583,"PHASE4":6585,"NA":6587},{"trials":6571,"activeCount":100},[],{"trials":6573,"activeCount":100},[],{"trials":6575,"activeCount":100},[6576],{"nctId":6577,"briefTitle":6578,"status":286,"phases":6579,"primaryCompletion":4852,"completion":4852,"start":5107,"enrollment":6580,"conditions":6581,"interventions":6582},"NCT00527423","Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD",[89],157,[5087],[6568],{"trials":6584,"activeCount":100},[],{"trials":6586,"activeCount":100},[],{"trials":6588,"activeCount":100},[],{"intervention":6590,"totalTrials":273,"cells":6591},"R475",{"EARLY_PHASE1":6592,"PHASE1":6594,"PHASE2":6596,"PHASE3":6605,"PHASE4":6607,"NA":6609},{"trials":6593,"activeCount":100},[],{"trials":6595,"activeCount":100},[],{"trials":6597,"activeCount":100},[6598],{"nctId":6599,"briefTitle":6600,"status":655,"phases":6601,"enrollment":100,"conditions":6602,"interventions":6604},"NCT01053702","Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury",[89],[6603],"Thermal Injury Pain",[6590],{"trials":6606,"activeCount":100},[],{"trials":6608,"activeCount":100},[],{"trials":6610,"activeCount":100},[],{"intervention":6612,"totalTrials":273,"cells":6613},"REGN14256",{"EARLY_PHASE1":6614,"PHASE1":6616,"PHASE2":6618,"PHASE3":6630,"PHASE4":6632,"NA":6634},{"trials":6615,"activeCount":100},[],{"trials":6617,"activeCount":100},[],{"trials":6619,"activeCount":100},[6620],{"nctId":6621,"briefTitle":6622,"status":414,"phases":6623,"primaryCompletion":6117,"completion":6117,"start":6624,"enrollment":15,"conditions":6625,"interventions":6627},"NCT05081388","COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease",[88,89],"2021-11-08",[6626],"SARS-CoV-2",[6612,6628,6629],"imdevimab","casirivimab + imdevimab",{"trials":6631,"activeCount":100},[],{"trials":6633,"activeCount":100},[],{"trials":6635,"activeCount":100},[],{"intervention":6628,"totalTrials":273,"cells":6637},{"EARLY_PHASE1":6638,"PHASE1":6640,"PHASE2":6642,"PHASE3":6648,"PHASE4":6650,"NA":6652},{"trials":6639,"activeCount":100},[],{"trials":6641,"activeCount":100},[],{"trials":6643,"activeCount":100},[6644],{"nctId":6621,"briefTitle":6622,"status":414,"phases":6645,"primaryCompletion":6117,"completion":6117,"start":6624,"enrollment":15,"conditions":6646,"interventions":6647},[88,89],[6626],[6612,6628,6629],{"trials":6649,"activeCount":100},[],{"trials":6651,"activeCount":100},[],{"trials":6653,"activeCount":100},[],{"intervention":6629,"totalTrials":273,"cells":6655},{"EARLY_PHASE1":6656,"PHASE1":6658,"PHASE2":6660,"PHASE3":6666,"PHASE4":6668,"NA":6670},{"trials":6657,"activeCount":100},[],{"trials":6659,"activeCount":100},[],{"trials":6661,"activeCount":100},[6662],{"nctId":6621,"briefTitle":6622,"status":414,"phases":6663,"primaryCompletion":6117,"completion":6117,"start":6624,"enrollment":15,"conditions":6664,"interventions":6665},[88,89],[6626],[6612,6628,6629],{"trials":6667,"activeCount":100},[],{"trials":6669,"activeCount":100},[],{"trials":6671,"activeCount":100},[],{"intervention":422,"totalTrials":273,"cells":6673},{"EARLY_PHASE1":6674,"PHASE1":6676,"PHASE2":6678,"PHASE3":6684,"PHASE4":6686,"NA":6688},{"trials":6675,"activeCount":100},[],{"trials":6677,"activeCount":100},[],{"trials":6679,"activeCount":100},[6680],{"nctId":412,"briefTitle":413,"status":414,"phases":6681,"primaryCompletion":416,"completion":417,"start":418,"enrollment":419,"conditions":6682,"interventions":6683},[89],[17],[312,61,422],{"trials":6685,"activeCount":100},[],{"trials":6687,"activeCount":100},[],{"trials":6689,"activeCount":100},[],{"intervention":6691,"totalTrials":273,"cells":6692},"SDREGN2810",{"EARLY_PHASE1":6693,"PHASE1":6695,"PHASE2":6697,"PHASE3":6709,"PHASE4":6711,"NA":6713},{"trials":6694,"activeCount":100},[],{"trials":6696,"activeCount":100},[],{"trials":6698,"activeCount":100},[6699],{"nctId":6700,"briefTitle":6701,"status":414,"phases":6702,"primaryCompletion":2017,"completion":2017,"start":6703,"enrollment":1995,"conditions":6704,"interventions":6706},"NCT03430063","A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer",[89],"2018-05-29",[6705],"Advanced Non-Small Cell Lung Carcinoma",[6691,6707,6708],"SDREGN2810\u002Fipi","HDREGN2810",{"trials":6710,"activeCount":100},[],{"trials":6712,"activeCount":100},[],{"trials":6714,"activeCount":100},[],{"intervention":6707,"totalTrials":273,"cells":6716},{"EARLY_PHASE1":6717,"PHASE1":6719,"PHASE2":6721,"PHASE3":6727,"PHASE4":6729,"NA":6731},{"trials":6718,"activeCount":100},[],{"trials":6720,"activeCount":100},[],{"trials":6722,"activeCount":100},[6723],{"nctId":6700,"briefTitle":6701,"status":414,"phases":6724,"primaryCompletion":2017,"completion":2017,"start":6703,"enrollment":1995,"conditions":6725,"interventions":6726},[89],[6705],[6691,6707,6708],{"trials":6728,"activeCount":100},[],{"trials":6730,"activeCount":100},[],{"trials":6732,"activeCount":100},[],{"intervention":6708,"totalTrials":273,"cells":6734},{"EARLY_PHASE1":6735,"PHASE1":6737,"PHASE2":6739,"PHASE3":6745,"PHASE4":6747,"NA":6749},{"trials":6736,"activeCount":100},[],{"trials":6738,"activeCount":100},[],{"trials":6740,"activeCount":100},[6741],{"nctId":6700,"briefTitle":6701,"status":414,"phases":6742,"primaryCompletion":2017,"completion":2017,"start":6703,"enrollment":1995,"conditions":6743,"interventions":6744},[89],[6705],[6691,6707,6708],{"trials":6746,"activeCount":100},[],{"trials":6748,"activeCount":100},[],{"trials":6750,"activeCount":100},[],{"intervention":6752,"totalTrials":273,"cells":6753},"REGN1500 250 mg SC\u002F15 mg\u002Fkg IV\u002F450 mg SC",{"EARLY_PHASE1":6754,"PHASE1":6756,"PHASE2":6758,"PHASE3":6769,"PHASE4":6771,"NA":6773},{"trials":6755,"activeCount":100},[],{"trials":6757,"activeCount":100},[],{"trials":6759,"activeCount":100},[6760],{"nctId":6761,"briefTitle":6762,"status":286,"phases":6763,"primaryCompletion":6764,"completion":6765,"start":6766,"enrollment":1973,"conditions":6767,"interventions":6768},"NCT02265952","Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)",[89],"2016-11-21","2018-07-23","2015-02-04",[3355],[6752],{"trials":6770,"activeCount":100},[],{"trials":6772,"activeCount":100},[],{"trials":6774,"activeCount":100},[],{"intervention":6776,"totalTrials":273,"cells":6777},"REGN5459",{"EARLY_PHASE1":6778,"PHASE1":6780,"PHASE2":6782,"PHASE3":6794,"PHASE4":6796,"NA":6798},{"trials":6779,"activeCount":100},[],{"trials":6781,"activeCount":100},[],{"trials":6783,"activeCount":100},[6784],{"nctId":6785,"briefTitle":6786,"status":286,"phases":6787,"primaryCompletion":6788,"completion":6788,"start":6789,"enrollment":3191,"conditions":6790,"interventions":6793},"NCT04083534","First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)",[88,89],"2025-05-01","2019-09-26",[6791,6792],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma",[6776],{"trials":6795,"activeCount":100},[],{"trials":6797,"activeCount":100},[],{"trials":6799,"activeCount":100},[],{"intervention":6801,"totalTrials":258,"cells":6802},"ziv-aflibercept",{"EARLY_PHASE1":6803,"PHASE1":6805,"PHASE2":6839,"PHASE3":6841,"PHASE4":6843,"NA":6845},{"trials":6804,"activeCount":100},[],{"trials":6806,"activeCount":100},[6807,6816,6821,6831],{"nctId":6808,"briefTitle":6809,"status":286,"phases":6810,"primaryCompletion":6811,"start":6812,"enrollment":15,"conditions":6813,"interventions":6815},"NCT00082823","Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma",[88],"2008-05","2004-01",[6814],"Cancer",[6801],{"nctId":6817,"briefTitle":6809,"status":286,"phases":6818,"primaryCompletion":6811,"start":6812,"enrollment":15,"conditions":6819,"interventions":6820},"NCT00083213",[88],[6814],[6801],{"nctId":6822,"briefTitle":6823,"status":286,"phases":6824,"primaryCompletion":6825,"start":6826,"conditions":6827,"interventions":6830},"NCT00036946","VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma",[88],"2002-03","2001-11",[6828,6829],"Lymphoma","Unspecified Adult Solid Tumor, Protocol Specific",[6801],{"nctId":6832,"briefTitle":6833,"status":286,"phases":6834,"primaryCompletion":6835,"start":6836,"conditions":6837,"interventions":6838},"NCT00045266","VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma",[88],"2007-02","2002-04",[6828,6829],[6801],{"trials":6840,"activeCount":100},[],{"trials":6842,"activeCount":100},[],{"trials":6844,"activeCount":100},[],{"trials":6846,"activeCount":100},[],{"intervention":6848,"totalTrials":763,"cells":6849},"REGN727",{"EARLY_PHASE1":6850,"PHASE1":6852,"PHASE2":6873,"PHASE3":6875,"PHASE4":6877,"NA":6879},{"trials":6851,"activeCount":100},[],{"trials":6853,"activeCount":100},[6854,6860,6866],{"nctId":6855,"briefTitle":6856,"status":286,"phases":6857,"primaryCompletion":4764,"completion":4764,"start":5599,"enrollment":4046,"conditions":6858,"interventions":6859},"NCT01161082","Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin",[88],[23],[6848],{"nctId":6861,"briefTitle":6862,"status":286,"phases":6863,"primaryCompletion":5876,"completion":5876,"start":5194,"enrollment":146,"conditions":6864,"interventions":6865},"NCT01026597","Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers",[88],[20],[6848],{"nctId":6867,"briefTitle":6868,"status":286,"phases":6869,"primaryCompletion":6279,"completion":6279,"start":6870,"enrollment":308,"conditions":6871,"interventions":6872},"NCT01074372","Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers",[88],"2010-03",[14],[6848],{"trials":6874,"activeCount":100},[],{"trials":6876,"activeCount":100},[],{"trials":6878,"activeCount":100},[],{"trials":6880,"activeCount":100},[],{"intervention":6882,"totalTrials":763,"cells":6883},"REGN88",{"EARLY_PHASE1":6884,"PHASE1":6886,"PHASE2":6909,"PHASE3":6911,"PHASE4":6913,"NA":6915},{"trials":6885,"activeCount":100},[],{"trials":6887,"activeCount":100},[6888,6896,6902],{"nctId":6889,"briefTitle":6890,"status":286,"phases":6891,"primaryCompletion":5018,"completion":6892,"start":6893,"enrollment":308,"conditions":6894,"interventions":6895},"NCT01026519","A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis",[88],"2009-05","2008-09",[943],[6882],{"nctId":6897,"briefTitle":6898,"status":286,"phases":6899,"primaryCompletion":5205,"completion":5205,"start":4718,"enrollment":2077,"conditions":6900,"interventions":6901},"NCT01011959","A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects",[88],[943],[6882],{"nctId":6903,"briefTitle":6904,"status":286,"phases":6905,"primaryCompletion":5018,"completion":5018,"start":6906,"enrollment":6319,"conditions":6907,"interventions":6908},"NCT01055899","Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis",[88],"2008-07",[943],[6882,6882,6882],{"trials":6910,"activeCount":100},[],{"trials":6912,"activeCount":100},[],{"trials":6914,"activeCount":100},[],{"trials":6916,"activeCount":100},[],{"intervention":6918,"totalTrials":136,"cells":6919},"REGN6490",{"EARLY_PHASE1":6920,"PHASE1":6922,"PHASE2":6940,"PHASE3":6942,"PHASE4":6944,"NA":6946},{"trials":6921,"activeCount":100},[],{"trials":6923,"activeCount":100},[6924,6932],{"nctId":6925,"briefTitle":6926,"status":414,"phases":6927,"primaryCompletion":6928,"completion":6928,"start":6929,"enrollment":1171,"conditions":6930,"interventions":6931},"NCT04616079","Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers",[88],"2021-06-01","2020-11-19",[26],[6918],{"nctId":6933,"briefTitle":6934,"status":414,"phases":6935,"primaryCompletion":6936,"completion":6936,"start":6937,"enrollment":777,"conditions":6938,"interventions":6939},"NCT04616105","Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers",[88],"2021-05-28","2020-11-18",[26],[6918],{"trials":6941,"activeCount":100},[],{"trials":6943,"activeCount":100},[],{"trials":6945,"activeCount":100},[],{"trials":6947,"activeCount":100},[],{"intervention":6949,"totalTrials":136,"cells":6950},"VEGF Trap",{"EARLY_PHASE1":6951,"PHASE1":6953,"PHASE2":6971,"PHASE3":6973,"PHASE4":6975,"NA":6977},{"trials":6952,"activeCount":100},[],{"trials":6954,"activeCount":100},[6955,6964],{"nctId":6956,"briefTitle":6957,"status":286,"phases":6958,"primaryCompletion":6959,"completion":6906,"start":6960,"enrollment":528,"conditions":6961,"interventions":6963},"NCT00383370","Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD",[88],"2007-09","2006-10",[6962],"Neovascular Age Related Macular Degeneration",[6949,6949],{"nctId":6965,"briefTitle":6966,"status":286,"phases":6967,"primaryCompletion":4986,"completion":5083,"start":6968,"enrollment":1310,"conditions":6969,"interventions":6970},"NCT00320775","Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD",[88],"2005-06",[5087],[6949],{"trials":6972,"activeCount":100},[],{"trials":6974,"activeCount":100},[],{"trials":6976,"activeCount":100},[],{"trials":6978,"activeCount":100},[],{"intervention":6980,"totalTrials":136,"cells":6981},"REGN1193",{"EARLY_PHASE1":6982,"PHASE1":6984,"PHASE2":6999,"PHASE3":7001,"PHASE4":7003,"NA":7005},{"trials":6983,"activeCount":100},[],{"trials":6985,"activeCount":100},[6986,6993],{"nctId":6987,"briefTitle":6988,"status":414,"phases":6989,"primaryCompletion":289,"completion":289,"start":548,"enrollment":4046,"conditions":6990,"interventions":6992},"NCT02284425","Study of REGN1193 in Patients With Type 2 Diabetes Mellitus",[88],[6991],"Diabetes Mellitus, Type 2",[6980],{"nctId":6994,"briefTitle":6995,"status":286,"phases":6996,"primaryCompletion":3370,"completion":3370,"start":4754,"enrollment":2018,"conditions":6997,"interventions":6998},"NCT01933763","An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193",[88],[14],[6980],{"trials":7000,"activeCount":100},[],{"trials":7002,"activeCount":100},[],{"trials":7004,"activeCount":100},[],{"trials":7006,"activeCount":100},[],{"intervention":7008,"totalTrials":136,"cells":7009},"REGN1500",{"EARLY_PHASE1":7010,"PHASE1":7012,"PHASE2":7029,"PHASE3":7031,"PHASE4":7033,"NA":7035},{"trials":7011,"activeCount":100},[],{"trials":7013,"activeCount":100},[7014,7021],{"nctId":7015,"briefTitle":7016,"status":286,"phases":7017,"primaryCompletion":7018,"completion":7018,"start":467,"enrollment":3445,"conditions":7019,"interventions":7020},"NCT01749878","Study to Assess the Safety and Tolerability of Single Doses of REGN1500",[88],"2016-01",[4228],[7008],{"nctId":7022,"briefTitle":7023,"status":286,"phases":7024,"primaryCompletion":4783,"completion":4783,"start":3312,"enrollment":7025,"conditions":7026,"interventions":7028},"NCT02107872","Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500",[88],55,[7027],"Metabolic Disorders",[7008],{"trials":7030,"activeCount":100},[],{"trials":7032,"activeCount":100},[],{"trials":7034,"activeCount":100},[],{"trials":7036,"activeCount":100},[],{"intervention":7038,"totalTrials":136,"cells":7039},"REGN668",{"EARLY_PHASE1":7040,"PHASE1":7042,"PHASE2":7059,"PHASE3":7061,"PHASE4":7063,"NA":7065},{"trials":7041,"activeCount":100},[],{"trials":7043,"activeCount":100},[7044,7051],{"nctId":7045,"briefTitle":7046,"status":286,"phases":7047,"primaryCompletion":468,"completion":468,"start":5039,"enrollment":268,"conditions":7048,"interventions":7050},"NCT01259323","Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis",[88],[7049],"Dermatitis",[7038,7038,7038],{"nctId":7052,"briefTitle":7053,"status":286,"phases":7054,"primaryCompletion":7055,"completion":7055,"start":7056,"enrollment":3767,"conditions":7057,"interventions":7058},"NCT01015027","Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers",[88],"2010-07","2009-10",[20],[7038],{"trials":7060,"activeCount":100},[],{"trials":7062,"activeCount":100},[],{"trials":7064,"activeCount":100},[],{"trials":7066,"activeCount":100},[],{"intervention":5062,"totalTrials":136,"cells":7068},{"EARLY_PHASE1":7069,"PHASE1":7071,"PHASE2":7084,"PHASE3":7086,"PHASE4":7088,"NA":7090},{"trials":7070,"activeCount":100},[],{"trials":7072,"activeCount":100},[7073,7077],{"nctId":5056,"briefTitle":5057,"status":286,"phases":7074,"primaryCompletion":4705,"completion":4705,"start":3313,"enrollment":3767,"conditions":7075,"interventions":7076},[88],[5060],[5062,5062,5062,5049,5049],{"nctId":7078,"briefTitle":7079,"status":286,"phases":7080,"primaryCompletion":428,"completion":5231,"start":3274,"enrollment":7081,"conditions":7082,"interventions":7083},"NCT01271972","Study of Nesvacumab (REGN910\u002F SAR307746)",[88],53,[5060],[5062],{"trials":7085,"activeCount":100},[],{"trials":7087,"activeCount":100},[],{"trials":7089,"activeCount":100},[],{"trials":7091,"activeCount":100},[],{"intervention":7093,"totalTrials":136,"cells":7094},"REGN2222",{"EARLY_PHASE1":7095,"PHASE1":7097,"PHASE2":7112,"PHASE3":7114,"PHASE4":7116,"NA":7118},{"trials":7096,"activeCount":100},[],{"trials":7098,"activeCount":100},[7099,7105],{"nctId":7100,"briefTitle":7101,"status":286,"phases":7102,"primaryCompletion":6056,"completion":6056,"start":427,"enrollment":3861,"conditions":7103,"interventions":7104},"NCT02121080","Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers",[88],[14],[7093],{"nctId":7106,"briefTitle":7107,"status":286,"phases":7108,"primaryCompletion":7109,"completion":7109,"start":6016,"enrollment":1995,"conditions":7110,"interventions":7111},"NCT02828397","Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects",[88],"2016-09",[14],[7093],{"trials":7113,"activeCount":100},[],{"trials":7115,"activeCount":100},[],{"trials":7117,"activeCount":100},[],{"trials":7119,"activeCount":100},[],{"intervention":7121,"totalTrials":273,"cells":7122},"VEGF Trap-Eye",{"EARLY_PHASE1":7123,"PHASE1":7125,"PHASE2":7134,"PHASE3":7136,"PHASE4":7138,"NA":7140},{"trials":7124,"activeCount":100},[],{"trials":7126,"activeCount":100},[7127],{"nctId":7128,"briefTitle":7129,"status":286,"phases":7130,"primaryCompletion":7131,"completion":5107,"start":5084,"enrollment":895,"conditions":7132,"interventions":7133},"NCT00320814","Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema",[88],"2006-08",[2938],[7121],{"trials":7135,"activeCount":100},[],{"trials":7137,"activeCount":100},[],{"trials":7139,"activeCount":100},[],{"trials":7141,"activeCount":100},[],{"intervention":7143,"totalTrials":273,"cells":7144},"REGN9533",{"EARLY_PHASE1":7145,"PHASE1":7147,"PHASE2":7157,"PHASE3":7159,"PHASE4":7161,"NA":7163},{"trials":7146,"activeCount":100},[],{"trials":7148,"activeCount":100},[7149],{"nctId":7150,"briefTitle":7151,"status":286,"phases":7152,"primaryCompletion":7153,"completion":7153,"start":7154,"enrollment":4046,"conditions":7155,"interventions":7156},"NCT06665828","Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults",[88],"2026-01-29","2025-03-04",[26],[7143],{"trials":7158,"activeCount":100},[],{"trials":7160,"activeCount":100},[],{"trials":7162,"activeCount":100},[],{"trials":7164,"activeCount":100},[],{"intervention":7166,"totalTrials":273,"cells":7167},"Odronextamab multiple dose levels",{"EARLY_PHASE1":7168,"PHASE1":7170,"PHASE2":7182,"PHASE3":7184,"PHASE4":7186,"NA":7188},{"trials":7169,"activeCount":100},[],{"trials":7171,"activeCount":100},[7172],{"nctId":7173,"briefTitle":7174,"status":286,"phases":7175,"primaryCompletion":7176,"completion":7176,"start":7177,"enrollment":5206,"conditions":7178,"interventions":7181},"NCT02290951","Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies",[88],"2025-08-21","2015-01-09",[7179,7180],"Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukemia",[7166,7166],{"trials":7183,"activeCount":100},[],{"trials":7185,"activeCount":100},[],{"trials":7187,"activeCount":100},[],{"trials":7189,"activeCount":100},[],{"intervention":292,"totalTrials":273,"cells":7191},{"EARLY_PHASE1":7192,"PHASE1":7194,"PHASE2":7200,"PHASE3":7202,"PHASE4":7204,"NA":7206},{"trials":7193,"activeCount":100},[],{"trials":7195,"activeCount":100},[7196],{"nctId":284,"briefTitle":285,"status":286,"phases":7197,"primaryCompletion":288,"completion":288,"start":289,"enrollment":96,"conditions":7198,"interventions":7199},[88],[17],[61,292,293,294,295,296],{"trials":7201,"activeCount":100},[],{"trials":7203,"activeCount":100},[],{"trials":7205,"activeCount":100},[],{"trials":7207,"activeCount":100},[],{"intervention":293,"totalTrials":273,"cells":7209},{"EARLY_PHASE1":7210,"PHASE1":7212,"PHASE2":7218,"PHASE3":7220,"PHASE4":7222,"NA":7224},{"trials":7211,"activeCount":100},[],{"trials":7213,"activeCount":100},[7214],{"nctId":284,"briefTitle":285,"status":286,"phases":7215,"primaryCompletion":288,"completion":288,"start":289,"enrollment":96,"conditions":7216,"interventions":7217},[88],[17],[61,292,293,294,295,296],{"trials":7219,"activeCount":100},[],{"trials":7221,"activeCount":100},[],{"trials":7223,"activeCount":100},[],{"trials":7225,"activeCount":100},[],{"intervention":294,"totalTrials":273,"cells":7227},{"EARLY_PHASE1":7228,"PHASE1":7230,"PHASE2":7236,"PHASE3":7238,"PHASE4":7240,"NA":7242},{"trials":7229,"activeCount":100},[],{"trials":7231,"activeCount":100},[7232],{"nctId":284,"briefTitle":285,"status":286,"phases":7233,"primaryCompletion":288,"completion":288,"start":289,"enrollment":96,"conditions":7234,"interventions":7235},[88],[17],[61,292,293,294,295,296],{"trials":7237,"activeCount":100},[],{"trials":7239,"activeCount":100},[],{"trials":7241,"activeCount":100},[],{"trials":7243,"activeCount":100},[],{"intervention":295,"totalTrials":273,"cells":7245},{"EARLY_PHASE1":7246,"PHASE1":7248,"PHASE2":7254,"PHASE3":7256,"PHASE4":7258,"NA":7260},{"trials":7247,"activeCount":100},[],{"trials":7249,"activeCount":100},[7250],{"nctId":284,"briefTitle":285,"status":286,"phases":7251,"primaryCompletion":288,"completion":288,"start":289,"enrollment":96,"conditions":7252,"interventions":7253},[88],[17],[61,292,293,294,295,296],{"trials":7255,"activeCount":100},[],{"trials":7257,"activeCount":100},[],{"trials":7259,"activeCount":100},[],{"trials":7261,"activeCount":100},[],{"intervention":296,"totalTrials":273,"cells":7263},{"EARLY_PHASE1":7264,"PHASE1":7266,"PHASE2":7272,"PHASE3":7274,"PHASE4":7276,"NA":7278},{"trials":7265,"activeCount":100},[],{"trials":7267,"activeCount":100},[7268],{"nctId":284,"briefTitle":285,"status":286,"phases":7269,"primaryCompletion":288,"completion":288,"start":289,"enrollment":96,"conditions":7270,"interventions":7271},[88],[17],[61,292,293,294,295,296],{"trials":7273,"activeCount":100},[],{"trials":7275,"activeCount":100},[],{"trials":7277,"activeCount":100},[],{"trials":7279,"activeCount":100},[],{"intervention":1017,"totalTrials":273,"cells":7281},{"EARLY_PHASE1":7282,"PHASE1":7284,"PHASE2":7290,"PHASE3":7292,"PHASE4":7294,"NA":7296},{"trials":7283,"activeCount":100},[],{"trials":7285,"activeCount":100},[7286],{"nctId":1009,"briefTitle":1010,"status":414,"phases":7287,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":766,"conditions":7288,"interventions":7289},[88],[1015],[1017,133],{"trials":7291,"activeCount":100},[],{"trials":7293,"activeCount":100},[],{"trials":7295,"activeCount":100},[],{"trials":7297,"activeCount":100},[],{"intervention":7299,"totalTrials":273,"cells":7300},"REGN1154 or placebo",{"EARLY_PHASE1":7301,"PHASE1":7303,"PHASE2":7312,"PHASE3":7314,"PHASE4":7316,"NA":7318},{"trials":7302,"activeCount":100},[],{"trials":7304,"activeCount":100},[7305],{"nctId":7306,"briefTitle":7307,"status":286,"phases":7308,"primaryCompletion":4763,"completion":4763,"start":7309,"enrollment":5163,"conditions":7310,"interventions":7311},"NCT01540539","Intravenous\u002FSubcutaneous FIH Study of REGN1154 in Healthy Volunteers",[88],"2012-03",[14],[7299],{"trials":7313,"activeCount":100},[],{"trials":7315,"activeCount":100},[],{"trials":7317,"activeCount":100},[],{"trials":7319,"activeCount":100},[],{"intervention":7321,"totalTrials":273,"cells":7322},"REGN421",{"EARLY_PHASE1":7323,"PHASE1":7325,"PHASE2":7335,"PHASE3":7337,"PHASE4":7339,"NA":7341},{"trials":7324,"activeCount":100},[],{"trials":7326,"activeCount":100},[7327],{"nctId":7328,"briefTitle":7329,"status":286,"phases":7330,"primaryCompletion":6340,"completion":6340,"start":7331,"enrollment":5000,"conditions":7332,"interventions":7334},"NCT00871559","A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies",[88],"2009-06",[7333],"Advanced Solid Malignancies",[7321],{"trials":7336,"activeCount":100},[],{"trials":7338,"activeCount":100},[],{"trials":7340,"activeCount":100},[],{"trials":7342,"activeCount":100},[],{"intervention":7344,"totalTrials":273,"cells":7345},"bbT369",{"EARLY_PHASE1":7346,"PHASE1":7348,"PHASE2":7359,"PHASE3":7361,"PHASE4":7363,"NA":7365},{"trials":7347,"activeCount":100},[],{"trials":7349,"activeCount":100},[7350],{"nctId":7351,"briefTitle":7352,"status":414,"phases":7353,"primaryCompletion":7354,"completion":7354,"start":7355,"enrollment":6319,"conditions":7356,"interventions":7358},"NCT05169489","A Study of bbT369 in Relapsed and\u002For Refractory B Cell Non-Hodgkin's Lymphoma (NHL)",[88],"2025-09-19","2022-01-24",[7357],"Diffuse Large B Cell Lymphoma (DLBCL)",[7344],{"trials":7360,"activeCount":100},[],{"trials":7362,"activeCount":100},[],{"trials":7364,"activeCount":100},[],{"trials":7366,"activeCount":100},[],{"intervention":7368,"totalTrials":273,"cells":7369},"REGN728",{"EARLY_PHASE1":7370,"PHASE1":7372,"PHASE2":7381,"PHASE3":7383,"PHASE4":7385,"NA":7387},{"trials":7371,"activeCount":100},[],{"trials":7373,"activeCount":100},[7374],{"nctId":7375,"briefTitle":7376,"status":286,"phases":7377,"primaryCompletion":7309,"completion":7309,"start":7378,"enrollment":3767,"conditions":7379,"interventions":7380},"NCT01197391","Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers",[88],"2010-08",[20],[7368],{"trials":7382,"activeCount":100},[],{"trials":7384,"activeCount":100},[],{"trials":7386,"activeCount":100},[],{"trials":7388,"activeCount":100},[],{"intervention":7390,"totalTrials":273,"cells":7391},"REGN5713-5714-5715",{"EARLY_PHASE1":7392,"PHASE1":7394,"PHASE2":7405,"PHASE3":7407,"PHASE4":7409,"NA":7411},{"trials":7393,"activeCount":100},[],{"trials":7395,"activeCount":100},[7396],{"nctId":7397,"briefTitle":7398,"status":286,"phases":7399,"primaryCompletion":7400,"completion":7400,"start":7401,"enrollment":4194,"conditions":7402,"interventions":7404},"NCT03969849","Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants",[88],"2020-03-27","2019-06-03",[14,7403],"Birch Pollen Allergy",[7390],{"trials":7406,"activeCount":100},[],{"trials":7408,"activeCount":100},[],{"trials":7410,"activeCount":100},[],{"trials":7412,"activeCount":100},[],{"intervention":7414,"totalTrials":273,"cells":7415},"REGN1400",{"EARLY_PHASE1":7416,"PHASE1":7418,"PHASE2":7428,"PHASE3":7430,"PHASE4":7432,"NA":7434},{"trials":7417,"activeCount":100},[],{"trials":7419,"activeCount":100},[7420],{"nctId":7421,"briefTitle":7422,"status":286,"phases":7423,"primaryCompletion":3370,"completion":3370,"start":3313,"enrollment":2018,"conditions":7424,"interventions":7425},"NCT01727869","Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer",[88],[6814],[7414,7426,7427],"Erlotinib","Cetuximab",{"trials":7429,"activeCount":100},[],{"trials":7431,"activeCount":100},[],{"trials":7433,"activeCount":100},[],{"trials":7435,"activeCount":100},[],{"intervention":7426,"totalTrials":273,"cells":7437},{"EARLY_PHASE1":7438,"PHASE1":7440,"PHASE2":7446,"PHASE3":7448,"PHASE4":7450,"NA":7452},{"trials":7439,"activeCount":100},[],{"trials":7441,"activeCount":100},[7442],{"nctId":7421,"briefTitle":7422,"status":286,"phases":7443,"primaryCompletion":3370,"completion":3370,"start":3313,"enrollment":2018,"conditions":7444,"interventions":7445},[88],[6814],[7414,7426,7427],{"trials":7447,"activeCount":100},[],{"trials":7449,"activeCount":100},[],{"trials":7451,"activeCount":100},[],{"trials":7453,"activeCount":100},[],{"intervention":7427,"totalTrials":273,"cells":7455},{"EARLY_PHASE1":7456,"PHASE1":7458,"PHASE2":7464,"PHASE3":7466,"PHASE4":7468,"NA":7470},{"trials":7457,"activeCount":100},[],{"trials":7459,"activeCount":100},[7460],{"nctId":7421,"briefTitle":7422,"status":286,"phases":7461,"primaryCompletion":3370,"completion":3370,"start":3313,"enrollment":2018,"conditions":7462,"interventions":7463},[88],[6814],[7414,7426,7427],{"trials":7465,"activeCount":100},[],{"trials":7467,"activeCount":100},[],{"trials":7469,"activeCount":100},[],{"trials":7471,"activeCount":100},[],{"intervention":313,"totalTrials":273,"cells":7473},{"EARLY_PHASE1":7474,"PHASE1":7476,"PHASE2":7482,"PHASE3":7484,"PHASE4":7486,"NA":7488},{"trials":7475,"activeCount":100},[],{"trials":7477,"activeCount":100},[7478],{"nctId":302,"briefTitle":303,"status":286,"phases":7479,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":7480,"interventions":7481},[88],[310],[312,61,313],{"trials":7483,"activeCount":100},[],{"trials":7485,"activeCount":100},[],{"trials":7487,"activeCount":100},[],{"trials":7489,"activeCount":100},[],{"intervention":6090,"totalTrials":273,"cells":7491},{"EARLY_PHASE1":7492,"PHASE1":7494,"PHASE2":7500,"PHASE3":7502,"PHASE4":7504,"NA":7506},{"trials":7493,"activeCount":100},[],{"trials":7495,"activeCount":100},[7496],{"nctId":6083,"briefTitle":6084,"status":286,"phases":7497,"primaryCompletion":1041,"completion":1041,"start":6086,"enrollment":6087,"conditions":7498,"interventions":7499},[88],[14],[6090,6069],{"trials":7501,"activeCount":100},[],{"trials":7503,"activeCount":100},[],{"trials":7505,"activeCount":100},[],{"trials":7507,"activeCount":100},[],{"intervention":4709,"totalTrials":273,"cells":7509},{"EARLY_PHASE1":7510,"PHASE1":7512,"PHASE2":7518,"PHASE3":7520,"PHASE4":7522,"NA":7524},{"trials":7511,"activeCount":100},[],{"trials":7513,"activeCount":100},[7514],{"nctId":4701,"briefTitle":4702,"status":286,"phases":7515,"primaryCompletion":4704,"completion":4704,"start":4705,"enrollment":528,"conditions":7516,"interventions":7517},[88],[2937,2938],[4708,4709,4694],{"trials":7519,"activeCount":100},[],{"trials":7521,"activeCount":100},[],{"trials":7523,"activeCount":100},[],{"trials":7525,"activeCount":100},[],{"intervention":1047,"totalTrials":273,"cells":7527},{"EARLY_PHASE1":7528,"PHASE1":7530,"PHASE2":7536,"PHASE3":7538,"PHASE4":7540,"NA":7542},{"trials":7529,"activeCount":100},[],{"trials":7531,"activeCount":100},[7532],{"nctId":1038,"briefTitle":1039,"status":286,"phases":7533,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":1043,"conditions":7534,"interventions":7535},[88],[1045],[1047,41],{"trials":7537,"activeCount":100},[],{"trials":7539,"activeCount":100},[],{"trials":7541,"activeCount":100},[],{"trials":7543,"activeCount":100},[],{"intervention":7545,"totalTrials":273,"cells":7546},"REGN10933+REGN10987",{"EARLY_PHASE1":7547,"PHASE1":7549,"PHASE2":7560,"PHASE3":7562,"PHASE4":7564,"NA":7566},{"trials":7548,"activeCount":100},[],{"trials":7550,"activeCount":100},[7551],{"nctId":7552,"briefTitle":7553,"status":286,"phases":7554,"primaryCompletion":7555,"completion":7555,"start":7556,"enrollment":7557,"conditions":7558,"interventions":7559},"NCT04519437","Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19",[88],"2021-11-22","2020-07-26",974,[20,5261],[7545],{"trials":7561,"activeCount":100},[],{"trials":7563,"activeCount":100},[],{"trials":7565,"activeCount":100},[],{"trials":7567,"activeCount":100},[],{"intervention":7569,"totalTrials":273,"cells":7570},"REGN17092",{"EARLY_PHASE1":7571,"PHASE1":7573,"PHASE2":7582,"PHASE3":7584,"PHASE4":7586,"NA":7588},{"trials":7572,"activeCount":100},[],{"trials":7574,"activeCount":100},[7575],{"nctId":7576,"briefTitle":7577,"status":286,"phases":7578,"primaryCompletion":7154,"completion":7154,"start":7579,"enrollment":146,"conditions":7580,"interventions":7581},"NCT05923424","A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults",[88],"2023-11-28",[14],[7569],{"trials":7583,"activeCount":100},[],{"trials":7585,"activeCount":100},[],{"trials":7587,"activeCount":100},[],{"trials":7589,"activeCount":100},[],{"intervention":7591,"totalTrials":273,"cells":7592},"ALN-APOC3",{"EARLY_PHASE1":7593,"PHASE1":7595,"PHASE2":7606,"PHASE3":7608,"PHASE4":7610,"NA":7612},{"trials":7594,"activeCount":100},[],{"trials":7596,"activeCount":100},[7597],{"nctId":7598,"briefTitle":7599,"status":286,"phases":7600,"primaryCompletion":7601,"completion":7601,"start":7602,"enrollment":308,"conditions":7603,"interventions":7605},"NCT06784349","ALN-APOC3 in Adult Participants With Dyslipidemia",[88],"2026-02-25","2025-01-27",[7604],"Dyslipidemia",[7591],{"trials":7607,"activeCount":100},[],{"trials":7609,"activeCount":100},[],{"trials":7611,"activeCount":100},[],{"trials":7613,"activeCount":100},[],{"intervention":1058,"totalTrials":273,"cells":7615},{"EARLY_PHASE1":7616,"PHASE1":7618,"PHASE2":7624,"PHASE3":7626,"PHASE4":7628,"NA":7630},{"trials":7617,"activeCount":100},[],{"trials":7619,"activeCount":100},[7620],{"nctId":1049,"briefTitle":1050,"status":414,"phases":7621,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":7622,"interventions":7623},[88],[1056],[1058,133],{"trials":7625,"activeCount":100},[],{"trials":7627,"activeCount":100},[],{"trials":7629,"activeCount":100},[],{"trials":7631,"activeCount":100},[],{"intervention":5150,"totalTrials":273,"cells":7633},{"EARLY_PHASE1":7634,"PHASE1":7636,"PHASE2":7642,"PHASE3":7644,"PHASE4":7646,"NA":7648},{"trials":7635,"activeCount":100},[],{"trials":7637,"activeCount":100},[7638],{"nctId":5141,"briefTitle":5142,"status":286,"phases":7639,"primaryCompletion":5144,"completion":5144,"start":5145,"enrollment":5146,"conditions":7640,"interventions":7641},[88],[5148],[2471,5150],{"trials":7643,"activeCount":100},[],{"trials":7645,"activeCount":100},[],{"trials":7647,"activeCount":100},[],{"trials":7649,"activeCount":100},[],{"intervention":7651,"totalTrials":273,"cells":7652},"REGN7257",{"EARLY_PHASE1":7653,"PHASE1":7655,"PHASE2":7666,"PHASE3":7668,"PHASE4":7670,"NA":7672},{"trials":7654,"activeCount":100},[],{"trials":7656,"activeCount":100},[7657],{"nctId":7658,"briefTitle":7659,"status":414,"phases":7660,"primaryCompletion":7661,"completion":7661,"start":7662,"enrollment":766,"conditions":7663,"interventions":7665},"NCT04409080","REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy",[88],"2024-10-17","2021-01-13",[7664],"Severe Aplastic Anemia (SAA)",[7651],{"trials":7667,"activeCount":100},[],{"trials":7669,"activeCount":100},[],{"trials":7671,"activeCount":100},[],{"trials":7673,"activeCount":100},[],{"intervention":7675,"totalTrials":273,"cells":7676},"REGN15160",{"EARLY_PHASE1":7677,"PHASE1":7679,"PHASE2":7689,"PHASE3":7691,"PHASE4":7693,"NA":7695},{"trials":7678,"activeCount":100},[],{"trials":7680,"activeCount":100},[7681],{"nctId":7682,"briefTitle":7683,"status":286,"phases":7684,"primaryCompletion":7685,"completion":7685,"start":7686,"enrollment":5588,"conditions":7687,"interventions":7688},"NCT05293678","Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody\u002FIes in Adult Healthy Volunteers as Related to COVID-19",[88],"2023-01-26","2022-04-12",[20],[7675,7675],{"trials":7690,"activeCount":100},[],{"trials":7692,"activeCount":100},[],{"trials":7694,"activeCount":100},[],{"trials":7696,"activeCount":100},[],{"intervention":1070,"totalTrials":273,"cells":7698},{"EARLY_PHASE1":7699,"PHASE1":7701,"PHASE2":7707,"PHASE3":7709,"PHASE4":7711,"NA":7713},{"trials":7700,"activeCount":100},[],{"trials":7702,"activeCount":100},[7703],{"nctId":1060,"briefTitle":1061,"status":286,"phases":7704,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":7705,"interventions":7706},[88],[1067,1026],[133,1069,1070,1071,1072,1032,1031],{"trials":7708,"activeCount":100},[],{"trials":7710,"activeCount":100},[],{"trials":7712,"activeCount":100},[],{"trials":7714,"activeCount":100},[],{"intervention":1072,"totalTrials":273,"cells":7716},{"EARLY_PHASE1":7717,"PHASE1":7719,"PHASE2":7725,"PHASE3":7727,"PHASE4":7729,"NA":7731},{"trials":7718,"activeCount":100},[],{"trials":7720,"activeCount":100},[7721],{"nctId":1060,"briefTitle":1061,"status":286,"phases":7722,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":7723,"interventions":7724},[88],[1067,1026],[133,1069,1070,1071,1072,1032,1031],{"trials":7726,"activeCount":100},[],{"trials":7728,"activeCount":100},[],{"trials":7730,"activeCount":100},[],{"trials":7732,"activeCount":100},[],{"intervention":7734,"totalTrials":273,"cells":7735},"REGN14284",{"EARLY_PHASE1":7736,"PHASE1":7738,"PHASE2":7747,"PHASE3":7749,"PHASE4":7751,"NA":7753},{"trials":7737,"activeCount":100},[],{"trials":7739,"activeCount":100},[7740],{"nctId":7741,"briefTitle":7742,"status":286,"phases":7743,"primaryCompletion":4241,"completion":4241,"start":7744,"enrollment":3767,"conditions":7745,"interventions":7746},"NCT05505448","A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants",[88],"2022-09-15",[20],[7734],{"trials":7748,"activeCount":100},[],{"trials":7750,"activeCount":100},[],{"trials":7752,"activeCount":100},[],{"trials":7754,"activeCount":100},[],{"intervention":4302,"totalTrials":273,"cells":7756},{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7765,"PHASE3":7767,"PHASE4":7769,"NA":7771},{"trials":7758,"activeCount":100},[],{"trials":7760,"activeCount":100},[7761],{"nctId":4294,"briefTitle":4295,"status":414,"phases":7762,"primaryCompletion":4297,"completion":4297,"start":4298,"enrollment":4205,"conditions":7763,"interventions":7764},[88],[3160,4300],[4276,4302],{"trials":7766,"activeCount":100},[],{"trials":7768,"activeCount":100},[],{"trials":7770,"activeCount":100},[],{"trials":7772,"activeCount":100},[],{"intervention":7774,"totalTrials":273,"cells":7775},"REGN668: Injection Rate 1",{"EARLY_PHASE1":7776,"PHASE1":7778,"PHASE2":7789,"PHASE3":7791,"PHASE4":7793,"NA":7795},{"trials":7777,"activeCount":100},[],{"trials":7779,"activeCount":100},[7780],{"nctId":7781,"briefTitle":7782,"status":286,"phases":7783,"primaryCompletion":7784,"completion":7784,"start":7785,"enrollment":4289,"conditions":7786,"interventions":7787},"NCT01484600","Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers",[88],"2012-02","2011-12",[20],[7774,7788],"REGN668: Injection Rate 2",{"trials":7790,"activeCount":100},[],{"trials":7792,"activeCount":100},[],{"trials":7794,"activeCount":100},[],{"trials":7796,"activeCount":100},[],{"intervention":7788,"totalTrials":273,"cells":7798},{"EARLY_PHASE1":7799,"PHASE1":7801,"PHASE2":7807,"PHASE3":7809,"PHASE4":7811,"NA":7813},{"trials":7800,"activeCount":100},[],{"trials":7802,"activeCount":100},[7803],{"nctId":7781,"briefTitle":7782,"status":286,"phases":7804,"primaryCompletion":7784,"completion":7784,"start":7785,"enrollment":4289,"conditions":7805,"interventions":7806},[88],[20],[7774,7788],{"trials":7808,"activeCount":100},[],{"trials":7810,"activeCount":100},[],{"trials":7812,"activeCount":100},[],{"trials":7814,"activeCount":100},[],{"intervention":7816,"totalTrials":273,"cells":7817},"89Zr˗DFO˗REGN3504",{"EARLY_PHASE1":7818,"PHASE1":7820,"PHASE2":7830,"PHASE3":7832,"PHASE4":7834,"NA":7836},{"trials":7819,"activeCount":100},[],{"trials":7821,"activeCount":100},[7822],{"nctId":7823,"briefTitle":7824,"status":414,"phases":7825,"primaryCompletion":605,"completion":605,"start":7826,"enrollment":136,"conditions":7827,"interventions":7829},"NCT03746704","Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies",[88],"2019-09-04",[7828],"Advanced PD-L1 Positive Malignancies",[7816],{"trials":7831,"activeCount":100},[],{"trials":7833,"activeCount":100},[],{"trials":7835,"activeCount":100},[],{"trials":7837,"activeCount":100},[],{"intervention":7839,"totalTrials":273,"cells":7840},"REGN2009",{"EARLY_PHASE1":7841,"PHASE1":7843,"PHASE2":7852,"PHASE3":7854,"PHASE4":7856,"NA":7858},{"trials":7842,"activeCount":100},[],{"trials":7844,"activeCount":100},[7845],{"nctId":7846,"briefTitle":7847,"status":286,"phases":7848,"primaryCompletion":428,"completion":428,"start":342,"enrollment":7849,"conditions":7850,"interventions":7851},"NCT01893528","Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers",[88],49,[14],[7839],{"trials":7853,"activeCount":100},[],{"trials":7855,"activeCount":100},[],{"trials":7857,"activeCount":100},[],{"trials":7859,"activeCount":100},[],{"intervention":7861,"totalTrials":273,"cells":7862},"Fasinumab AI",{"EARLY_PHASE1":7863,"PHASE1":7865,"PHASE2":7877,"PHASE3":7879,"PHASE4":7881,"NA":7883},{"trials":7864,"activeCount":100},[],{"trials":7866,"activeCount":100},[7867],{"nctId":7868,"briefTitle":7869,"status":286,"phases":7870,"primaryCompletion":7871,"completion":7872,"start":156,"enrollment":7873,"conditions":7874,"interventions":7875},"NCT03491904","To Assess the Patients' Ability to Self-Administer Fasinumab",[88],"2020-01-15","2020-12-15",100,[4901,4902],[7861,7876],"Fasinumab PFS",{"trials":7878,"activeCount":100},[],{"trials":7880,"activeCount":100},[],{"trials":7882,"activeCount":100},[],{"trials":7884,"activeCount":100},[],{"intervention":7876,"totalTrials":273,"cells":7886},{"EARLY_PHASE1":7887,"PHASE1":7889,"PHASE2":7895,"PHASE3":7897,"PHASE4":7899,"NA":7901},{"trials":7888,"activeCount":100},[],{"trials":7890,"activeCount":100},[7891],{"nctId":7868,"briefTitle":7869,"status":286,"phases":7892,"primaryCompletion":7871,"completion":7872,"start":156,"enrollment":7873,"conditions":7893,"interventions":7894},[88],[4901,4902],[7861,7876],{"trials":7896,"activeCount":100},[],{"trials":7898,"activeCount":100},[],{"trials":7900,"activeCount":100},[],{"trials":7902,"activeCount":100},[],{"intervention":1103,"totalTrials":273,"cells":7904},{"EARLY_PHASE1":7905,"PHASE1":7907,"PHASE2":7913,"PHASE3":7915,"PHASE4":7917,"NA":7919},{"trials":7906,"activeCount":100},[],{"trials":7908,"activeCount":100},[7909],{"nctId":1096,"briefTitle":1097,"status":414,"phases":7910,"primaryCompletion":1099,"completion":1099,"start":832,"enrollment":268,"conditions":7911,"interventions":7912},[88],[1101],[1103,133],{"trials":7914,"activeCount":100},[],{"trials":7916,"activeCount":100},[],{"trials":7918,"activeCount":100},[],{"trials":7920,"activeCount":100},[],{"intervention":7922,"totalTrials":763,"cells":7923},"REGN10933+REGN10987 combination therapy",{"EARLY_PHASE1":7924,"PHASE1":7926,"PHASE2":7928,"PHASE3":7949,"PHASE4":7951,"NA":7953},{"trials":7925,"activeCount":100},[],{"trials":7927,"activeCount":100},[],{"trials":7929,"activeCount":100},[7930,7940],{"nctId":7931,"briefTitle":7932,"status":286,"phases":7933,"primaryCompletion":7934,"completion":7935,"start":7936,"enrollment":7937,"conditions":7938,"interventions":7939},"NCT04426695","Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",[88,89],"2021-05-07","2021-10-22","2020-06-10",2252,[3003],[7922],{"nctId":7941,"briefTitle":7942,"status":286,"phases":7943,"primaryCompletion":7944,"completion":7945,"start":7872,"enrollment":7946,"conditions":7947,"interventions":7948},"NCT04666441","COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection",[89],"2021-03-04","2021-09-21",1149,[3003],[7922],{"trials":7950,"activeCount":100},[],{"trials":7952,"activeCount":100},[],{"trials":7954,"activeCount":100},[7955],{"nctId":7956,"briefTitle":7957,"status":918,"phases":7958,"conditions":7959,"interventions":7960},"NCT04617535","Compassionate Use of REGN-COV2 for the Treatment of COVID-19",[],[3003],[7922],{"intervention":7962,"totalTrials":763,"cells":7963},"REGN4461",{"EARLY_PHASE1":7964,"PHASE1":7966,"PHASE2":7975,"PHASE3":7987,"PHASE4":7989,"NA":7991},{"trials":7965,"activeCount":100},[],{"trials":7967,"activeCount":100},[7968],{"nctId":7969,"briefTitle":7970,"status":286,"phases":7971,"primaryCompletion":834,"completion":834,"start":7972,"enrollment":1210,"conditions":7973,"interventions":7974},"NCT03530514","A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers",[88],"2018-04-24",[14],[7962],{"trials":7976,"activeCount":100},[7977],{"nctId":7978,"briefTitle":7979,"status":414,"phases":7980,"primaryCompletion":1630,"completion":7981,"start":7982,"enrollment":528,"conditions":7983,"interventions":7986},"NCT05088460","A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)",[89],"2024-04-18","2022-02-28",[7984,7985],"Familial Partial Lipodystrophy","Metabolic Abnormalities",[7962],{"trials":7988,"activeCount":100},[],{"trials":7990,"activeCount":100},[],{"trials":7992,"activeCount":100},[7993],{"nctId":7994,"briefTitle":7995,"status":1654,"phases":7996,"conditions":7997,"interventions":8001},"NCT04710056","Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling",[],[7998,7999,8000],"Lipodystrophy","Generalized Lipodystrophy (GLD)","Monogenic Obesity (MOB)",[7962],{"intervention":1165,"totalTrials":136,"cells":8003},{"EARLY_PHASE1":8004,"PHASE1":8006,"PHASE2":8008,"PHASE3":8014,"PHASE4":8016,"NA":8018},{"trials":8005,"activeCount":100},[],{"trials":8007,"activeCount":100},[],{"trials":8009,"activeCount":100},[8010],{"nctId":1154,"briefTitle":1155,"status":414,"phases":8011,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":1159,"conditions":8012,"interventions":8013},[89],[1161,34,1082,1162,1127,1163],[1165,41],{"trials":8015,"activeCount":100},[],{"trials":8017,"activeCount":100},[],{"trials":8019,"activeCount":100},[8020],{"nctId":8021,"briefTitle":8022,"status":918,"phases":8023,"conditions":8024,"interventions":8026},"NCT06063746","Compassionate Use of Vidutolimod",[],[8025],"Refractory Melanoma",[8027],"Vidutolimod",{"intervention":8029,"totalTrials":136,"cells":8030},"REGN3470-3471-3479",{"EARLY_PHASE1":8031,"PHASE1":8033,"PHASE2":8043,"PHASE3":8045,"PHASE4":8047,"NA":8049},{"trials":8032,"activeCount":100},[],{"trials":8034,"activeCount":100},[8035],{"nctId":8036,"briefTitle":8037,"status":286,"phases":8038,"primaryCompletion":8039,"completion":8039,"start":8040,"enrollment":823,"conditions":8041,"interventions":8042},"NCT02777151","Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers",[88],"2017-04-26","2016-05-27",[14],[8029],{"trials":8044,"activeCount":100},[],{"trials":8046,"activeCount":100},[],{"trials":8048,"activeCount":100},[],{"trials":8050,"activeCount":100},[8051],{"nctId":8052,"briefTitle":8053,"status":1654,"phases":8054,"conditions":8055,"interventions":8057},"NCT03576690","R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease",[],[8056],"Ebola Virus Disease",[8029],{"intervention":1679,"totalTrials":136,"cells":8059},{"EARLY_PHASE1":8060,"PHASE1":8062,"PHASE2":8068,"PHASE3":8070,"PHASE4":8072,"NA":8074},{"trials":8061,"activeCount":100},[],{"trials":8063,"activeCount":100},[8064],{"nctId":1670,"briefTitle":1671,"status":286,"phases":8065,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":1676,"conditions":8066,"interventions":8067},[88],[14],[1679,1680,1663,1681],{"trials":8069,"activeCount":100},[],{"trials":8071,"activeCount":100},[],{"trials":8073,"activeCount":100},[],{"trials":8075,"activeCount":100},[8076],{"nctId":8077,"briefTitle":8078,"status":286,"phases":8079,"primaryCompletion":8080,"completion":8080,"start":8081,"enrollment":2077,"conditions":8082,"interventions":8083},"NCT05546957","Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants",[92],"2023-04-06","2023-01-05",[26],[1679,8084,8085],"rivaroxaban low dose","rivaroxaban high dose",{"intervention":8087,"totalTrials":273,"cells":8088},"aflibercept 2 mg",{"EARLY_PHASE1":8089,"PHASE1":8091,"PHASE2":8093,"PHASE3":8095,"PHASE4":8097,"NA":8099},{"trials":8090,"activeCount":100},[],{"trials":8092,"activeCount":100},[],{"trials":8094,"activeCount":100},[],{"trials":8096,"activeCount":100},[],{"trials":8098,"activeCount":100},[],{"trials":8100,"activeCount":100},[8101],{"nctId":8102,"briefTitle":8103,"status":286,"phases":8104,"primaryCompletion":8105,"completion":8106,"start":8107,"enrollment":8108,"conditions":8109,"interventions":8111},"NCT06769412","A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)",[],"2025-08-15","2025-09-01","2025-07-01",550000,[8110],"Retinal Vasculitis",[8087],{"intervention":8113,"totalTrials":273,"cells":8114},"ALIROCUMAB SAR236553",{"EARLY_PHASE1":8115,"PHASE1":8117,"PHASE2":8119,"PHASE3":8121,"PHASE4":8123,"NA":8125},{"trials":8116,"activeCount":100},[],{"trials":8118,"activeCount":100},[],{"trials":8120,"activeCount":100},[],{"trials":8122,"activeCount":100},[],{"trials":8124,"activeCount":100},[],{"trials":8126,"activeCount":100},[8127],{"nctId":8128,"briefTitle":8129,"status":414,"phases":8130,"primaryCompletion":8131,"completion":8131,"start":8132,"enrollment":332,"conditions":8133,"interventions":8134},"NCT03379558","Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study",[],"2020-09-04","2017-12-19",[23],[8113],{"intervention":8136,"totalTrials":273,"cells":8137},"REGN5458",{"EARLY_PHASE1":8138,"PHASE1":8140,"PHASE2":8142,"PHASE3":8144,"PHASE4":8146,"NA":8148},{"trials":8139,"activeCount":100},[],{"trials":8141,"activeCount":100},[],{"trials":8143,"activeCount":100},[],{"trials":8145,"activeCount":100},[],{"trials":8147,"activeCount":100},[],{"trials":8149,"activeCount":100},[8150],{"nctId":8151,"briefTitle":8152,"status":688,"phases":8153,"conditions":8154,"interventions":8155},"NCT05164250","Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)",[],[125],[8136],{"intervention":8157,"totalTrials":273,"cells":8158},"aflibercept 2mg",{"EARLY_PHASE1":8159,"PHASE1":8161,"PHASE2":8163,"PHASE3":8165,"PHASE4":8167,"NA":8169},{"trials":8160,"activeCount":100},[],{"trials":8162,"activeCount":100},[],{"trials":8164,"activeCount":100},[],{"trials":8166,"activeCount":100},[],{"trials":8168,"activeCount":100},[],{"trials":8170,"activeCount":100},[8171],{"nctId":8172,"briefTitle":8173,"status":286,"phases":8174,"primaryCompletion":8175,"completion":8176,"start":8177,"enrollment":8178,"conditions":8179,"interventions":8180},"NCT07105228","Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study",[],"2025-08-30","2025-09-15","2025-07-15",290000,[8110],[8157],{"intervention":8084,"totalTrials":273,"cells":8182},{"EARLY_PHASE1":8183,"PHASE1":8185,"PHASE2":8187,"PHASE3":8189,"PHASE4":8191,"NA":8193},{"trials":8184,"activeCount":100},[],{"trials":8186,"activeCount":100},[],{"trials":8188,"activeCount":100},[],{"trials":8190,"activeCount":100},[],{"trials":8192,"activeCount":100},[],{"trials":8194,"activeCount":100},[8195],{"nctId":8077,"briefTitle":8078,"status":286,"phases":8196,"primaryCompletion":8080,"completion":8080,"start":8081,"enrollment":2077,"conditions":8197,"interventions":8198},[92],[26],[1679,8084,8085],{"intervention":8085,"totalTrials":273,"cells":8200},{"EARLY_PHASE1":8201,"PHASE1":8203,"PHASE2":8205,"PHASE3":8207,"PHASE4":8209,"NA":8211},{"trials":8202,"activeCount":100},[],{"trials":8204,"activeCount":100},[],{"trials":8206,"activeCount":100},[],{"trials":8208,"activeCount":100},[],{"trials":8210,"activeCount":100},[],{"trials":8212,"activeCount":100},[8213],{"nctId":8077,"briefTitle":8078,"status":286,"phases":8214,"primaryCompletion":8080,"completion":8080,"start":8081,"enrollment":2077,"conditions":8215,"interventions":8216},[92],[26],[1679,8084,8085]]